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ABSTRACT 
Induced proteolysis of pathogenic proteins via degrader molecules, such as Proteolysis 
Targeting Chimeras (PROTACs), is emerging as a promising therapeutic strategy. In 
particular, induced proximity of Cullin-RING ubiquitin Ligases (CRLs) with various neo-
substrates has proven successful in mediating proteasomal degradation of previously 
undruggable proteins. Hijacking enzymes to carry out biochemical reactions on neo-
substrates stands in stark contrast to conventional pharmacological approaches and exposes 
degrader molecules to unusually complex pharmacodynamics. While the first PROTACs 
entered the clinic in 2019, much about the organization and regulation of the frequently co-
opted CRLs remains elusive. In particular, the COP9 Signalosome (CSN) is essential to 
regulate CRL activity and assembly through cleaving Nedd8 from cullin scaffolds, yet it 
remains unknown how CSN becomes activated. We combine structural and kinetic 
analyses to identify mechanisms that contribute to CSN activation and Nedd8 
deconjugation, detailing the kinetic picture of the deneddylation-disassembly cycle that 
promotes rapid remodeling of the cellular CRL network. Furthermore, we establish Protein 
Interaction Kinetics and Estimation of Stoichiometries (PIKES) analysis, a systematic 
proteomic profiling platform that integrates cellular engineering, affinity purification, 
chemical stabilization and quantitative mass spectrometry to investigate the dynamics of 
interchangeable multiprotein complexes. Using PIKES, we show that ligase assemblies of 
Cullin4 with individual substrate receptors differ in abundance by up to 200-fold and that 
Cand1 acts as an exchange factor to remodel the CRL4 ligase pool. Integrating quantitative 
data and model simulations of CRL-mediated substrate turnover, we show that high 
substrate receptor levels can enhance the potency of degraders.  
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1 - INTRODUCTION TO CULLIN-RING UBIQUITIN LIGASES 
1.1 The Ubiquitin Proteasome System 
Facing the challenge of spatially and temporally controlling the abundance and function of 
billions of protein molecules at a timescale of minutes, eukaryotes evolved hundreds of 
enzymes, collectively termed the Ubiquitin Proteasome System (UPS) (Hershko and 
Ciechanover, 2003). In addition to clearing misfolded and dysfunctional proteins, rapid 
depletion of signaling proteins provides a mechanism to control fundamental processes 
such as cell cycle (Deshaies, 1995; King et al., 1996). The UPS is highly conserved from 
yeast to humans, whereby ubiquitin (Ub), a 76-amino-acid polypeptide, can serve as the 
mark for protein degradation by the 26S proteasome. 
Historically, the canonical signal recognized by the proteasome was believed to be a chain 
of at least four ubiquitin molecules covalently attached to a Lys residue of a protein 
substrate (Ravid and Hochstrasser, 2008). However, recent research showed that 
conjugation of substrates with multiple mono-ubiquitins as well as branched chains with 
various linkages can mediate and even improve recognition by the proteasome (Dimova et 
al., 2012; Lu et al., 2015b; Meyer and Rape, 2014; Yau and Rape, 2016). The modification 
of proteins with ubiquitin, referred to as ubiquitination, is achieved through a three-step 
cascade of biochemical reactions: first, ubiquitin is activated via its C-terminal Gly76 
residue in an ATP-dependent process carried out by an E1 ubiquitin-activating enzyme. 
The intermediate ubiquitin adenylate is bound to a Cys residue of the E1 enzyme via a 
high-energy thioester linkage. Second, the E1-bound ubiquitin moiety is transferred to a 
Cys residue on an E2 ubiquitin-conjugating enzyme in a transesterification reaction. In a 
third step, ubiquitin is transferred to a Lys residue of a substrate protein via an E3 ubiquitin-
ligating enzyme (Hershko and Ciechanover, 1998; Varshavsky, 1997). This last step is 
catalyzed by E3 ubiquitin ligases of two main families that function through distinct 
mechanisms: HECT (homologous to the E6AP carboxyl terminus) domain ligases first 
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accept the ubiquitin moiety on a Cys residue before transferring it onto substrates. RING 
(really interesting new gene) domain ligases use scaffolding proteins to bring substrates 
into proximity with E2 enzymes which discharge ubiquitin directly onto the substrate to 
yield a Ub-protein conjugate. In each case, an isopeptide bond forms between the carboxyl 
group of Ub and the lysine Ɛ-amino group of the substrate. (Deshaies and Joazeiro, 2009a; 
Zheng and Shabek, 2017). Recently, the discovery of RING-IBR-RING (RBRs) defined a 
third family of RING-HECT hybrid E3 enzymes (Wenzel et al., 2011; Zheng and Shabek, 
2017). 
Figure 1.1. The Ubiquitin Proteasome System – UPS. (1) Ubiquitin is activated via binding to a Ub-E1 
enzyme and formation of a ubiquitin-adenylate. (2) Activated Ub-AMP is then transferred onto a Cys residue 
within the E1 enzyme which can then associate with a second Ub molecule to form a fully charged E1 
complex. (3) Ubiquitin is then transferred to an E2 enzyme through a transesterification reaction. (4) Several 
hundred E3 ligases can either serve as a scaffold for E2 and substrate or receive the Ub-moiety from the E2 
enzyme on an active site Cys residue to eventually facilitate substrate ubiquitination. (5) Substrate proteins 
can either be released by E3 ligases as mono-ubiquitin conjugates or enter processive cycles of ubiquitin 
chain formation to yield poly-ubiquitin conjugates. (6) Mono- and poly-ubiquitination (a,b) of substrate 
proteins can either alter protein function while poly-ubiquitination via K48 chains is the primary recognition 
signal or the 26S Proteasome to mediate protein degradation (c). Adopted from (Deshaies and Joazeiro, 
2009b; Pickart, 2004) 
In humans, selectivity within the UPS is conferred by hundreds of E3 ubiquitin ligases 
which recognize substrates via degradation signals, referred to as degrons (Zheng and 
Shabek, 2017). A typical UPS degron comprises a set of characteristics to successfully 
mediate ubiquitination and proteasomal degradation: i) an interface to recruit the E3 ligase 
(primary recognition determinant); ii) one or multiple Ub-acceptor Lys moieties; iii) the 
ability to bind the 26S proteasome; and iv) a location within the substrate, usually in 
Figure 1.1 
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proximity to an unstructured region, that enables unfolding by the proteasome 
(Aufderheide et al., 2015; Ravid and Hochstrasser, 2008).  
A mono-Ub-protein conjugate can undergo further processive ubiquitination resulting in a 
poly-Ub-protein conjugate (Pierce et al., 2009). The Lys residue within ubiquitin that 
serves as the acceptor for the next transfer determines the architecture of emerging chains. 
The main chain types recognized by the 26S proteasome are linked via Lys48 and Lys11, 
while Lys29- and Lys63-linked chains mediate proteasomal degradation less frequently. 
Ubiquitin, attached to proteins in various linkages and branches, serves as a post-
transcriptional code which, besides its roles in proteolysis, can regulate the activity, 
localization, and interactions of many cellular proteins (Komander and Rape, 2012).  
Proteins are designed as robust, tightly folded, biological polymers, built from amino acids 
chemically linked via peptide bonds. The hydrolysis of a peptide bond at physiological pH 
is estimated to take place at a half-life of ~400 years (Pickart, 2004; Wolfenden and Snider, 
2001). The kinetic stability of proteins at physiological conditions underscores the 
complexity of breaking down thousands of different proteins via one universal molecular 
machine. Degradation of most cellular proteins is facilitated by a 2.5-MDa, ATP-driven, 
32-subunit protease – termed the proteasome – consisting of a 20S core particle capped by 
one or two 19S particles. While the 20S core harbors proteolytic activity, the 19S cap 
functions as a substrate recognition, de-ubiquitination, and unfolding module. Ubiquitin 
receptors within the 19S cap are spatially positioned in a way that a poly-Ub conjugate is 
recognized with an affinity high enough to initiate substrate de-ubiquitination, unfolding, 
and subsequently degradation within the 20S proteolytic chamber (Aufderheide et al., 
2015; Förster et al., 2013; Matyskiela and Martin, 2013). 
1.2 Cullin-RING Ubiquitin Ligases  
The human genome encodes more than 600 E3 Ubiquitin ligases, most of which contain a 
RING domain, and only ~40 E2 and two E1 enzymes (Deshaies and Joazeiro, 2009a; 
Sarikas et al., 2011). Cells afford such a large number E3 enzymes to ensure specific 
targeting of individual proteins for ubiquitination. Within the superfamily of RING-E3s, 
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the Cullin-RING ligases (CRLs) are the largest class and make up as many as 240 distinct 
enzyme complexes (Skaar et al., 2013; Zheng and Shabek, 2017) which are responsible for 
~20% ubiquitin-dependent protein turnover in human cells (Soucy et al., 2009). CRLs are 
further divided into subfamilies based on the identity of their catalytic cullin scaffolding 
protein: the founding member Cullin1 or SCF family, and the Cullin2, Cullin3, Cullin4A, 
and Cullin4B, as well as the Cullin5 and Cullin7 subfamilies. All CRL ligases share a 
common architecture and bind an Adapter-Substrate Receptor module (A•SR) on the N-
terminal end of the scaffold and one of two RING proteins (Rbx1 or Rbx2) on the C-
terminal domain. While the A•SR modules mediate substrate recognition and recruitment, 
the RING serves as a platform to recruit and position an E2 enzyme to compose a fully 
functional ligase complex. Within each subclass, several dozen individual substrate 
receptors (SR) utilize the same, subclass-specific adapter (A) protein to assemble with a 
cullin backbone.  
Within prototypical SCF/CRL1 complexes, the Skp1 adapter protein and one of ~69 Fbox 
proteins form A•SR modules that associate with Cullin1 (Jin et al., 2004). While the SR 
modules of Cul1-3, Cul5, and Cul7 are structurally related, the Cullin4 subfamily diverges 
from the norm. Compared to other CRLs, the Cul4 adapter protein DDB1 is considerably 
larger and more flexible. Cul4 SRs also contain distinct but variable motifs on which ligase 
assembly is based (Lydeard et al., 2013; Zimmerman et al., 2010). The adapter DDB1 
contains three WD40-like beta-propeller domains – BPA, BPB, and BPC (beta-propeller 
A-C) – of which BPB tethers DDB1 onto the Cul4 scaffold (Zimmerman et al., 2010). 
Substrate receptors in the cullin4 family are referred to as DCAFs (DDB1-Cul4-associated 
Factors) or DWDs (DDB1-binding WD40 proteins). The majority of DCAFs contain six 
or more WD40 motifs which again fold into donut-shaped beta-propeller domains (Angers 
et al., 2006; He et al., 2006a; Higa et al., 2006; Jin et al., 2006). DCAF proteins associate 
with DDB1 via a N-terminal alpha-helix motif, termed the H-box, which inserts itself 
between the BPA and BPC domains of DDB1. The beta-propeller of the DCAF packs 
against those of DDB1, positioning the ‘top’ surface of the beta-propeller to recruit and 
present substrates. While the H-box motif can be identified in seven cellular DCAFs, the 
13 amino acid motif is poorly conserved, making the prediction and identification of all 
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human DCAFs a major challenge (Li et al., 2010; Scrima et al., 2008; Zimmerman et al., 
2010). Currently, the exact number of true DCAF proteins is not known and estimates 
range from 25-115 (Hannah and Zhou, 2015; Lee and Zhou, 2007). 
Figure 1.2. Architecture of cullin-RING ubiquitin ligases. (A) The prototypical subfamily CRL ligases is 
SCF or CRL1, which is composed of a Cul1 scaffold tightly associated with the RING protein Rbx1 on the 
C-terminal end and assembled with one of 69 individual A•SR modules. Skp1 serves as the CRL1 adapter 
protein while various Fbox proteins serve as specific substrate recognition subunits. (B) Structural model of 
a CRL1SKP2 ligase complex (PDB xxx). (C) The architecture of CRL4 complexes resembles SCF except for 
a few important distinctions. CRL4 uses DDB1 as the adapter protein and DCAFs or DWDs as substrate 
receptors. Structurally, CRL4s are distinct due to their large and mobile adapter protein and a A•SR binding 
mode that differs from other CRL families. (D) Structural model of a CRLCRBN ligase complex (PDB xxx). 
The structural models in (B) and (D) are adopted from (Cavadini et al., 2016). 
The combinatorial nature of CRLs reminds of a drill that uses an adapter with multiple 
different bits to work on various types of screws. The engineering of drills as well as the 
modular evolution of CRLs comes with three advantages: first, it appears economical to 
evolve an efficient catalytic core once and then expand its applicability through additional 
specificity modules. Second, the use of an adapter allows for virtually unlimited expansion 
Figure 1.2 
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of the repertoire of substrate receptors, providing CRLs with functionality and plasticity. 
Third, separating specificity modules from catalytic cores and only assembling full ligases 
when they are needed, might prevent promiscuous ubiquitination of unintended substrates, 
which could potentially be caused by the enormous speed of CRL-mediated ubiquitination 
occuring in milliseconds (Pierce et al., 2009). Considering all of the above, regulating 
proper CRL ligase assembly and function on a time scale that allows for rapid responses to 
cellular signals within minutes poses a major challenge to all eukaryotic cells.  
1.3 Regulation of CRL Ligases via Nedd8, Cand1, and CSN 
Following the discovery of SCF/CRL1 as the first CRL ubiquitin ligase complex ~20 years 
ago (Feldman et al., 1997; Patton et al., 1998; Skowyra et al., 1997), most research on CRL 
regulation has been conducted on the prototypical SCF complexes. Definitive experimental 
evidence about regulation of CRL complexes other than SCF is sparse, although structural 
similarities and shared regulatory proteins suggest uniform mechanisms (Lydeard et al., 
2013). In brief, all CRL ligases are thought to undergo cycles of activation and inactivation 
via Nedd8 and the Cop9 Signalosome (CSN), as well as cycles of substrate receptor 
exchange driven by Cand1. These mechanisms are posited to ensure timed activation and 
stable CRL assembly when substrates are present. 
Early studies in Arabidopsis thaliana and budding yeast revealed that cullin scaffolds are 
modified with the protein Rub1 (Liakopoulos et al., 1998; Linghu et al., 2002; Del Pozo 
and Estelle, 1999). In humans, the Rub1 homologue and ubiquitin-like protein Nedd8 is 
conjugated onto conserved Lys residues of cullin scaffolds in a three-step cascade similar 
to that of ubiquitination. This process is termed neddylation. The Nedd8-E2 (Ubc12 or 
UBE2F) enzyme binds cullins via the RING domain of Rbx1/2, and with the help of DCN 
proteins (Nedd8 E3s) positions its active site close to a Lys moiety on the C-terminal 
globular domain of the cullin to discharge Nedd8 (Enchev et al., 2015). The modification 
of a cullin complex with Nedd8 has two major regulatory roles: first, cullin neddylation 
leads to activation of ubiquitin transfer activity by inducing structural rearrangements of 
the C-terminal domain and the RING. This conformational change allows the Ub-E2 to be 
positioned nearby its substrate, closing a gap that is estimated to be as wide as 50Å in the 
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non-neddylated state (Boh et al., 2011; Duda et al., 2008; Saha and Deshaies, 2008; 
Yamoah et al., 2008). Second, modification with Nedd8 blocks Cand1 from accessing the 
cullin scaffold to prevent A•SR exchange (Liu et al., 2002; Zheng et al., 2002a).  
Initially, Cand1 was thought to be an inhibitor of CRL function since structural studies 
revealed that it tightly wrapped around the cullin core, occupying both, the N-terminal 
A•SR binding site as well as the C-terminal neddylation site. The Cullin•Cand1 complex 
was deemed incompatible with Ubiquitin or Nedd8 transfer activity (Goldenberg et al., 
2004). For many years, this observation stood in contrast with genetic studies performed 
in plants and worms which suggested a positive role of Cand1 in CRL regulation (Bosu et 
al., 2010; Chuang et al., 2004; Feng et al., 2004; Lo and Hannink, 2006; Zhang et al., 2008). 
This longstanding paradox was resolved when Cand1 was shown to act as an A•SR module 
exchange factor (Pierce et al., 2013; Wu et al., 2013; Zemla et al., 2013). The necessity of 
an A•SR exchange factor within the SCF system became apparent when in vitro studies 
revealed that Skp1•Fbox modules dissociate from Cul1 with a half-life of more than one 
week (Pierce et al., 2013). These extreme stabilities (Kd values in the picomolar range) 
restrict the re-arrangement and plasticity of SCF complexes dramatically, particularly 
when considering that cullin scaffolds are present at limiting amounts and A•SR modules 
in multiple fold excess (Bennett et al., 2010). Practically, this would have meant that a free 
A•SR would have to wait several days to assemble with a cullin scaffold following 
substrate engagement in order to take is turn to form an active ligase. This conundrum 
resolved when it was shown that Cand1 can act as a catalyst for A•SR exchange by 
increasing the off-rate of Skp1•Fbox modules from Cul1 by one million-fold. This 
exchange activity shortens SCF complex dissociation to less than one second (Pierce et al., 
2013). Cand1 can only exhibit its exchange function on inactive, de-neddylated CRL 
complexes. To ensure that Cullin cores are held in prompt equilibrium with their A•SR 
pools, Nedd8 must be deconjugated from CRLs once substrate demand decreases to make 
them accessible to Cand1’s exchange function. 
The Cop9 Signalosome (CSN) is an eight-subunit protein complex harboring a JAMM 
motif (JAB1-MPN-MOV34 metalloenzyme motif) within a metalloprotease active site. 
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CSN serves as the main cullin deneddylase (Cope et al., 2002; Lyapina et al., 2001). The 
holoenzyme as well as its CSN5 active site subunit in isolation display no activity towards 
non-cullin Nedd8-conjugates. This lack of activity suggests an autoinhibitory mechanism 
preventing promiscuous deneddylation activity (Birol et al., 2014; Lingaraju et al., 2014). 
Structural and biochemical studies, including the work described in this thesis, revealed 
that the C-terminal cullin domain is wedged in between CSN subunits CSN2 and CSN4, 
leading to the optimal positioning of the CSN5/6 active site dimer and the release of 
autoinhibition allowing CRL-specific deneddylation (Cavadini et al., 2016; Mosadeghi et 
al., 2016). Additionally, the CSN-CRL binding mechanisms evolved so that CSN senses 
whether the CRL is occupied by a substrate. CSN competes with substrate proteins for the 
space around the A•SR module on the N-terminal domain of the cullin. Through this 
competition, substrates inhibit CSN’s deneddylation activity when bound to CRLs 
(Cavadini et al., 2016; Emberley et al., 2012; Enchev et al., 2012; Fischer et al., 2011a). 
Interestingly, CSN can stably associate with its product and thereby inhibit non-neddylated 
CRLs. This phenomenon cannot be explained by current kinetic models but it has been 
proposed that substrates compete with CSN for CRL access to trigger their own 
ubiquitination (Bennett et al., 2010; Emberley et al., 2012; Enchev et al., 2015). 
The regulatory factors Nedd8, Cand1 and CSN join forces to ensure proper CRL ligase 
function through timed cycles of inhibition and activation (Figure 1.3) (Liu et al., 2018; 
Sievers et al., 2018). In human cells, only ~10% of all Skp1•Fbox modules assemble into 
~250 nM SCF ligases at steady state (Figure 1.3-1). Cul1 scaffolds are limiting with a 
Skp1•Fbox pool in four-fold excess over total Cul1 (Reitsma et al., 2017). This quantitative 
picture of SCF ligase organization makes obvious that efficient recycling of cullin scaffolds 
is paramount to enable new ligase assembly through integration of A•SR modules from a 
large free repertoire (~90%). This is ensured via the exchange activity of Cand1, which 
keeps Cul1 in a rapid and dynamic equilibrium with the A•SR pool. CRLs can escape rapid 
cycles of exchange and neddylation/deneddylation via substrate association (Figure 1.3-2), 
creating a disequilibrium that favors the assembly of A•SR modules for which substrates 
are available. Once the N-terminal end of a cullin is occupied by a substrate, deneddylation 
via CSN is inhibited and the exchange cycle put on hold. The CRL complex becomes 
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trapped in its fully activated state, polyubiquitinating the substrate until it is released and 
degraded. Once substrate dissociates, CSN is able to bind the CRL to facilitate rapid de-
neddylation which allows the complex to re-enter the Cand1 exchange cycle (Figure 1.3-
3). In this complex regulatory network, the role of Nedd8 and CSN is similar to a chuck 
key which is used to tighten or loosen the adapter of a drill. Nedd8, just like the tightening 
chuck key, ensures stability and function at high speeds, while CSN, like the loosing chuck 
key, reverses this activating signal and enables exchange to a different adapter•bit 
combination. 
Figure 1.3. The Cand1-Nedd8-CSN Regulation Cycle on the example of SCF/CRL1. (1) Once a fully 
assembled SCF complex is born, it can either become neddylated and bind substrate (2), or, if substrate is 
not available become de-neddylated rapidly to enter the Cand1-driven exchange regime (3). Cand1-mediated 
exchange ensures that limited amounts of Cul1 scaffold is kept in equilibrium with large pools of A•SR 
modules (FBP/SKP1 for Fbox protein and SKP1 complexes). An adaptive disequilibrium is created towards 
CRL complexes with available substrates due to the substrate’s ability to inhibite CSN-mediated de-
neddylation and therefore Cand1-mediated A•SR exchange. This illustration is adopted from (Reitsma et al., 
2017). 
  
Figure 1.3 
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1.4 Pharmacological Targeting of the UPS and CRLs 
The UPS is essential to cellular function and involved in every major signaling pathway. 
Besides proteostasis and cell cycle, the UPS also regulates immune signaling, 
mitochondrial fission, fusion and degradation, and different forms of cell death including 
apoptosis, neuronal function and tumorigenesis (Thibaudeau and Smith, 2019). Upon 
realization that cancer cells frequently rely on a functional UPS, initial discoveries of 26S 
proteasome inhibitors (PIs) in the 1990’s (Rock et al., 1994) were followed by the 
development of bortezomib (Velcade®) as a first-generation PI approved for relapse-
refractory multiple myeloma (RR-MM). Since its approval in 2003, bortezomib continues 
to be an important cornerstone in MM therapy (Goldberg, 2007). Bortezomib is based on 
an early lead compound termed MG-132, a peptide aldehyde which continues to be used 
in research due to its low cost, decent potency and reversibility (Thibaudeau and Smith, 
2019). Several years later, carfilzomib (Kyprolis®) was developed from the naturally 
derived compound epoxomicin and shown to act through a different mechanism of action. 
Carfilzomib was approved by the FDA as a second-generation PI for RR-MM in 2012. In 
2015 ixazomib was approved as the first orally bioavailable PI, showing promising results 
for indications beyond MM in ongoing trials (Thibaudeau and Smith, 2019).  
The profound role of neddylation in CRL biology and its involvement in various cancers 
spurred the development of potent inhibitors of the Nedd8-E1 (NAE) enzyme and CSN 
(Brownell et al., 2010; Schlierf et al., 2016; Soucy et al., 2009). Prevonedistat, a NAE 
enzyme inhibitor (MLN4924), is currently being evaluated in 34 clinical trials, 20 of which 
are actively recruiting (www.clinicaltrials.gov). MLN4924 and CSN5i-3 (CSN inhibitor) 
also serve as valuable tools to study cullin-RING ligase function and regulation in research. 
Millennium Therapeutics (now Takeda), the same company which developed the Nedd8-
E1 inhibitor MLN4924, subsequently developed a highly potent Ubiquitin-E1 inhibitor 
(Hyer et al., 2018). While clinical trials so far have failed, MLN7243, just like CSN5-3 and 
MLN4924, provides a valuable research tool. 
While substrate recognition through E3 enzymes is highly specific, the chemistry of 
conjugating ubiquitin molecules to a Lys residue within a protein substrate is fairly 
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promiscuous. This realization led to the hypothesis that it should be possible for any 
substrate protein to be ubiquitinated and subsequently degraded through the UPS if brought 
in proximity with a Ub-E3 enzyme. The concept of  artificial and targeted protein 
degradation via proteolysis targeting chimeras (PROTACs) was experimentally 
demonstrated for the first time in the early 2000’s by the Crews and Deshaies laboratories 
(Sakamoto et al., 2001, 2003). These seminal studies made it obvious that targeting of the 
UPS was not limited to conventional pharmacology of inhibiting enzyme activity but could 
be extended to co-opting the proteolytic machinery for therapeutic benefit. While initial 
development of PROTAC molecules was limited to a few ligase-ligands and targets, 
mechanistic discoveries involving lenalidomide and other IMiDs sparked new enthusiasm. 
IMiDs were initially banned for then teratogenic effects, but later repurposed to treat 
multiple myeloma and leprosy. IMiDs were subsequently shown to recruit zinc finger 
transcription factors to the CRL4CRBN ubiquitin ligase which mediates the IMiD-dependent 
ubiquitination and proteasomal degradation of IKZF1 and IKZF3 (Gandhi et al., 2014; 
Krönke et al., 2014; Lu et al., 2014). This discovery not only provided in-vivo proof that 
chemically inducible protein degradation can work in humans, but also revealed a new 
ligase-ligand which could be conjugated to other substrate-recruiting moieties to target a 
variety of neo-substrates for inducible degradation (Nabet et al., 2018; Winter et al., 2015). 
Within the last five years, more than thirty PROTAC-like molecules have been reported. 
The field of targeted protein degradation currently holds the promise against many 
previously undruggable proteins and represents a new class of medicines (An and Fu, 2018; 
Deshaies, 2015; Paiva and Crews, 2019; Scudellari, 2019). The emergence of these new 
pharmaceuticals moved cullin-RING ligases into the spotlight of drug development. The 
complex mechanism involved with redirecting CRL ligases towards novel target proteins 
exposes degrader drugs to unusually complicated pharmacodynamics (Bulatov and Ciulli, 
2015). Therefore, it is of great general interest to investigate the composition, dynamics, 
and regulation of CRL ligases in detail. These studies aim to guide rational design for 
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degraders and facilitate a better understanding of how these medicines will work in 
patients. 
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2 - STRUCTURAL AND KINETIC ANALYSIS OF CSN 
ACTIVATION AND THE CULLIN-RING UBIQUITIN LIGASE 
DENEDDYLATION CYCLE 
This chapter is based on the accepted manuscript draft prior to formatting by eLife which 
was published as: 
R Mosadeghi, KM Reichermeier, M Winkler, A Schreiber, JM Reitsma, Y Zhang, F Stengel, J Cao, M Kim, 
MJ Sweredoski, S Hess, A Leitner, R Aebersold, M Peter, RJ Deshaies, RI Enchev; Structural and kinetic 
analysis of the COP9-Signalosome activation and the cullin-RING ubiquitin ligase deneddylation cycle. 
eLife (2016); PMID: 27031283; DOI: 10.7554/eLife.12102 
2.1 Summary 
The COP9-Signalosome (CSN) regulates cullin–RING ubiquitin ligase (CRL) activity and 
assembly by cleaving Nedd8 from cullins. Free CSN is autoinhibited, and it remains 
unclear how it becomes activated. We combine structural and kinetic analyses to identify 
mechanisms that contribute to CSN activation and Nedd8 deconjugation. Both CSN and 
neddylated substrate undergo large conformational changes upon binding, with important 
roles played by the N-terminal domains of Csn2 and Csn4 and the RING domain of Rbx1 
in enabling formation of a high affinity, fully active complex. The RING domain is crucial 
for deneddylation, and works in part through conformational changes involving insert-2 of 
Csn6. Nedd8 deconjugation and re-engagement of the active site zinc by the autoinhibitory 
Csn5 glutamate-104 diminish affinity for Cul1/Rbx1 by ~100-fold, resulting in its rapid 
ejection from the active site. Together, these mechanisms enable a dynamic deneddylation-
disassembly cycle that promotes rapid remodeling of the cellular CRL network. 
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2.2 Introduction 
Cullin–RING ubiquitin ligases comprise one of the largest families of regulatory enzymes 
in eukaryotic cells (Deshaies and Joazeiro, 2009a). With as many as 240 different enzyme 
complexes, these E3s control a broad array of biological processes (Skaar et al., 2013). 
CRLs comprise seven distinct cullin–RING cores, each of which interacts with its own 
dedicated set of adaptor–substrate receptor complexes. Although ubiquitination by CRL 
enzymes is often regulated by covalent modifications of the substrate that stimulate binding 
to the substrate receptor, the CRL enzymes themselves are also subject to regulation.  
A key mechanism that controls the activity of all known CRLs is the conjugation of the 
ubiquitin-like protein Nedd8 to a conserved lysine residue in the cullin subunit (e.g. K720 
in human Cul1) (Enchev et al., 2015). The available structural and biochemical data 
indicate that Nedd8 conjugation (neddylation) stabilizes a profound conformational change 
in the C-terminal domain of the cullin. It loosens the interaction of the WHB domain with 
the RING subunit, allowing both of them to sample a greater conformational space (Duda 
et al., 2008), thereby enhancing the ability of the RING domain to promote ubiquitin 
transfer to substrate (Duda et al., 2008; Saha and Deshaies, 2008; Yamoah et al., 2008). 
In addition to direct effects on ubiquitin ligase activity, Nedd8 also protects Skp1/Cul1/F-
box (SCF) complexes from the substrate receptor exchange factor (SREF) Cand1 (Pierce 
et al., 2013; Schmidt et al., 2009; Wu et al., 2013; Zemla et al., 2013). Cand1 binds 
unmodified SCF complexes and promotes rapid dissociation of the F-box protein 
(FBP)/Skp1 substrate receptor–adaptor module from the Cul1/Rbx1 core. Cand1 can 
subsequently be dissociated from Cul1 by a different FBP/Skp1 complex, and as a result 
Cand1 functions as an SREF that accelerates the rate at which Cul1/Rbx1 comes to 
equilibrium with different FBP/Skp1 substrate receptor–adaptor complexes (Pierce et al., 
2013). Importantly, the SREF activity of Cand1 is tightly restricted by Nedd8. Cand1 is 
not able to bind stably to Cul1 and promote dissociation of FBP/Skp1 when Cul1 is 
conjugated to Nedd8 (Liu et al., 2002; Pierce et al., 2013). These observations underscore 
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the importance of neddylation not only for controlling the enzymatic activity of CRLs, but 
also potentially for controlling the repertoire of assembled CRLs. 
The key role of Nedd8 in CRL biology highlights the importance of the enzymatic 
pathways that attach and remove Nedd8 (Enchev et al., 2015). Of particular significance is 
the rate of Nedd8 deconjugation, because it serves as the gateway for the exchange cycle; 
once Nedd8 is removed, a CRL complex is susceptible to the potent SREF activity of 
Cand1, and its substrate receptor can be exchanged (Pierce et al., 2013). Deconjugation of 
Nedd8 is mediated by the COP9-signalosome (CSN), which is an eight-subunit Nedd8 
isopeptidase (Lyapina et al., 2001). The enzymatic activity of CSN resides in its Csn5 
subunit, which contains a metalloprotease active site referred to as the ‘JAMM’ domain 
(Cope et al., 2002). The JAMM domain has the general structure E76-Xn-H138-X-H140-X10-
D151 (the subscripts refer to the sequence position of these residues in human Csn5), 
wherein the H and D residues coordinate a zinc ion. The fourth zinc-coordination site is 
occupied by a water molecule that that also forms a hydrogen bond to E76 (Ambroggio et 
al., 2004; Sato et al., 2008; Tran et al., 2003). Deneddylation of CRLs by CSN is rapid but 
can be regulated by CRL substrates (Emberley et al., 2012; Enchev et al., 2012; Fischer et 
al., 2011b). Structural analysis suggests that a CRL ubiquitination substrate bound to a 
substrate receptor sterically prevents concurrent binding of CSN (Enchev et al., 2012; 
Fischer et al., 2011b). This suggests a model wherein a CRL complex has a higher 
probability of being conjugated to Nedd8 (and therefore of being shielded from Cand1) as 
long as it is bound to substrate. Upon dissociation of substrate, a race ensues between 
binding of either a new substrate or CSN. If CSN wins, Nedd8 is removed, paving the way 
for Cand1 to initiate substrate receptor exchange. 
Recently, a crystal structure of free CSN was determined (Lingaraju et al., 2014). A major 
insight to emerge from the structure was the unexpected finding that Csn5 was present in 
an autoinhibited state, wherein a glutamate (Csn5-E104) within the ‘insert-1’ (INS1) 
sequence common to JAMM family members (Sato et al., 2008) forms a fourth ligand to 
the zinc, displacing the catalytic Csn5-E76-bound water molecule and shifting Csn5-E76. 
Csn5-E104 is found in all Csn5 orthologs, but not in other JAMM proteins, suggesting that 
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this mode of regulation is conserved but unique to CSN. Comparison of the structure of 
free CSN to the structure of a catalytically-dead mutant CSN bound to Nedd8-conjugated 
SCFSkp2 determined by negative stain electron microscopy (Enchev et al., 2012) implied 
that binding of substrate to CSN may induce several conformational changes in the latter, 
including movement of the N-terminal domains (NTD) of Csn2 and Csn4 towards the 
cullin. The latter movement, in turn, might be further propagated to the Csn5/6 module 
(Lingaraju et al., 2014). Moreover, it is reasonable to expect that during catalysis INS1 
moves out of the active site and Csn5-E76 adopts a position similar to that observed in a 
crystallographic structure of Csn5 in isolation (Echalier et al., 2013). Interestingly, if Csn5-
E104 is mutated to an alanine, CSN more rapidly cleaves the simple model substrate 
ubiquitin-rhodamine (Lingaraju et al., 2014). This was interpreted to mean that the primary 
reason for the autoinhibited state is to keep CSN off until it binds a physiologic substrate, 
which would prevent spurious cleavage of non-cullin Nedd8 conjugates and possibly even 
ubiquitin conjugates. However, the full extent of the conformational changes required to 
form an activated complex between CSN and its neddylated substrate, as well as the 
detailed molecular basis for these changes, remains to be established. Therefore, at present, 
the mechanism of how CSN is switched on and off and the significance of this switching 
behavior remains unknown.  
2.3 Results 
Structural insights from cryo EM and single particle analysis of a CSN-SCF-
Nedd8Skp2/Cks1 complex 
To gain detailed insights into the molecular determinants underlying activation of CSN, 
we performed cryo electron microscopy (cryo EM) and single particle analysis of 
CSN5H138A (we use the nomenclature CSN#x where # refers to subunit number and x to the 
specific mutation) in complex with neddylated SCFSkp2/Cks1 (the sample is described in 
Enchev et al., 2012) (Figure 2.1A – figure supplements 2.1A–D). The Csn5-H138A mutant 
lacks one of the JAMM ligands that coordinate the catalytic zinc. This mutant forms a 
normal CSN complex that has been extensively characterized (Enchev et al., 2012). We 
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used ~75000 single molecular images for the final three-dimensional reconstruction and 
the structure was refined to a nominal resolution of 7.2 Å, according to the ‘gold standard’ 
criterion of a Fourier shell correlation (FSC) of 0.143 (Rosenthal and Henderson, 2003; 
Scheres and Chen, 2012) (Figure 2.1–figure supplements 2.1C–D). However, some regions 
in the density map were better defined than others (see below). To avoid over-
interpretation, for the subsequent analysis we low-pass filtered the map to 8.5 Å, according 
to the more stringent criterion of an FSC of 0.5. 
The cryo EM structure reported here, alongside the available crystal structure of CSN 
(Lingaraju et al., 2014), enabled us to visualize a broad array of conformational changes 
that take place upon complex formation in both CSN and neddylated Cul1/Rbx1, well 
beyond what was possible with the prior lower resolution model based on negative stain 
EM (Figure 2.1). Specifically, this allowed us to describe movements of the N-terminal 
domains of Csn2 and Csn4, the MPN domains of Csn5 and Csn6. Moreover, in contrast to 
our previous work, we could locate the RING domain of Rbx1, as well as Nedd8 and the 
winged-helix B (WHB) domain of Cul1 relative to Csn5. Nevertheless, the present 
resolution precludes the determination of the exact orientations of the latter domains, but 
notably the relative positions of the RING, WHB, and Nedd8 reported here have not been 
reported in any structural model of a cullin, and strongly suggest that both the enzyme and 
substrate undergo significant conformational rearrangements to enable catalysis. 
To obtain the model shown in Figure 2.1, we initially docked the crystal structure of CSN 
(Lingaraju et al., 2014) and a model of Cul1-Nedd8/Rbx1/Skp1/Skp2/Cks1 (Enchev et al., 
2012) as rigid bodies into the electron density map (Figure 2.1–figure supplements 2.1E–
H). We observed very good matches between the respective map segments and the atomic 
coordinates for the scaffold subunits Csn1, Csn3, Csn7, and Csn8, the winged-helix 
domains of Csn2 and Csn4 (Figure 2.1–figure supplement 2.1E), and the helical bundle 
formed by the C-termini of all eight CSN subunits (Figure 2.1–figure supplement 2.1F) as 
well as the expected recovery of secondary structure at this resolution. Similarly, there was 
a very good overlap between the coordinates of Cul1 (with the exception of helix29 and 
the WHB domain, see below) and Skp1 and the corresponding electron density segments 
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(Figure 2.1–figure supplement 2.1G). However, the local resolution was lower without 
recovery of secondary structure in the N-terminal domain of Cul1. Moreover, the density 
of the substrate receptor Skp2/Cks1 was poorly defined (Figure 2.1–figure supplement 
2.1G), indicating a potential flexibility in this region. Since the presence of Skp1/Skp2 had 
modest effects on the affinity and deneddylation activity (see below), we did not interpret 
this observation further. 
In contrast to the large segments of CSN that were unaltered upon binding substrate, there 
was nearly no overlap between the EM density map and the N-terminal portions of Csn2 
and Csn4, as well as the MPN-domains of Csn5 and Csn6, the RING domain of Rbx1, the 
WHB domain of Cul1, and Nedd8 (Figure 2.1–figure supplement 2.1H). We thus docked 
these domains individually (Figure 2.1B). A Csn2 N-terminal fragment encompassing the 
portion between its crystallographically resolved N-terminus (amino acid 30) through to a 
flexible loop at amino acid 180 was docked as a rigid body (Figure 2.1–figure supplement 
2.1I), positioning it close to the four-helical bundle and helix 24 of Cul1 (Zheng et al., 
2002b). An N-terminal fragment of Csn4, spanning amino acids 1 to 295, which ends in a 
previously reported hinge loop (Lingaraju et al., 2014), was also docked independently as 
a rigid body (Figure 2.1–figure supplement 2.1J). The resulting conformation of Csn4 
resembles a crystal form of Csn4 observed in isolation (Lingaraju et al., 2014). The two N-
terminal helical repeat motifs of Csn4 make contacts with the winged-helix A domain of 
Cul1 (Figure 2.1B and Figure 2.1–figure supplement 2.1J, right hand panel, red arrow and 
green circle). Moreover, these positions of Csn2 and Csn4 delineated a density in the map, 
which could accommodate the RING domain of Rbx1 (Figure 2.1B and Figure 2.1–figure 
supplement 2.1J, right hand panel, black ellipse), with the RING proximal to two conserved 
helices between amino acids 160 and 197 of Csn4 (Figures 2.1B and Figure 2.1–figure 
supplement 2.1K, black arrow) and a loop in Csn2 located between residues 289 and 306. 
The exact orientation of the RING domain awaits a structure at higher resolution. 
To improve the fit of Csn5 and Csn6, we moved their MPN domains as rigid bodies into 
the neighboring map segment of similar shape and dimensions (Figure 2.1–figure 
supplement 2.1L). The local resolution in this region was lower, presumably due to higher 
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flexibility around the catalytic site. Importantly, after docking Csn5, we observed two 
empty neighboring densities (Figure 2.1–figure supplement 2.1L, right hand panel, circles), 
which accommodated the two yet undocked protein components – Nedd8 and the WHB 
domain of Cul1 (Figure 2.1–figure supplement 2.1M). The docking of the latter was 
enabled by allowing helix 29 and the WHB, amino acids 690 to the C-terminus of Cul1, to 
move as a rigid body towards Csn5. However, we did not observe an electron density 
around helix 29 of Cul1, consistent with a structural flexibility in this region. This model 
places the neddylated WHB domain in close binding proximity to the RING domain, as 
well as both INS1 and INS2 of Csn5. The hydrophobic patch of Nedd8 is facing INS1, and 
not the WHB domain, as has been reported for the isolated neddylated C-terminal domain 
of Cul5 (Duda et al., 2008). Similar to the RING domain, we cannot be fully certain about 
the exact orientations of Nedd8 and the WHB domain at the present resolution. 
Nevertheless, to further substantiate this docking, we mutagenized conserved charged 
residues in the INS2 domain of Csn5 as well as the WHB domain, and as expected all of 
these constructs showed reduced catalytic activity in deneddylation assays (Figure 2.1–
figure supplement 2.1N, O).  
We sought orthogonal experimental validation for the molecular docking of the individual 
subunits and domains in the electron density map by performing cross-linking coupled to 
mass spectrometric analysis of the cross-linked peptides (Leitner et al., 2014) following 
the procedure described in (Birol et al., 2014)(Supplemental tables 2.1-2.5). For the cross-
linker used in this study (disuccinimidylsuberate H12/D12), the maximum predicted distance 
between two cross-linked lysine residues is generally accepted to be below ~ 30 Å (Politis 
et al., 2014). As shown in supplementary files 1, out of the 39 high-confidence inter-subunit 
cross-links detected within the CSN5H138A–N8-SCFSkp2/Cks1 complex at a false discovery 
rate (FDR) of 5 percent, the great majority was within regions of modeled atomic structure 
and only six links exhibited a distance larger than 30 Å when	mapped	onto	our	model. 
However, all of these larger-distance links are connected to the flexibly positioned Skp2 
density. Moreover, we further performed similar cross-linking experiments on a number of 
different CSN-CRL complexes, varying the substrate receptor, the cullin, and the 
neddylation state (Supplemental tables 2.1-2.5). All results were consistent with the 
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architecture proposed here for CSN5H138A-N8-SCFSkp2/Cks1. Intriguingly, when taking into 
account cross-links with an FDR of up to 0.25 (Supplemental tables 2.2 and 2.3), we found 
two cross-links that support proximity of K290 in Csn4 and K89 in the RING domain 
(Supplemental table 2.2), as well as K32 in Csn4-NTD and K587 in Cul1, which is in the 
immediate vicinity of the WHA domain of Cul1 (Supplemental table 2.3), as suggested by 
our EM reconstruction. 
Development and validation of an assay to measure binding of CSN to substrate and 
product. 
To understand how the structure of CSN and the CSN–SCF complex relates to substrate 
binding and the mechanism of deneddylation, we sought to develop quantitative binding 
assays to measure interaction of CSN with its substrates and products. To this end, the 
environmentally-sensitive dye dansyl was conjugated to the C-terminus of Cul1 using 
‘sortagging’ (Theile et al., 2013) to generate dansylated Cul1/Rbx1 (Cul1d/Rbx1)(Figure 
2.2–figure supplement 2.2A). Cul1d/Rbx1 exhibited normal E3 activity (Figure 2.2–figure 
supplement 2.2B) and bound CSN with an affinity similar to Cul1/Rbx1 based on their IC50 
values for competitive inhibition of a deneddylation reaction (Figure 2.2–figure 
supplement 2.2C; Emberley et al., 2012). When Cul1d/Rbx1 was incubated with CSN (all 
CSN preparations used in this work are shown in Figure 2.2–figure supplement 2.2D), we 
observed an increase in dansyl fluorescence (Figure 2.2A). This signal was due to specific 
binding because it was chased upon addition of excess unlabeled Cul1/Rbx1 (Figure 2.2A, 
titration shown in Figure 2.2–figure supplement 2.2E) or Cand1 (Figure 2.2–figure 
supplement 2.2F), which competes for substrate deneddylation by CSN (Emberley et al., 
2012; Enchev et al., 2012). Thus, we concluded that the increase in dansyl fluorescence 
accurately reported on the interaction of CSN with Cul1d/Rbx1. Using this assay we 
determined that CSN bound Cul1d/Rbx1 with a Kd of 310 nM (Figure 2.2B). Cul1d/Rbx1 
binding to CSN was only modestly affected by the addition of free Nedd8 (Figure 2.2–
figure supplement 2.2G) or assembly with Skp2/Skp1 (Figure 2.2–figure supplement 2.2H) 
or Fbxw7/Skp1 (Figure 2.2–figure supplement 2.2I).  
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We next sought to measure binding of neddylated Cul1d/Rbx1 (Cul1d-N8/Rbx1) to CSN 
but it was not possible because the substrate was rapidly deneddylated. To circumvent this 
problem, we performed binding assays with the extensively characterized inactive mutant 
CSN5H138A (assay confirming loss of activity is shown in Figure 2.2–figure supplement 
2.2A). Remarkably, CSN5H138A bound Cul1d-N8/Rbx1 ~200-fold more tightly than CSN 
bound Cul1d/Rbx1 (Kd 1.6 nM vs. 310 nM; Figures 2.3A–B). Note that the estimated Kd 
falls well below the fixed concentration of Cul1d-N8/Rbx1 used in the assay. This 
introduces greater uncertainty into our estimate but nevertheless we can conclude with 
confidence that the binding of substrate to CSN5H138A is very tight (≤5 nM; see Materials 
and Methods for further discussion of this matter). As reported above for CSN binding to 
product, addition of Skp2/Skp1 or Fbxw7/Skp1 had comparatively minor effects on affinity 
(Figure 2.3–figure supplements 2.3B–C). Thus, for the sake of simplicity, we used 
Cul1d/Rbx1 heterodimer for the remaining binding experiments.  
The strikingly high affinity we observed for binding of CSN5H138A to Cul1d-N8/Rbx1 led 
us to question whether it was mainly due to Nedd8 or whether the H138A mutation might 
also enhance affinity. To this end, we measured binding of CSN5H138A to Cul1d/Rbx1 and 
observed an unexpectedly low Kd of ~10 nM (Figure 2.3B, Figure 2.3–figure supplement 
3D), which was confirmed with an independent preparation of CSN5H138A (Figure 2.3–
figure supplement 2.3E). Thus, neddylation improved affinity of Cul1d/Rbx1 for 
CSN5H138A by ~6-fold, whereas the Csn5-H138A mutation improved affinity for 
Cul1d/Rbx1 by ~30-fold. The high affinity binding of CSN5H138A to substrate was supported 
by an orthogonal competition experiment in which 100 nM CSN5H138A completely blocked 
deneddylation of 75 nM Cul1-N8/Rbx1 (Figure 2.3–figure supplement 2.3A). We 
considered the possibility that the Csn5-H138A mutation might enable formation of an 
aberrant, super-tight enzyme:substrate ([ES]) complex that does not normally form 
between the wild type proteins. However, as will be described later on, this hypothesis was 
rejected based on kinetic arguments. 
We next sought to determine whether the large differences we observed in Kd values were 
due to differences in kon or koff. Remarkably, despite a 200-fold difference in Kd for 
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CSN5H138A binding to substrate compared to CSN binding to product, the kon values for 
formation of these complexes were nearly identical (2.0 x 107 M-1 sec-1 for CSN–product 
and 2.2 x 107 M-1 sec-1 for CSN5H138A–substrate; Figure 2.3C).  This suggested that the 
difference in affinity was driven by a large difference in koff. To test this hypothesis, we 
directly measured koff values for select [ES] and enzyme-product complexes by pre-forming 
the complex and then adding excess unlabeled Cul1/Rbx1 chase and monitoring the 
reduction in dansyl fluorescence over time (Figure 2.3C and Figure 2.3–figure supplement 
3F-I; for this and a subsequent experiment in Figure 2.4B, we used CSN5E76A/ 5H138A in one 
of the assays instead of CSN5H138A; the double mutant behaved like CSN5H138A in that it 
bound Cul1d/Rbx1 with the same affinity as shown in Figure 2.3–figure supplement 2.3J.). 
Consistent with the predictions from the Kd and kon values, substrate dissociated very 
slowly from CSN5E76A,5H138A, whereas product dissociated ~65-fold faster from CSN. This 
suggests that as substrate is deneddylated to product, its affinity for CSN is strongly 
reduced and its koff speeds up. 
The N-terminal domains of Csn2 and Csn4 and the RING of Rbx1 promote enzyme–
substrate interaction. 
Armed with assays to measure binding and deneddylation of substrate, we next sought to 
test the implications that emerged from our structural analysis of the CSN5H138A–N8-
SCFSkp2/Cks1 complex. First, we investigated the roles of the NTDs of Csn2 and Csn4, both 
of which, upon binding substrate, underwent conformational changes and made contact 
with Cul1 and the RING domain of Rbx1 (Figures 2.1B–C, Figure 2.1–figure supplements 
2.1I–K) (Lingaraju et al., 2014). To measure the effect of these mutations on binding to 
Cul1d-N8/Rbx1, we combined them with Csn5-H138A to prevent deneddylation. Deletion 
of the first 269 amino acids of Csn2, observed to interact with Cul1 but not the RING 
domain of Rbx1, caused a massive loss in binding to substrate (Kd > 1300 nM; Figure 2.3B, 
Figure 2.3–figure supplement 2.3K). Thus, the contact we observed between Csn2-NTD 
and N8-SCFSkp2/Cks1 was critical to formation of the [ES] complex. By contrast, deletion of 
the first 297 amino acids NTD of Csn4 (4∆N), a portion which was observed to form 
interfaces with both Cul1 and the RING domain of Rbx1, had a relatively modest effect; 
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CSN4∆N,5H138A bound Cul1d/Rbx1 and Cul1d-N8/Rbx1 with Kd values of > 750 nM and 20 
nM, respectively (Figure 2.3B, Figure 2.3–figure supplement 2.3L-M).  
In addition to the motions of the Csn2 and Csn4 NTDs, our structural analysis revealed 
formation of substantial interfaces between CSN and the RING domain of Rbx1. To test 
the role of the RING domain in complex formation, we generated both Cul1/Rbx1 and 
Cul1d/Rbx1 in which the RING domain can be deleted by introducing a TEV protease 
cleavage site (Dougherty et al., 1989) after residue 37 of Rbx1 to generate Cul1 (or 
Cul1d)/Rbx1TEV (Figure 2.4A). This was essential, because it would not be possible to 
conjugate Nedd8 to Cul1/Rbx1 expressed as a mutant lacking the RING domain. After 
conjugating Nedd8 to the purified complex, we treated it with TEV protease to remove the 
RING domain, yielding Cul1 (or Cul1d)-N8/Rbx1∆RING (Figure 2.4A). The truncated 
Cul1/Rbx1∆RING was inactive in an ubiquitylation assay (Figure 2.4–figure supplement 
2.4A) but behaved as a monodisperse sample with the expected hydrodynamic radius upon 
size exclusion chromatography (Figure 2.4–figure supplement 2.4B). Notably, Cul1d-
N8/Rbx1∆RING bound CSN5E76A,5H138A and CSN5E76A with affinities (12 nM and 13 nM 
respectively; Figure 2.3B, Figure 2.3–figure supplement 2.3N) similar to that observed for 
binding of wild type Cul1d-N8/Rbx1 to CSN4∆N,5H138A. Given the similar effects of the 
Csn4-∆NTD and Rbx1-∆RING mutations on complex formation, we next tested whether 
their effects arose from loss of the interface that forms between these domains (Figure 2.1–
figure supplement 2.1K). However, double mutant analysis suggested that the Csn4-∆N 
and Rbx1-∆RING mutations had largely independent effects on binding (Figure 2.4B). The 
overall picture that emerged from these studies in light of the structural data is that the 
interaction of Csn2-NTD with neddylated substrate makes a large contribution to binding 
energy, with modest enhancements independently provided by the Csn4-NTD and Rbx1-
RING domains. 
The ‘E-vict’ enables efficient clearance of product from the CSN active site 
The striking difference in the Kd for CSN5H138A binding to substrate compared to CSN 
binding to product suggested that a conformational rearrangement of the [ES] complex 
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occurs upon cleavage of the isopeptide bond, resulting in a large increase in the product 
koff, and thereby preventing the enzyme from becoming product-inhibited. However, we 
were puzzled by the relatively minor impact of Nedd8 on the affinity of Cul1d/Rbx1 for 
CSN5H138A; whereas substrate bound with Kd of 1.6 nM, product binding was only ~6-fold 
weaker (Figure 2.3B). Why, then, did CSN bind so much less tightly to product? We 
reasoned that a key difference between CSN5H138A and CSN is the absence of the active 
site zinc from CSN5H138A, which prevents formation of a stable apo-CSN complex in which 
E104 of the INS1 domain of Csn5 is bound to the active site zinc. If this conjecture is 
correct, it makes the prediction that CSN5E104A, which should also be unable to form stable 
apo-CSN, should likewise exhibit high affinity for product. This was confirmed: CSN5E104 
bound Cul1d/Rbx1 with a Kd of 26 nM (Figure 2.3B, Figure 2.3–figure supplement 2.3O). 
Furthermore, measurement of koff values revealed that product dissociated from CSN5H138A 
and CSN5E104A about 8-fold more slowly than it dissociated from CSN (Figure 2.3C). Based 
on these observations, we propose the ‘E-vict’ hypothesis, which is described in more detail 
in the Discussion. The essence of this hypothesis is that, following cleavage of the 
isopeptide bond and dissociation of Nedd8, INS1 of Csn5 engages the active site zinc. This 
accelerates the rate of dissociation of deneddylated Cul1/Rbx1, thereby preventing CSN 
from becoming clogged with product. We note that Csn5-E76 also contributes to the 
operation of this mechanism, because CSN5E76A bound tightly to product (Figure 2.3–figure 
supplement 2.3P). We speculate that engagement of the active site zinc by Csn5-E104 
forces Csn5-E76 into a configuration that promotes egress of product. Further insights into 
the exact sequence of events that accelerates product dissociation await high-resolution 
structures of CSN bound to Cul1/Rbx1 in various states. 
Kinetic effects of binding-defective mutations on substrate deneddylation 
We next sought to address the effects of the enzyme and substrate mutations described in 
the preceding sections on the deneddylation reaction. We previously showed that CSN2∆N 
has severely reduced catalytic activity (Enchev et al., 2012), which is consistent with the 
binding data reported here. CSN4∆N exhibited a 20-fold defect in substrate cleavage (Figure 
2.5A, Figure 2.5–figure supplement 2.5A). Meanwhile, the kcat for cleavage of Cul1-
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N8/Rbx1∆RING by CSN was reduced by a staggering ~18,000-fold relative to wild type 
substrate (Figures 2.5A–B). Given that the neddylated ∆RING substrate bound to CSN 
with only modestly reduced affinity, we surmised that the principal defect of this mutant 
might be its failure either to induce the activating conformational change in CSN, and/or 
to position accurately the isopeptide bond in the active site. Although we do not have the 
tools to address the latter point, we queried the former by examining the Csn6-∆INS2 
mutation, which partially mimics the effect of substrate binding in that it destabilizes the 
autoinhibited state (Lingaraju et al., 2014). The Csn6-∆INS2 mutation slightly weakened 
binding to wild type product (Figure 2.3B, Figure 2.3–figure supplement 2.3Q) but 
completely suppressed the modest binding defect of the neddylated ∆RING substrate 
(Figure 2.3B, Figure 2.3–figure supplement 2.3R) and promoted an ~8-fold increase in its 
deneddylation rate (Figure 2.5–figure supplement 2.5B). This partial suppression effected 
by Csn6-∆INS2 suggests that the RING domain contributes to the constellation of 
conformational changes in CSN that occur upon substrate binding. Note that the CSN6∆INS2 
enzyme nevertheless exhibited a > 1,000-fold defect towards the Cul1-N8/Rbx1∆RING 
substrate, strongly indicating further functions of the RING domain, which may include a 
potential role in substrate positioning as well. 
A noteworthy feature of the deneddylation reactions carried out with CSN4∆N enzyme or 
∆RING substrate is that although kcat was reduced in both cases, KM was also reduced 
(Figure 2.5A). Whereas these results imply that deletion of the Csn4-NTD or Rbx1-RING 
improved affinity of the [ES] complex, our direct binding measurements indicated this was 
not the case. To understand this apparent paradox, it is essential to consider the kinetic 
behavior of CSN-mediated deneddylation. The formal definition of KM for a deneddylation 
reaction (Equation 1), as stipulated by Briggs and Haldane (Briggs and Haldane, 1925), is: 
KM = (koff + kcat)/kon.. In the special case of Michaelis-Menten kinetics, which is based on 
the assumption that koff is much larger than kcat, the expression simplifies to koff/kon, or Kd. 
Equation 1: Cul1-N8/Rbx1 deneddylation by CSN. The vertical red bar indicates 
the cleaved bond. 
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However, kcat for CSN (~1.1 sec-1) is actually much faster than koff measured for 
dissociation of substrate from the CSN5E76A, 5H138A mutant (0.017 sec-1). The implication of 
this is that almost every binding event between CSN and substrate results in catalysis, and 
KM (200 nM; Figure 2.5A and (Emberley et al., 2012) is much larger than Kd (1.6 nM, 
Figure 2.3B). But, if kcat is reduced by mutation, the Briggs-Haldane equation predicts that 
KM should approach Kd. Indeed, this is exactly what we see for reactions that exhibit 
reduced kcat, including reactions with mutant CSN4∆N enzyme or mutant ∆RING substrate 
(Figure 2.5A). In the slowest reaction (cleavage of Cul1/Rbx1∆RING by CSN) the KM (5 nM) 
is in the same range as the Kd with which this substrate bound to CSN5E76A, H138A (12 nM; 
Figure 2.3B), and approaches the Kd measured for binding of substrate to CSN5H138A (1.6 
nM). This provides strong support for our proposal that the CSN5H138A–Cul1d/Rbx1 
complex is representative of the affinity that develops during normal catalysis.  
Functional significance of Csn5 INS1 in vitro and in cells 
To understand the significance of the E-vict mechansim to CSN function in vitro and in 
cells, we measured the kcat for CSN5E104A and observed that it is 2.5-fold slower than for 
CSN (Figure 2.5A, Figure 2.5–figure supplements 2.5C–E). This was unexpected, because 
it was reported that the Csn5-E104A mutation enhances the catalytic activity of CSN 
towards an unnatural substrate (Lingaraju et al., 2014). Interestingly, a similar reduced rate 
was observed in both single- and multi-turnover reactions, indicating that under our 
specific reactions conditions, the activating conformational changes/chemical step are 
affected at least as much as product dissociation. This may not be the case in cells, where 
substrate receptors and other factors may further stabilize product binding. 
To test if Csn5-E104 contributes to CSN function in vivo, we generated a partial knockout 
of Csn5 in HEK293T cells using CRISPR/Cas9 (Shalem et al., 2014). This cell line 
expressed severely reduced levels of Csn5 and consequently displayed hyper-accumulation 
of Nedd8-conjugated endogenous Cul1 (Figure 2.6A), but retained sufficient protein to 
survive. We introduced either an empty retrovirus or retroviruses coding for Flag-tagged 
wild type or mutant Csn5 proteins into these cells, and then monitored the Cul1 neddylation 
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status by immunoblotting. In contrast to wild type FlagCsn5, cells expressing FlagCsn5-
E104A, H138A, or E76A did not regain a normal pattern of Cul1 neddylation (Figure 
2.6A). The same was observed for Cul2, Cul3, Cul4A, and Cul5 (Figure 2.6–figure 
supplement 2.6A). Consistent with reduced CSN activity, as revealed by increased cullin 
neddylation, Skp2 levels were reduced in cells expressing mutant Csn5 proteins (Figure 
2.6A) (Cope and Deshaies, 2006; Wee et al., 2005). To test whether mutations in the 
catalytic site of Csn5 resulted in increased affinity for Cul1, we immunoprecipitated wild 
type and mutant FlagCsn5 proteins and probed for co-precipitation of endogenous Cul1. In 
addition to the mutants described above, we surveyed a much broader panel of catalytic 
site substitutions to determine whether the results observed in our in vitro experiments were 
specific to the mutations employed or were a general consequence of disrupting the active 
site. As shown in Figure 2.6B, the results were concordant with what was observed in vitro. 
On the one hand, FlagCsn5–H138A retrieved high levels of Cul1-N8. The same was true for 
FlagCsn5 carrying mutations in other core residues of the JAMM domain (e.g. H140 and 
D151) (Cope et al., 2002). On the other hand, FlagCsn5-E104A retrieved high levels of 
unmodified Cul1. We propose that this arises from its ability to bind and deneddylate 
substrate (albeit at a reduced rate), but then remain tightly bound to the product due to loss 
of the E-vict mechanism. 
The unexpected reduction in activity observed for Csn5-E104A both in vitro and in cells 
(Figures 2.5A, 2.6A) suggested that the adjacent residue, T103, may also be important for 
deneddylation. A T103I mutation in Drosophila melanogaster impedes proper interaction 
of photoreceptor neurons with lamina glial cells in the developing brain. If this mutant also 
causes a loss of CSN deneddylase activity, it would explain the recessive nature of this 
mutation in flies (Suh et al., 2002). Indeed, like Csn5-E104A, Csn5-T103I did not restore 
a normal Cul1 neddylation pattern when expressed in Csn5-depleted cells (Figure 2.6C) 
and exhibited low deneddylase activity in vitro (Figures 2.5A, Figure 2.5–figure 
supplement 2.5F). In contrast to CSN5E104A, however, CSN5T103I bound Cul1d/Rbx1 product 
with low affinity, both in vitro (Figure 2.3B, Figure 2.3–figure supplement 2.3S) and in 
cells (Figure 2.6B). Therefore, although CSN5E104A and CSN5T103I both have diminished 
catalytic activity, their defects appear to have distinct molecular bases. To further explore 
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the divergent effects of Csn5-E104A and Csn5-T103I mutations on Cul1 binding, 
HEK293T stably expressing wild type or mutant versions of FlagCsn5 were grown in 
‘heavy’ SILAC medium (wild type), or ‘light’ SILAC medium (mutants). Each mutant 
lysate was individually mixed with wild type lysate, and then subjected to 
immunoprecipitation and SILAC mass spectrometry. Whereas all CSN subunits exhibited 
light:heavy ratios of ~1 (Figure 2.6–figure supplement 2.6B), the FlagCsn5-E104A pull-
down showed elevated levels of all cullins compared to wild type, whereas FlagCsn5-T103I 
pulled down cullins at levels equal to or less than wild type FlagCsn5 (Figure 2.6D). 
2.4 Discussion 
‘Induced fit’ underlies interaction of substrate with CSN and triggers enzyme 
activation 
Figure 2.7 displays a model that incorporates published data and data presented in this 
manuscript. Panels A-C show a schematic view of the structural transitions that occur upon 
substrate binding, and collectively contribute to efficient catalysis, whereas panel D 
provides the rate constants for the deneddylation cycle. We tentatively propose the 
following sequence of events. Free CSN exists in an inactive state in which E104 of Csn5-
INS1 forms a fourth ligand to zinc (Figure 2.7A) (Lingaraju et al., 2014). In this state the 
NTDs of both Csn2 and Csn4 are in “open” conformations relative to the cullin substrate, 
and the MPN domains of Csn5/Csn6 are in a distal position relative to it. Substrate binds 
this state rapidly (Figure 2.7B), likely driven by electrostatic interactions between Cul1 
and Csn2-NTD. This would account for the similar, extremely fast kon values that we 
measured for different combinations of Cul1d/Rbx1 and CSN. Binding of CSN to 
neddylated substrate results in a series of conformational changes in both complexes 
(Figure 2.7B). These include (i) the translocation of the N-terminal helical repeats of Csn2 
towards the CTD of Cul1, (ii) the movement of the NTD of Csn4 towards the RING domain 
of Rbx1 and the WHA domain of Cul1, (iii) the translocation of the MPN domains of Csn5–
Csn6 towards the neddylated WHB domain of Cul1, (iv) movement of the WHB domain 
towards Csn5, (v) the opening of the interface between Nedd8 and the WHB domain, and 
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(vi) the formation of a new interface between Csn5 and Nedd8 probably involving the 
hydrophobic patch of Nedd8 and neighboring residues, as well as a tenuous interface 
between the WHB and the Rbx1 RING domain. Furthermore, although not structurally 
resolved in the present study, movements of Csn5-E76 and E104 towards and away from 
the zinc atom (vii), respectively, probably similar to the conformation reported in (Echalier 
et al., 2013), must occur to enable catalysis. Finally, a series of other unresolved 
movements are likely to be germane including (viii) positioning of the extended C-terminus 
of Nedd8, and the corresponding portion of the WHB domain for catalysis as well as 
contacts between the INS1 and INS2 domains of Csn5 and the WHB domain of Cul1.  
To probe the significance of the conformational changes summarized above, we generated 
and analyzed mutant enzymes. Deletion of Csn2-NTD virtually eliminated substrate 
binding (Figure 2.3–figure supplement 2.3K), suggesting that movement of this domain 
(motion i) enables a high affinity interaction between CSN and neddylated CRLs. 
Meanwhile a mutant lacking Csn4-NTD, CSN4∆N,5H138A, bound Cul1-N8/Rbx1 ~10-fold 
less tightly than CSN5H138A, albeit still with a relatively high affinity (20 nM, Figure 2.3B). 
A similar effect on binding affinity was seen with a substrate lacking the RING domain of 
Rbx1 (Figure 2.3B). Even though the RING and Csn4-NTD domains are adjacent in the 
enzyme-substrate [ES] complex (Figure 2.1), double mutant analysis suggests that they 
make substantially independent contributions to binding energy (Figure 2.4B). 
Interestingly, enzyme assays revealed a much greater effect of deleting the RING than 
deleting the Csn4-NTD, suggesting that the RING domain makes a profound contribution 
to catalysis in a manner that does not depend on its proximity to Csn4-NTD. We do not 
know the extent to which the reduced catalytic rates for these mutants arise from defects in 
enzyme activation versus substrate positioning, but we note that cleavage of ∆RING 
substrate was accelerated by ~8-fold upon deletion of Csn6-INS2, suggesting that at least 
a small part of the problem with this substrate is that it failed to properly trigger activating 
conformational changes in CSN.  
In addition to the movements of individual domains, formation of the [ES] complex is 
accompanied by wholesale translocation of the Csn5 and Csn6 subunits. We suggest that 
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this motion contributes primarily a kcat effect, because deletion of Csn6-INS2, which is 
proposed to facilitate this motion, enhanced kcat but had no noteworthy impact on binding 
to substrate (Figure 2.3B), and removal of Csn5 from the complex did not substantially 
affect CSN assembly with substrate (Enchev et al., 2012). We cannot conclude much about 
the other motions enumerated above, but we note that mutations that are predicted to reside 
near the interface of the Csn5-INS2 and Cul1-WHB domains cause significant reductions 
in substrate deneddylation (Figure 2.1–figure supplements 2.1N–O). In addition, 
reorientation of Nedd8 away from Cul1-WHB and towards Csn5 as predicted here is 
consistent with the prior observation that the hydrophobic patch of Nedd8 recruits UBXD7 
to neddylated CRLs (Besten et al., 2012). Presumably, the conformational changes that 
occur during the activation process are connected in some manner. Interestingly, CSN5E104A 
and CSN6∆INS2 both cleave ubiquitin-rhodamine at 0.04 sec-1 (which is ~6-fold faster than 
wild type CSN), but CSN5E104A,6∆INS2 is yet 5-fold faster (0.2 sec-1) than either single mutant 
(Lingaraju et al., 2014). The activities of the single and double mutants imply that the Csn6-
∆INS2 mutation must destabilize binding of Csn5-E104 to the catalytic zinc, but only in a 
small fraction (≤20%) of complexes. Meanwhile, movements at the Csn4/6 interface must 
do more to the active site than simply disrupt the interaction of Csn5-E104 with the 
catalytic zinc, implying the existence of at least two inputs to CSN activation. Resolving 
how binding of substrate is connected to enzyme activation awaits high-resolution 
structural analyses of the enzyme and substrate in various states.  
A kinetic model for the CSN enzyme cycle reveals an essential role for the E-vict 
mechanism in sustaining rapid catalysis 
Upon formation of an [ES] complex, the conformational changes that occur in both CSN 
and substrate culminate in cleavage of the isopeptide bond that links Nedd8 to cullin. 
Although we don’t know the microscopic rate constants for the various conformational 
changes and bond cleavage, all evidence points to the former being slower than the latter, 
which can occur with k ≥ 6.3 sec-1, based on the kcat for cleavage of N8-CRL4ADDB2 by 
CSN6∆INS2 (Lingaraju et al., 2014). The actual cleavage may be even faster because this 
measurement was made under multi-turnover conditions, in which case product 
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dissociation may have been rate limiting. Regardless, the sum total rate of the activating 
conformational motions plus isopeptide bond cleavage reported here (~1 sec-1) is 
considerably faster than substrate dissociation from CSN5H138A (~0.017 sec-1), indicating 
that CSN conforms to Briggs-Haldane kinetics and essentially every [ES] complex that 
forms proceeds to cleavage, the physiological implications of which are considered in the 
next section.  
Cleavage of the isopeptide bond initiates a series of events leading to product release. 
Removal of Nedd8 increases dissociation of Cul1/Rbx1 by ~7-10 fold. We propose that 
dissociation of the cleaved Nedd8 also removes an impediment to Csn5-INS1, which can 
now bind the catalytic site zinc via E104 to return CSN to its apo state. This engagement, 
which we refer to as the ‘E-vict’ mechanism, is a critical step in what is likely to be a series 
of conformational rearrangements that include repositioning of Csn5-E76. Collectively, 
these movements reduce the affinity of CSN for product and accelerate its rate of 
dissociation by an additional order of magnitude. The removal of Nedd8 and E-vict 
together bring about an ~100-fold loss in affinity of Cul1/Rbx1 for CSN. The slow 
dissociation of product from CSN mutants that were unable to undergo E-vict (0.12-0.16 
sec-1; Figure 2.3C) suggests that this mechanism is important for maintaining physiological 
rates of CRL deneddylation. This is further supported by the observation that Csn5-E104A, 
but not wild type Csn5, co-precipitates substantial amounts of deneddylated Cul1 from 
cells (Fig. 2.6B). Slow clearance of product could explain, in part, the failure of this mutant 
to complement a Csn5 deficiency (Fig. 2.6A). The E-vict mechanism presents an elegant 
solution to a fundamental challenge facing enzymes: how to achieve high specificity 
without compromising rapid turnover. 
We note that the product koff for Cul1d/Rbx1 (1.1 sec-1) is similar to the kcat we measured 
for both single- and multi-turnover reactions. This suggests that depending on the exact 
structure of the neddylated CRL substrate, the rate-limiting step may vary from one 
deneddylation reaction to another. Regardless, our biochemical and cell-based data suggest 
that if the E-vict mechanism did not exist, product dissociation would become the Achilles 
heel of deneddylation reactions. 
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CSN in its cellular milieu 
The kinetic parameters reported here coupled with quantitative measurements of protein 
concentrations by selected reaction monitoring mass spectrometry ((Bennett et al., 2010) 
and J.R. and R.J.D., unpublished data) allow a preliminary estimate of the steady-state 
distribution of CSN in cells. The total cullin concentration in the 293T cell line used in this 
work is ~2200 nM. Meanwhile, the CSN concentration is ~450 nM. Although the total 
amount of Nedd8-conjugated cullins was not measured, immunoblot data suggest that 
~1000 nM is a reasonable estimate. The Kd reported here for the [ES] complex (~2 nM), 
thus predicts potentially near-complete saturation of the cellular CSN pool with neddylated 
cullins. This implies that formation of new [ES] complexes is limited by the slowest step 
in the catalytic cycle, i.e. either the conformational rearrangements or product dissociation. 
In vitro, CSN follows Briggs-Haldane kinetics and cleaves Nedd8 off nearly every 
neddylated CRL that it binds. Because CSN is not in equilibrium with its substrates in our 
simplified in vitro system, it cannot rely on differences in substrate Kd to achieve 
specificity. Thus, differences in koff on the order of ≤10-fold, which might occur with 
different cullins or substrate adaptors, would be predicted to have minimal effects on 
catalytic efficiency provided that kon remains roughly the same, as was observed for 
different configurations of substrate and product in this study. Importantly, this parameter 
can potentially be profoundly altered by ubiquitylation substrates, E2 enzyme, or other in 
vivo binding partners of Nedd8-conjugated CRLs, which compete with CSN (Emberley et 
al., 2012; Enchev et al., 2012; Fischer et al., 2011b) and thus should reduce its apparent 
kon. It is also conceivable that binding partners might alter the partitioning of the CSN–N8-
CRL complex either by increasing koff and/or reducing kcat, such that N8-CRL bound to an 
ubiquitylation substrate dissociates prior to completion of the conformational 
rearrangements that culminate in its deneddylation.  
Based on measurements reported here, it is likely that CSN complexes in cells are 
constantly undergoing catalysis, dissociating rapidly from product, and rebinding other 
CRLs on the time-scale of a few seconds or less. Consistent with this picture, addition of a 
Nedd8 conjugation inhibitor to cells leads to nearly complete disappearance of neddylated 
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cullins within 5 minutes, and this does not account for the time it takes the drug to 
equilibrate across the membrane and deplete the cellular pool of Nedd8~Ubc12 thioesters 
(Soucy et al., 2009). The dynamic properties of CSN measured here reveal a CRL network 
of extreme plasticity that can be reconfigured in minutes to respond to changing regulatory 
inputs. Although quantitative studies of CRL network dynamics remain in their infancy, it 
is evident that the tools are at hand to begin to understand how these remarkable enzymes 
function and are regulated within cells. 
2.5 Materials and Methods 
Cloning. All eight wild type CSN subunits were cloned into a single pFBDM baculovirus 
transfer MultiBac vector (Berger et al., 2004). His6-Csn5 was inserted into the first multiple 
cloning site (MCS1) of a pFBDM vector using NheI/XmaI and Csn1 was put into MCS2 
of the same vector with BssHII/NotI. Similarly, Csn2 was inserted into a second pFBDM 
vector using BssHII/NotI and StrepII2x-Csn3, containing an N-terminal PreScission-
cleavable StrepII2x-tag, using NheI/XmaI. From this plasmid the Csn2/StrepII2x-Csn3 gene 
cassette was excised out with AvrII/PmeI and inserted into pFBDMCsn1/His6Csn5, whose 
multiplication module had been linearized with BstZ17I and SpeI, yielding pFBDMCsn1/His6-
Csn5/Csn2/StrepII2x-Csn3. A pFBDMCsn4/Csn7b vector was generated using BssHII/NotI to insert 
Csn4 and NheI/XmaI for Csn7b, and the resultant gene cassette was inserted into linearized 
pFBDMCsn1/His6-Csn5/Csn2/StrepII2x-Csn3, resulting in pFBDMCsn1/His6-Csn5/Csn2/StrepII2x-Csn3/Csn4/Csn7b. 
Finally, a pFBDMCsn6/Csn8 vector was generated using BssHII/NotI for Csn6 and 
NheI/XmaI for Csn8 insertion. Once again the resultant gene cassette was inserted into 
linearized pFBDMCsn1/His6-Csn5/Csn2/StrepII2x-Csn3/Csn4/Csn7b, yielding the full wild type CSN 
vector pFBDMCsn1/His6-Csn5/Csn2/StrepII2x-Csn3/Csn4/Csn7b/Csn6/Csn8. A similar cloning strategy was 
applied for the generation of CSN5E76A, CSN5E76A, H138A, CSN5E212R, D213R, and CSN4∆N1-297, 
except that site-directed mutageneses were performed on pFBDMCsn1/His6Csn5 and 
pFBDMCsn4/Csn7b respectively. CSN5E104A and CSN5T103I were generated with the same 
general approach, except that that site-directed mutagenesis and sequence validation were 
performed on a pCRIITOPO plasmid (Invitrogen) containing StrepII2x-Csn5. Those 
mutants were then ligated into a MCS1 linearized pFBDMCsn1 plasmid. For the production 
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of CSN6∆Ins2 we used co-expression from two separate viruses. To this end we applied site-
directed mutagenesis on the pFBDMCsn6/Csn8 vector to delete amino acids 174-179 in Csn6, 
generating pFBDMCsn6∆Ins2/Csn8. The gene cassette of the latter was excised out using 
AvrII/PmeI and inserted into BstZ17I/SpeI linearized pFBDMCsn4/Csn7b, yielding 
pFBDMCsn4/Csn7b/Csn6∆Ins2/Csn8. The resultant bacmid was used together with a bacmid 
generated from pFBDMCsn1/His6-Csn5/Csn2/StrepII2x-Csn3 in order to generate two baculoviruses, 
which were used for co-infection to generate CSN6∆Ins2. An analogous strategy was applied 
to generate CSN4∆N/6∆Ins2, CSN5H138A/6∆Ins2, and CSN5H138A/4∆N. 
The TEV site in Rbx1 as well as mutations in the WHB domain of Cul1 were obtained by 
site-directed mutagenesis on the pFBDM-Cul1/Rbx1 vector described in (Enchev et al., 
2010), which further contained a C-terminal sortase tag described in the next section. 
Cloning of Cul3/Rbx1 used in the crosslinking/mass spectrometry experiments, Nedd8-
pro-peptide-StrepII2x and StrepII2x-Den1 are described in (Orthwein et al., 2015). 
Recombinant bacmid and virus generation as well as protein expression proceeded as 
described in (Enchev et al., 2012). All genes were validated by sequencing as wild type or 
mutant. 
Protein Purification and modifications. CSN and its mutant forms were purified as 
described in (Enchev et al., 2012). Nedd8-activating and conjugating enzymes were 
purified as described in (Emberley et al., 2012; Enchev et al., 2012). Fluorescently-labeled 
Cul1 substrates were conjugated with untagged Nedd8. Cul1-sortase was designed with 
GGGGSLPETGGHHHHHH inserted after the final amino acid of Cul1 into the pGEX 
vector described in (Emberley et al., 2012). All sortase reactions were done at 30 °C 
overnight with 30 µM Cul1/Rbx1, 50 µM Sortase and 250 µM GGGGK-dansyl in 50 mM 
Tris pH 7.6, 150 mM NaCl and 10 mM CaCl2 and purified by size exclusion 
chromatography to yield Cul1d/Rbx1. Cul1d/Rbx1 was neddylated and purified as in 
(Emberley et al., 2012) to yield Cul1d-N8/Rbx1. Cand1 and Sortase were purified as 
described in (Pierce et al., 2013). Production of Cul1/Rbx1 and Cul3/Rbx1 baculovirus 
constructs used for electron microscopy and crosslinking mass spectrometry, bacterial 
split-and-co-express Cul1/Rbx1∆RING, Nedd8 with native N- and C-termini, used for 
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electron microscopy and crosslinking mass spectrometry and for the experiments involving 
Cul1/Rbx1TEV, Den1 as well as the respective preparative neddylation were performed as 
described in (Enchev et al., 2012; Orthwein et al., 2015). Den1 was used in 1:50 ratio for 
10 min at 25 °C to remove poly-neddylation. Cul1/Rbx1 complexes with mutations in the 
WHB domain of Cul1 (Figure 2.1–figure supplement 2.1N, O) and Cul1/Rbx1TEV∆RING 
were purified from High Five insect cells as described in (Enchev et al., 2010). Dansylation 
of Cul1/Rbx1 variants expressed in insect cells was performed for 8 to 12 h at 30 °C while 
spinning at 5000 g, and purified by passing the dansylation reaction through a 5 ml HisTrap 
FF column (GE Healthcare) in 50 mM Tris-HCl, pH 7.6, 400 mM NaCl, 20 mM imidazole. 
The Cul1d/Rbx1-containing flow through was concentrated, neddylated (if required), and 
further purified over a Superdex 200 size exclusion column (GE Healthcare) equilibrated 
with 15 mM HEPES, pH 7.6, 150 mM NaCl, 2 mM DTT, 2 % (v/v) glycerol. Neddylation 
of Cul1/Rbx1TEV∆RING was performed at 25 °C for 12-14 h in 50 mM Tris-HCl, pH 7.6, 
100 mM NaCl, 2.5 mM MgCl2, 150 µM ATP, spinning at 2000 g, and was followed by 30 
min incubation with 1:50 (w/w) Den1 to remove poly-neddylation. The reaction was 
purified over a Strep-Tactin Superflow Cartridge (QIAGEN), and eluted in 15 mM HEPES, 
pH 7.6, 250 mM NaCl, 2 mM DTT, 2 % (v/v) glycerol, 2.5 mM d-desthiobiotin. RING 
cleavage was performed for 12-14 hours at 25 °C, spinning at 2000 g, in the presence of 
100 mM EDTA, pH 8 and 1:1 (w/w) TEV. Dansylation proceeded as described above. 
Deneddylation Assays. All deneddylation assays were performed in a buffer containing 25 
mM Tris-HCl, pH 7.5, 100 mM NaCl, 25 mM trehalose, 1 mM DTT, 1 % (v/v) glycerol, 
0.01 % (v/v) Triton X-100 and 0.1 mg/ml ovalbumin or BSA. Radioactive deneddylation 
reactions with bacterially expressed substrates were done as described (Emberley et al., 
2012). Radioactive deneddylation reactions with substrates expressed in insect cells were 
performed at 24 °C with 0.5 nM CSN (Figure 2.2–figure supplement 2.2C) or 2 nM CSN 
(Figure 3.5B).  All remaining radioactive deneddylation reactions were performed with 
bacterially expressed Cul1-N8/Rbx1 substrates (50 nM) and 2 nM CSN unless otherwise 
noted. Single-turnover reactions were done with 25 nM Cul1 substrates and 1 µM CSN on 
a Kintek RQF-3 Rapid Quench Flow at 24 °C. Single-turnover data were fit to one phase 
decay function: Y=(Y0 - EP)*exp(-kcat*X) + EP (where EP corresponds to reaction end 
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point value), to determine the kcat. Deneddylation assays in Figure 3.1–figure supplement 
3.1N, O were performed with 800 nM substrate and 20 nM enzyme and visualized by 
Coomassie stain. Depending on the exact protein preparations used and the laboratory, we 
observed rates for the wild type reaction ranging from 1.1-2.6 sec-1. 
Fluorescence Assays. All assays were performed in a buffer containing 30 mM Tris pH 
7.6, 100 mM NaCl, 0.25 mg/ml ovalbumin or BSA and 0.5 mM DTT with 30 nM dansyl-
labeled Cul1/Rbx1 and titrated concentrations of CSN. The mixtures were allowed to reach 
equilibrium by incubation at room temperature for ~ 10 minutes prior to measurements. 
Equilibrium binding assays using Cul1/Rbx1 variants expressed in insect cells (Figure 2.2, 
Figure 2.2–figure supplement 2.2E, Figure 2.3–figure supplement 2.3N, 2.3R, Figure 2.4B) 
were read at 530 nm on a CLARIOstar plate reader (BMG Labtech) in 384-well plates 
(Corning, low flange, black, flat bottom), 90 ul per well, while binding assays using 
bacterially expressed Cul1/Rbx1 variants were performed on a Fluorolog-3 (Jobin Yvon) 
(all other binding data figures). Binding assay with Cul1d-N8/Rbx1 (substrate) and 
CSN5E76A were allowed to equilibrate for only 45 seconds, because although this mutant 
exhibited an ~300-fold decrease in activity (data not shown) the residual activity was high 
enough to cause substantial deneddylation in a 10 minute incubation. It should be noted 
that several of the Kd values reported for CSN binding to Cul1d-N8/Rbx1 or Cul1d/Rbx1 
are below the concentration of the dansylated ligand (30 nM). While this is generally not 
the preferred approach, we found that 30 nM was the lowest concentration that consistently 
yielded highly reproducible results. The estimated Kd is very sensitive to the density of data 
points at the inflection point of the curve, and thus these estimates can be more prone to 
error. Nevertheless, different investigators in Zurich and Pasadena have consistently 
obtained an estimate of 1.6-5 nM for binding of CSN5H138A to Cul1d-N8/Rbx1 and of 9-13 
nM for binding to CSN5H138A to Cul1d/Rbx1, using different protein preparations. To 
estimate Kd, all data points were fitted to a quadratic equation, Y = Y0+(Ymax-
Y0)*(Kd+A+X-sqrt((Kd+A+X)^2-4A*X))/2*A where A equals concentration of labeled 
protein, using Prism (Graph Pad). On-rate and off-rate measurements were performed on 
a Kintek Stopped-flow SF-2004 by exciting at 340 nM and collecting emissions through a 
520 +/- 20 nm filter. For off-rate measurements, the concentrations of proteins used in each 
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reaction are provided in the legend of Figure 3–figure supplements 3F–I. Off rate data were 
fit to one phase decay function: Y=(Y0 - EP)*exp(-koff*X) + EP (where EP corresponds to 
reaction end point value).Whereas Kd, on-rate, and off-rate measurements with different 
configurations of Cul1 or different CSN mutants are directly comparable, off-rate 
measurements are not directly comparable to kcat measurements and may differ from 
expectation by a few fold because different buffers were used, the Cul1/Rbx1 preparations 
were from different sources (bacterial for kcat, baculoviral for koff), and the Cul1/Rbx1 
preparations carried different labels (dansylated Cul1 for koff, [32P]-Nedd8 for kcat.  
Cell Culture and SILAC Mass Spectrometry.  Cells were grown in Lonza DMEM 
containing 10% FBS (Invitrogen). Transient transfections were done with FugeneHD per 
the manufacturers instructions (Roche). Flag-tagged CSN5 coding sequences were cloned 
into a modified MSCV-IRES-GFP vector (containing a pBabe multiple cloning site) via 
BamHI and EcoRI. Lenti-CRISPR constructs were made as described (Shalem et al., 2014) 
using the targeting sequences 5’- CACCGCTCGGCGATGGCGGCGTCC - 3’ and 3’ - 
AAACGGACGCCGCCATCGCCGAGC - 5’. Lenti- and retroviruses were produced in 
293T cells and the supernatant subsequently used for transduction to establish stable cell 
lines. For Western Blot analysis cells were directly lysed in 2X SDS sample buffer. Lysates 
were sonicated for 15 seconds at 10 % of maximum amplitude using a Branson Digital 
Sonifier and boiled for 10 minutes at 100 ºC. SILAC labeling was in Invitrogen DMEM 
containing 10% FBS and 13C615N2-lysine and 13C6-arginine from Cambridge Isotope 
Laboratory. For immunoprecipitations, cells were lysed in Pierce Lysis Buffer containing 
cOmplete Protease Inhibitor Cocktail (Roche) and lysates were sonicated for 10 seconds at 
10 % of maximum amplitude using a Branson Digital Sonifier. After a 5 minute clearing 
at 18000 x g at 4°C, proteins were immunoprecipitated with M2 Flag agarose beads 
(Sigma) for 30 minutes and prepared for mass spectrometry as described in (Pierce et al., 
2013) Samples were analyzed using an EASY-nLC 1000 coupled to an Orbitrap Fusion 
and analyzed by MaxQuant (v 1.5.0.30).  
Digested peptides (250 ng) were loaded onto a 26-cm analytical HPLC column (75 µm ID) 
packed in-house with ReproSil-Pur C18AQ 1.9 µm resin (120 Å pore size, Dr. Maisch, 
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Ammerbuch, Germany). After loading, the peptides were separated with a 120 min gradient 
at a flow rate of 350 nL/min at 50°C (column heater) using the following gradient: 2-6% 
solvent B (7.5 min), 6–25% B (82.5 min), 25-40% B (30min), 40-100% B (1min), and 
100% B (9 min) where solvent A was 97.8% H2O, 2% ACN, and 0.2% formic acid) and 
solvent B was 19.8% H2O, 80% ACN, and 0.2% formic acid. The Orbitrap Fusion was 
operated in data-dependent acquisition (DDA) mode to automatically switch between a full 
scan (m/z=350–1500) in the Orbitrap at 120,000 resolving power and a tandem mass 
spectrometry scan of Higher energy Collisional Dissociation (HCD) fragmentation 
detected in ion trap (using TopSpeed). AGC target of the Orbitrap and ion trap was 400,000 
and 10,000 respectively.  
SILAC MS data analysis. Thermo RAW files were searched with MaxQuant (v 1.5.3.8) 
(Cox and Mann, 2008; Cox et al., 2011). Spectra were searched against human UniProt 
entries (91 647 sequences) and a contaminant database (245 sequences). In addition, 
spectra were searched against a decoy database (generated by reversing the target 
sequences) to estimate false discovery rates. Trypsin was specified as the digestion enzyme 
with up to two missed cleavages allowed. Variable modifications included oxidation of 
methionine and protein N-terminal acetylation. Carboxyamidomethylation of cysteine was 
specified as a fixed modification. SILAC was specified as the quantitation method with 
Arg6 and Lys8 specified as the heavy labeled amino acids. Precursor mass tolerance was 
less than 4.5 ppm after recalibration and fragment mass tolerance was 0.5 Da. False 
discovery rates at the peptide and protein levels were less than 1% as estimated by the 
decoy database search. Ratios were calculated for proteins quantified in at least two of the 
four biological replicates. 95% confidence intervals and adjusted p-values were calculated 
using the R package limma (Ritchie et al., 2015). 
Cross-linking coupled to mass spectrometry (XL-MS).  Chemical cross-linking of purified 
complexes was performed using DSS H12/D12 (Creative Molecules) as cross-linking agent 
and as previously described(Birol et al., 2014). Subsequent MS analysis and cross-link 
assignment and detection were carried out essentially as described (Leitner et al., 2014) on 
an Orbitrap Elite (Thermo Scientific) using the xQuest/xProphet software pipeline. 
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Western Blot Analysis. Proteins were separated by SDS-PAGE gel electrophoresis and 
transferred to a nitrocellulose membrane by wet blot. Primary antibodies used for detection 
were: anti-CSN5 mouse monoclonal Santa Cruz Biotechnology sc-393725, anti-Cul1 
mouse monoclonal Santa Cruz Biotechnology sc-17775, anti-Cul2 rabbit polyclonal 
Thermo Scientific #51-1800, anti-Cul3 rabbit polyclonal Cell Signaling #2769, anti-Cul4A 
rabbit polyclonal Cell Signaling #2699, anti-Cul5 rabbit polyclonal Bethyl Laboratories 
A302-173A, anti-β-actin mouse monoclonal Sigma A5316, and anti-GFP mouse 
monoclonal Clontech #632381. 
Sample preparation for electron microscopy and data collection. CSN5H138A-SCF-
Nedd8Skp2/Cks1samples for cryo-electron microscopy were generated by pre-incubating the 
purified components as described in (Enchev et al., 2012) and ran over a Superose 6 
increase 3.2/300 column (GE Healthcare) at 4 °C, eluting 50 µl fractions in 15 mM HEPES, 
pH 7.6, 100 mM NaCl, 0.5 mM DTT. The sample was kept on ice and its homogeneity and 
mono-dispersity from the peak elution was immediately confirmed by visualization in 
negative stain. For cryo EM preparation, the sample was diluted to 0.1 mg/ml and 2 µl were 
applied to Quantifoil grids (R1.2/1.3 Cu 400 mesh), freshly coated with an extra layer of 
thin carbon and glow-discharged for 2 min at 50 mA and 0.2 mbar vacuum. The grids were 
manually blotted to produce a thin sample film and plunge-frozen into liquid ethane. Data 
were collected automatically using EPU software in low dose mode on a Titan Krios 
transmission electron microscope, equipped with a Falcon II direct electron detector (FEI), 
and operated at 300 kV, an applied nominal defocus from -2.5 to - 5.0 µm in steps of 0.25 
µm, and 80,460-fold magnification, resulting in a pixel size of 1.74 Å on the sample scale. 
Images were collected as seven separate frames with a total dose of 25 e-/Å2. 
Electron microscopy data analysis. CTF-estimation and subsequent correction were 
performed using RELION (Scheres, 2012) and CTFFIND3 (Mindell and Grigorieff, 2003). 
All micrographs were initially visually inspected and only those with appropriate ice 
thickness as well as Thon rings in their power spectra showing regularity and extending to 
6 Å or beyond were used for subsequent analysis. In order to generate 2D references for 
automated particle selection, ~ 4,000 single particles were manually picked and subjected 
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to 2D classification in RELION. Six well-defined 2D class averages were selected, low-
pass filtered to 35 Å to prevent reference bias, and used as references. Approximately 
150,000 single particles were automatically selected and subjected to reference-free 2D 
and 3D classification, in order to de-select the particles, which resulted in poorly defined 
or noisy averages. Approximately half of these single particles resulted in a well-defined 
3D class average, which resembled the previously published negative stain EM map of the 
same complex (Enchev et al., 2012). This dataset was subject to 3D auto-refinement in 
RELION, using a version low-pass filtered to 50 Å as an initial reference. The converged 
map was further post-processed in RELION, using MTF-correction, FSC-weighting, and a 
soft spherical mask with a 5-pixel fall-off.  
Modeling, docking, and visualization. Csn7b was modeled using Csn7a as a template on 
the Phyre2 server (Kelley et al., 2015) and the modeled coordinates were aligned to Csn7a 
in PDB ID 4D10 (Lingaraju et al., 2014), effectively generating a CSN atomic model for 
the Csn7b-containing complex. Model visualization, molecular docking, distance 
measurements, and morph movie generation were performed with UCSF Chimera 
(Pettersen et al., 2004).  
Accession codes. The cryo electron microscopy density map of CSNCsn5H138A-SCF-
Nedd8Skp2/Cks1 will be deposited prior to publication in the Electron Microscopy Data Bank 
under accession code EMD###. 
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2.6 Figures and Supplemental Figures 
Figure 2.1. Cryo-electron microscopy of a CSN-SCF complex. (A) Molecular model of CSN5H138A-SCF-
N8Skp2/Cks1 docked into the cryo-electron density map (gray mesh). (B) Close-up view of the model, showing 
the observed conformations of Csn2, Csn4, Rbx1, Csn5/6, and WHB-Nedd8 and (C) a cartoon representation 
of the differences between the apo CSN and substrate-bound state. 
  
Figure 2.1 
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Figure 2.2 
Figure 2.2. Development and validation of a binding assay for CSN–Cul1/Rbx1 interaction. (A) 
Equilibrium binding of CSN to Cul1d/Rbx1 and competition by unlabeled Cul1/Rbx1. The indicated proteins 
were mixed and allowed to equilibrate prior to determination of dansyl fluorescence in a fluorometer. Note 
that Cul1/Rbx1 blocks the fluorescence enhancement caused by CSN. CSN, Cul1d/Rbx1, and Cul1/Rbx1 
were used at 350, 30, and 4000 nM, respectively. (B) Equilibrium binding of CSN to Cul1d/Rbx1. 
Cul1d/Rbx1 (30 nM) was mixed with increasing concentrations of CSN and the proteins were allowed to 
equilibrate prior to determining the change in dansyl fluorescence in triplicate samples. Error bars represent 
standard deviation. 
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Figure 2.3. Quantitative determination of enzyme–substrate binding affinities for wild type and mutant 
proteins. (A) Tight binding of CSN5H138A to substrate. Cul1d-N8/Rbx1 and CSN5H138A were mixed and 
allowed to equilibrate prior to determining the change in dansyl fluorescence. (B) Summary of Kd 
measurements for the indicated CSN complexes tested against unmodified Cul1d/Rbx1, Nedd8-conjugated 
Cul1d-N8/Rbx1 or Cul1d-N8/Rbx1∆RING ligand. Boxes shaded in gray indicate combinations that could 
not be analyzed due to deneddylation during the binding reaction. For some complexes that bound weakly it 
was not feasible to titrate to saturation and so a lower boundary for Kd is indicated. N.D., not determined. *, 
due to the configuration of our assay, extremely low Kd values cannot be reliably determined. (C) Summary 
of kon and koff measurements for the indicated CSN complexes tested against Cul1d/Rbx1 or Cul1d-
N8/Rbx1. Each reported koff is the mean of at least 8 replicates.   For comparison, koff values calculated 
from kon and Kd measurements are also shown.  For cases where kon was not measured (marked with 
asterisks) we assumed a value that was the average (1.83 x 107 M-1 sec-1) of the three measured kon values. 
Boxes shaded in gray indicate combinations that could not be analyzed due to deneddylation upon complex 
formation. N.D., not determined. 
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Figure 2.4. The N-terminal domains of Csn2 and Csn4 and the RING domain of Rbx1 play key roles 
in substrate binding and deneddylation. (A) Generation of Cul1-N8/Rbx1∆RING. Top: a TEV protease site 
was engineered between the N-terminal b-strand and the RING domain of Rbx1 as indicated. Only the first 
50 amino acids of Rbx1 are shown. Bottom: Purified protein was subjected to the indicated treatments (see 
Materials and Methods for details) and reactions were fractionated by SDS-PAGE and stained with 
Coomassie Blue. (B) Deletion of the Csn4-NTD and Rbx1-RING domains independently reduce affinity of 
CSN for substrate. The indicated proteins were mixed and allowed to equilibrate prior to determining the 
change in dansyl fluorescence in triplicate samples. Error bars represent standard deviation. Kd values 
measured in this experiment are also reported in Figure 3B. 
  
Figure 2.4 
C h a p t e r  2  
 
4 6  
Figure 2.5. The N-terminal domains of Csn2 and Csn4 and the RING domain of Rbx1 are important 
for CSN-mediated deneddylation. (A) Summary of kinetic parameters for the indicated CSN mutants in 
multi- or single-turnover deneddylation reactions with Cul1-N8/Rbx1 or Cul1-N8/Rbx1∆RING substrate.	Note	that	there	may	be	modest	discrepancies	between	these	kcat	values	and	koff	values	due	to	differences	in	assay	configurations	as	described	in	Materials	and	Methods. The ∆RING substrate used here and in panel 
B contains the sortase sequence at the C-terminus of Cul1 that was used for generation of dansylated Cul1.  
Control experiments revealed that this tag, with or without dansylation, reduced kcat by ~4-fold. In addition 
the wild type control for the ∆RING reaction exhibited kcat of 2.6 sec-1. The rates shown have been 
correspondingly adjusted to normalize them to other rates reported here. *, This rate is estimated from Figure 
5–figure supplement 5B. (B) Kinetic analysis of deneddylation of Cul1-N8/Rbx1∆RING by CSN.  
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Figure 2.6. Functional analysis of Csn5 active site and INS1 mutants in biochemical and cellular assays. 
(A) Csn5-E104 is important for CSN function in cells. CSN5 alleles in HEK293T cells were partially knocked 
out (KO) by CRISPR/Cas9 to yield a major decrease in Csn5 that was nonetheless compatible with viability. 
Wild type and the indicated Flag-tagged CSN5 mutants were reintroduced by transduction of recombinant 
retroviruses that co-expressed GFP. Lysates of transduced cells were separated by SDS-PAGE and blotted 
with antibodies to the indicated proteins.  CSN5 long refers to a long exposure of the Csn5 blot, captured to 
reveal residual Csn5 in the knock-out cells. # refers to transduced FlagCsn5 and * refers to endogenous Csn5. 
(B) Any mutation of a core JAMM domain residue in Csn5 results in enhanced binding to Cul1. Same as 
(A), except additional Csn5 mutants were tested and the cell lysates were immunoprecipitated with anti-Flag 
and the immunoprecipitates were blotted for the indicated proteins. (C) Csn5-T103 is important for CSN 
function in cells. Same as (A) except that the Csn5-T103I mutant was analyzed in parallel with Csn5-E104A 
and wild type. (D) SILAC mass spectrometry of endogenous proteins bound to FlagCsn5-E104A or FlagCsn5-
T103I, relative to wild type FlagCsn5. Cells expressing mutant and wild type FlagCsn5 proteins were grown in 
light and heavy medium, respectively. L:H ratios >1 indicate higher recovery of the listed protein from cells 
expressing mutant FlagCsn5, whereas ratios <1 indicate higher recovery from cells expressing wild type 
FlagCsn5. Gray bars: FlagCsn5-E104A; black bars: FlagCsn5-T103I. Error bars represent the 95% confidence 
interval as calculated by limma (Smyth). Each protein was quantified in at least two of the four biological 
replicates and error bars represent standard deviations. Ratios indicated by * differed significantly from 1.0 
(p<0.05). For CSN, only Csn5 is shown; the remainder is shown in Figure 6–figure supplement 6B. 
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Figure 2.7. Structural and kinetic models for CSN activation and the CSN enzyme cycle. (A-C) 
Proposed conformational changes that precede substrate cleavage. (D) Kinetic model for the deneddylation 
cycle. Substrate cleavage is indicated by the slash between N8 and SCF. The asterisk denotes the activated 
form of CSN. Numbers in red, black, green, and blue represent koff (sec-1), kon (M-1 sec-1), kcat (sec-1), and 
conformational change (sec-1) rates, respectively. For rates >1, the actual rate has not been measured but it is 
inferred to be >1 sec-1 because the overall rate for multiturnover catalysis is at least 1.1 sec-1 and thus all sub-
steps must be at least this fast. The koff of SCF from CSN varied depending upon whether the rate was 
measured directly or inferred from Kd and kon (see Fig. 3C). The arrow connecting CSN and N8-SCF•CSN* 
combines two separate steps: binding of N8-SCF to CSN, and activation of CSN to CSN*.  
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Figure supplement 2.1. Cryo-electron microscopy and single particle analysis of a CSN5H138A-N8-
SCFSkp2/Cks1 complex. (A) A representative cryo-electron micrograph of a CSN5H138A-N8-
SCFSkp2/Cks1 complex with some single molecular views indicated by white circles (left) and a power 
spectrum indicating Thon rings reaching 6 Å (right). Scale bar is 200 Å. (B) Representative two-dimensional 
class averages from the curated dataset, used for the subsequent analysis. Scale bar is as in (A). (C) Surface 
Figure Supplement 2.1 J-O 
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views of the final, post-processed cryo-electron map. (D). Resolution estimate according to the FSC criteria 
of 0.143 and 0.5. (E) Fit of the PCI-domain containing CSN subunits in the cryo-electron density map. 
Csn1,3,7, and 8 match the density very well but the N-terminal domains of Csn2 and Csn4 do not, but their 
winged-helix domains fit well. The horseshoe arrangement of the six winged-helix domains is indicated with 
a dotted black line. (F) All the C-terminal helices of the CSN subunits match well the electron density map. 
(G) Fit of SCF in the electron density map. (H) Same view as in Fig 1B but prior to flexible docking of the 
N-terminal domains of Csn2 and Csn4, the MPN domains of Csn5&6, the WHB domain of Cul1, and Nedd8. 
(I) Movement of the N-terminus of Csn2 from its crystallographically-determined position (left) into the EM 
density map (right). (J) Movement of the N-terminus of Csn4 from its crystallographically-determined 
position (left) into the EM density map (right). The two N-terminal helical repeats of Csn4, red arrow, are in 
close proximity to the WHA domain of Cul1 (green circle). (K) Localization of the RING domain of Rbx1. 
The unfilled density that is indicated by a black ellipse in the right-hand panel of S1J accommodates Rbx1 
(shown in red). The helices of Csn4 in close proximity to the RING domain of Rbx1 are indicated by a black 
arrow. (L) Re-localization of Csn5/6. Comparing the left and right panels, Csn5/6 move leftward to occupy 
unfilled density. The tan and green circles below Csn5/6 indicate densities that are occupied by Nedd8 and 
the WHB domain, as depicted in (M). (N, O) Deneddylation assays with (N) wild type Cul1-N8/Rbx1 and 
indicated CSN variants and (O) wild type CSN and mutant Cul1 variants. Note that all Cul1 constructs have 
an uncleaved C-terminal sortase tag, which is the reason for slower deneddylation of wild type Cul1-N8/Rbx1 
by wild type CSN relative to the kinetics reported elsewhere in this work. 
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Figure supplement 2.2. Supporting data for development and validation of CSN–Cul1d/Rbx1 binding 
assay. (A) Dansylation of Cul1/Rbx1 constructs. Upper panel: dansylation of bacterially expressed and 
purified Cul1/Rbx1. Lower panel: dansylation of Cul1/Rbx1 expressed and purified from insect cells. For 
details, see Materials and Methods. (B) Ubiquitination of 32P-labeled beta-catenin substrate peptide by 
dansylated SCF-TrCP was monitored as described (Saha and Deshaies, 2008). The kcat measured here (0.048 
min-1) compares favorably with that previously determined for wild type unmodified SCF (0.054 min-
1)(Saha and Deshaies, 2008). (C) IC50 study of the inhibitory effects of unlabeled (red) or dansylated (black) 
product. Cul1/Rbx1 and Cul1d/Rbx1 were separately titrated into a deneddylation reactions containing 50 
nM Cul1-[32P]N8/Rbx1 substrate and 0.5 nM CSN, and the resulting reaction rate was measured. (D) CSN 
preparations used in this study. 600 ng of each sample were fractionated by SDS-PAGE and stained with 
SYPRO Ruby. (E) IC50 for competitive inhibition of CSN-Cul1d/Rbx1 complex formation by unlabeled 
Cul1/Rbx1 (~ 390 nM) agrees with the Kd measured for binding of Cul1d/Rbx1 to CSN (310 nM). (F) 
Figure Supplement 2.2 E-I 
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Equilibrium binding of 100 nM CSN to 50 nM Cul1d/Rbx1 and competition by 500 nM Cand1. The indicated 
proteins were mixed and allowed to equilibrate prior to determination of dansyl fluorescence. (G-I) Free 
Nedd8 and F-box box proteins do not appreciably change affinity of Cul1d/Rbx1 for CSN. Same as Figure 
2C, except that either 5 µM free Nedd8 (G), 100 nM  Skp2/Skp1 (H) or 100 nM Fbxw7/Skp1 (I) was included 
in the binding reaction. All binding and activity measurements reported in this legend were carried out in 
triplicate and error bars represent standard deviation. 
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Figure supplement 2.3. Supporting experiments and titration curves for binding data in Figures 3B–
C. (A) CSN5H138A is inactive and is a dominant-negative inhibitor of deneddylation. CSN, CSN5H138A , 
and substrate were used at 2 nM, 100 nM, and 75 nM, respectively. For reactions containing with CSN and 
CSN5H138A, mutant enzyme was preincubated with substrate for 30 sec prior to initiating time-course by 
adding CSN. (B-E): The indicated proteins were mixed and allowed to equilibrate prior to determining the 
change in dansyl fluorescence. (B) CSN5H138A and dansylated, Nedd8-conjugated SCFSkp2. (C) 
CSN5H138A and dansylated, Nedd8-conjugated SCFFbxw7. Note that addition of Fbxw7–Skp1 greatly 
increased the variability in the measurement for unknown reasons. (D) CSN5H138A (first prep) and 
Cul1d/Rbx1, (E) CSN5H138A (second prep) and Cul1d/Rbx1, (F-I): The indicated CSN complexes were 
preincubated with Cul1d/Rbx1 for 10 min, followed by addition of unlabeled Cul1/Rbx1 chase and 
measurement of the decay in dansyl fluorescence over time. Final protein concentrations are listed for each 
experiment. (F) CSN (2000 nM), Cul1d/Rbx1 (200 nM), and Cul1/Rbx1 (3000 nM), (G) CSN5E104A (600 
nM), Cul1d/Rbx1 (200 nM), and Cul1/Rbx1 (3000 nM), (H) CSN5E76A,5H138A (400 nM), Cul1d/Rbx1 
(200 nM), and Cul1/Rbx1 (3000 nM), (I) CSN5E76A,5H138A (200 nM), Cul1d-N8/Rbx1 (100 nM), and 
Cul1/Rbx1 (1500 nM), (J-S): The indicated proteins were mixed and allowed to equilibrate prior to 
Figure Supplement 2.3 L-R 
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determining the change in dansyl fluorescence. (J) CSN5E76A, 5H138A and Cul1d/Rbx1, (K) CSN5H138A 
or CSN2∆N,5H138A and Cul1d-N8/Rbx1, (L) CSN4∆N,5H138A and Cul1d/Rbx1, (M) CSN4∆N,5H138A 
and Cul1d-N8/Rbx1, (N) CSN5E76A or CSN5E76A,5H138A and Cul1d-N8/Rbx1∆RING, (O) CSN5E104A 
and Cul1d/Rbx1, (P) CSN5E76A and Cul1d/Rbx1, (Q) CSN5H138A,6∆INS2 and Cul1d/Rbx1, (R) 
CSN5H138A,6∆INS2 and Cul1d-N8/Rbx1∆RING, (S) CSN5T103I and Cul1d/Rbx1. All measurements in 
panels B-E and J-S were carried out in triplicate and error bars represent standard deviation. The measurement 
in panel P was performed in duplicates but the experiment was repeated on three independent occasions, 
obtaining similar results. Several of these results were independently confirmed in Zurich and Pasadena 
including panels J, M, O, P, and Q. 
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Figure supplement 2.4. Biochemical characterization of Cul1/Rbx1TEV∆RING proteins. (A) 
Ubiquitination assay using the indicated Cul1-N8/Rbx1 variants (500 nM each) as an E3. Each reaction 
contained, in addition, 100 nM Ube1, 1000 nM Cdc34b, 750 nM Skp1/Fbxw7 and 4000 nM CyclinE 
phosphopeptide, labeled with FAM. The samples were incubated at 25°C for the indicated time points, 
analyzed by SDS PAGE and visualized by excitation at 473 nm. (B) Overlay of Superdex 200 size exclusion 
profiles of purified Cul1/Rbx1 variants isolated from insect cells.  
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Figure supplement 2.5. Kinetic analysis of deneddylation. (A) Deneddylation reactions were carried out 
in triplicate with CSN4∆N at varying concentrations of Cul1-[32P]N8/Rbx1 substrate and quantified to 
generate the curve shown. Estimates of kcat and KM are indicated. (B) Deneddylation assays of Cul1-
Figure Supplement 2.5 
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N8/Rbx1∆RING (100 nM), incubated with CSN (200 nM, upper panel) or CSN6∆INS2 (200 nM, lower 
panel). Samples were taken at the indicated time points, and visualized by SDS PAGE and Sypro Ruby 
staining. Note that the ∆RING substrate contained an unreacted Sortase tag at the C-terminus of Cul1 that 
reduced kcat by ~4-fold. (C) Multi-turnover deneddylation reactions were carried out with CSN or 
CSN5E104A and Cul1-[32P]N8/Rbx1.  Substrate was assayed at 1 and 1.3 µM to confirm that saturation 
was achieved. (D) Single-turnover deneddylation reactions were carried out with CSN on Cul1-
[32P]N8/Rbx1 +/- Skp1/Skp2, and with CSN5E104A on Cul1-[32P]N8/Rbx1. (E) Same as panel D except 
that CSN6∆INS2 was also evaluated. (F) Multi-turnover deneddylation reactions were carried out in triplicate 
with CSN5T103I at varying concentrations of Cul1-[32P]N8/Rbx1 substrate and quantified to generate the 
curve shown. Estimates of kcat and KM are indicated. 
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Figure supplement 2.6. Time course and titration data for Figure 6A and supplementary immunoblot 
for Figure 6B. (A) Same as Figure 6B except that samples were immunoblotted for different cullins. (B) 
SILAC data for CSN subunits from pull-down analysis shown in Figure 6D.  
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Supplemental Table 2.1-2.5. Cross-links within CSN5H138A-SCF-N8Skp2/Cks1. "Id" gives the amino acid 
sequence of the cross-linked peptides and the exact position of the two cross-linked lysine residues is 
indicated by the numbers of the letters a and b respectively for the first and second peptide. “Protein1” and 
“Protein2” denote the cross-linked protein names and “Residue 1” and “Residue 2” respectively defines the 
position of the cross-linked lysine within the sequence of the protein. “deltaS” is the delta score of the 
respective cross-link, which serves as a measure for how close the best assigned hit was scored in regard to 
the second best. “Id_Score” is a weighted sum of four subscores: xcorrc, xcorrx, match-odds, and TIC that 
is used to assess the quality of the composite MS2 spectrum as calculated by xQuest. “FDR” denotes the 
false-discovery rate as calculated by xProphet. The measured distance in Å is given for all cross-links, which 
fall within modeled residues. 
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3 – CELLULAR ORGANIZATION, KINETICS, AND 
REGULATION OF CULLIN4-RING UBIQUITIN LIGASES 
This chapter is based on the manuscript draft as submitted to the journal prior to revision 
and formatting by Molecular Cell: 
KM Reichermeier, R Straube, JM Reitsma, MJ Sweredoski, CM Rose, A Moradian, Willem den Besten, T 
Hinkle, E Verschueren, G Petzold, N Thomä, IE Wertz, RJ Deshaies, DS Kirkpatrick; PIKES analysis 
uncovers response to degraders and key regulatory mechanisms of CRL4 ligase networks (revised manuscript 
in press, Molecular Cell, DOI: 10.1016/j.molcel.2019.12.013)  
3.1 Summary 
Immunomodulatory Drugs (IMiDs) used for the treatment of multiple myeloma function 
by co-opting a Cullin4 RING ubiquitin Ligase (CRL4) to inducibly degrade oncogenic 
drivers. Despite intense efforts to rationally design degrader molecules that co-opt CRL4s, 
much about the organization and regulation of these ligases remains elusive. Here, we 
establish Protein Interaction Kinetics and Estimation of Stoichiometries (PIKES) analysis, 
a systematic proteomic profiling platform that integrates cellular engineering, affinity 
purification, chemical stabilization, and quantitative mass spectrometry to investigate the 
dynamics of interchangeable multiprotein complexes. Using PIKES, we show that ligase 
assemblies of Cullin4 with individual substrate receptors differ in abundance by up to 200-
fold and that Cand1 acts as an exchange factor to remodel the CRL4 ligase pool. Integrating 
quantitative data and model simulations of CRL-mediated substrate turnover, we show that 
high substrate receptor levels can enhance the potency of degraders. Beyond the CRL4 
network, we show how PIKES can reveal systems level biochemistry for cellular protein 
networks important to drug development. 
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3.2 Introduction 
Cullin-RING Ligases (CRLs) represent a collection of ~250 enzyme complexes that 
ubiquitinate protein substrates to alter their function or mark them for proteasomal 
degradation (Deshaies and Joazeiro, 2009a). Among these, the Cul4 family of CRLs 
regulate cell cycle, DNA damage repair, and are co-opted by therapeutic compounds to 
promote degradation of oncogenic protein (Hannah and Zhou, 2015; Jackson and Xiong, 
2009; Kortüm et al., 2015). CRL4s are composed of either a Cullin4A•Rbx1 or 
Cullin4B•Rbx1 catalytic core (hereafter Cul4A or Cul4B, or if referred to both Cul4) and 
an interchangeable adapter-substrate receptor module (A•SR). Like a drill that uses an 
adapter and various bits to accommodate a diverse range of screws, Cul4A/B scaffolds use 
the DDB1 adapter to engage an array of DDB1-Cul4 Associated Factors (DCAFs; substrate 
receptors) and ubiquitinate a range of substrates (Figure 3.1). 
The idea of chemically induced degradation was conceived nearly 20 years ago with the 
first Proteolysis Targeting Chimeras (PROTACs) (Sakamoto et al., 2001)  and surged when 
CRL4CRBN emerged as the long elusive target of thalidomide and its paralogs – also known 
as IMiDs (Gandhi et al., 2014; Ito et al., 2010; Krönke et al., 2014; Lu et al., 2014). IMiDs 
act as molecular glues to induce neo-substrate recruitment through the substrate receptor 
CRBN, catalyzing their ubiquitination and subsequent degradation. These initial 
discoveries were followed by a wave of studies demonstrating that IMiD-based PROTACs, 
as well as molecules co-opting other E3 ligases, can potently induce degradation of neo-
substrates (Bondeson et al., 2015; Han et al., 2017; Neklesa et al., 2017; Ottis et al., 2017; 
Paiva and Crews, 2019; Uehara et al., 2017; Winter et al., 2015; Zengerle et al., 2015; 
Zhang et al., 2018). Since 2015, more than thirty PROTAC-like molecules have been 
reported, giving rise to a promising new class of medicines (An and Fu, 2018; Deshaies, 
2015; Paiva and Crews, 2019).  
CRLs are dynamic protein assemblies with sophisticated regulatory mechanisms, exposing 
new degrader drugs to unusually complex pharmacodynamics (Bulatov and Ciulli, 2015). 
The cellular organization of endogenous CRL4 assemblies and their modes of regulation 
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have been hypothesized based on a recent model of Skp1-Cul1-Fbox (SCF/CRL1) 
complexes, for which Cand1/2 act as exchange factors for pools of non-substrate-bound 
A•SRs (Skp1•Fbox) residing in a dynamic equilibrium. Limiting amounts of Cul1 mandate 
that the system displays plasticity to cope with changes in SR expression (Liu et al., 2018; 
Pierce et al., 2013; Reitsma et al., 2017; Straube et al., 2017; Wu et al., 2013; Zemla et al., 
2013). Though rapid, the exchange cycle can temporarily be put on hold through substrate 
binding. This creates an adaptive disequilibrium favoring the stable assembly of ligase 
complexes for which substrates are present. Substrate driven assembly persists because 
fully assembled and substrate-bound SCF ligases become trapped in the Nedd8-modified 
state (Nedd8-Cul1A•SR•Substrate) and are protected from Cand1-mediated exchange. In this 
model, substrate sterically hinders the Cop9 Signalosome (CSN) Nedd8 deconjugase from 
accessing the neddylated SCF complex (Cavadini et al., 2016; Emberley et al., 2012; 
Enchev et al., 2012; Fischer et al., 2011b; Mosadeghi et al., 2016). Once substrate is 
released, CSN can bind SCF and quickly remove Nedd8, allowing Cand1/2-mediated 
recycling of catalytic cores.   
Given its clinical importance for the efficacy of IMiDs, sulfonamides (Han et al., 2017; 
Uehara et al., 2017) and emerging PROTAC molecules, understanding how the CRL4 
network is regulated is paramount. Key outstanding questions include: How many 
DDB1•DCAF modules exist per cell? What are the concentrations of the Cul4-bound and 
unbound DDB1•DCAF pools? Does Cand1 act as a CRL4 exchange factor and is it 
required for degradation of CRL4 substrates? How do substrate recruitment and DCAF 
expression affect CRL4 assembly and function? Importantly for degrader drug 
development, what factors determine the efficacy of molecules targeting CRL4s and what 
effect do these molecules have on the CRL4 network and its dynamics? 
Previously published studies have begun to elucidate the composition of cellular CRL4 
complexes (Angers et al., 2006; Bennett et al., 2010; He et al., 2006b; Higa et al., 2006; 
Jin et al., 2006). One challenge in interpreting past work is that over-expression and post-
lysis exchange can be confounding factors for CRLs (Reitsma et al., 2017). To shed light 
on CRL4 assembly and regulation, we developed a proteomic profiling platform to study 
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the dynamics, stoichiometry and regulatory mechanisms of endogenous CRL4 ligases in 
human cells. Protein Interaction Kinetics and Estimation of Stoichiometries (PIKES) 
analysis revealed new CRL4 biology and key considerations for degrader drug 
development. Looking beyond CRL4 ubiquitin ligases, PIKES provides a framework for 
systematic proteomic profiling of dynamic and interchangeable protein complexes.  
3.3 Results 
A toolbox to monitor endogenous CRL4 complexes 
The human genome encodes ~100 DCAF proteins that are predicted based on sequence to 
associate with DDB1 (Angers et al., 2006; He et al., 2006b; Higa et al., 2006; Lee and 
Zhou, 2007). It is currently unknown how many DCAFs truly assemble into CRL4s. 
Human embryonic kidney cells (293T/17) were genetically engineered using CRISPR to 
express either a 3xFLAG tag fused to the N-terminus of Cul4A, a 3xHA tag fused to the 
NTD of Cul4B, or both tags in the same cell (Figure 3.1). Selected single cell clones were 
tested for homozygous insertion of the epitope tags via western blot and genomic PCR. 
Morphology, cell doubling time and Cul4A and Cul4B mRNA expression closely 
resembled those of the parent population (Supplemental Item 3.1A-L). Using these 
engineered cell lines, endogenous CRL4A and CRL4B complexes were 
immunoprecipitated via their respective epitope tags and the eluates analyzed via LC-MS. 
Significance Analysis of Interactomes (SAINT) (Choi et al., 2011) identified 26 DCAFs to 
be associated with Cul4A and Cul4B, of which 24 were confirmed as DDB1-dependent in 
SILAC AP-MS experiments (Figure Supplement 3.1A-G). Besides DCAF proteins, all 
subunits of the Cop9 Signalosome (CSN), Cand1 (but not Cand2), cullin inhibitor glomulin 
(Duda et al., 2012; Tron et al., 2012), neddylation enzyme DCN1 (Cope and Deshaies, 
2003; Kurz et al., 2005; Wei and Deng, 2003), and p97 adapter protein Ubxd7 (Alexandru 
et al., 2008; Besten et al., 2012) were identified. The only proteins that weren’t predicted 
to assemble with Cul4 were three subunits of phosphatidylinositol 5-phosphate 4-kinase 
Type II (PIP4K2A, B and C) which were found to associate with Cul4B. Based on these 
initial experiments, we developed a targeted proteomics assay to quantitatively monitor 37 
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Cul4 interacting proteins. For this purpose, we used Parallel Reaction Monitoring (PRM) 
(Peterson et al., 2012) which allows targeted analysis of a selected subset of peptides to 
achieve more sensitivity compared to regular shotgun MS methods as well as accurate 
relative or absolute quantification when used with internal standards (Figure Supplement 
3.1H, I). 
Cand1/2 are CRL4 exchange factors and required for efficient substrate 
degradation 
After defining the endogenous repertoire of Cul4•DDB1•DCAF complexes, we sought to 
determine the stability of these interchangeable complexes during immunoprecipitation. 
Based on SCF ligases (Liu et al., 2018; Reitsma et al., 2017) and the robust association of 
Cand1 with endogenous Cul4, we hypothesized that CRL4s might exchange A•SR 
modules, with post-lysis exchange complicating interpretation of experimental results. A 
SILAC-based CRL4 exchange assay (Figure 3.2A) confirmed the time dependent 
exchange of nearly all CRL4 interactors (Figure 3.2B). Western blot analysis revealed that 
the majority of Cul4 molecules were rapidly de-neddylated upon cell lysis (Figure 3.2C), 
supporting the hypothesis that most CRL4 complexes are susceptible to Cand1/2-mediated 
exchange. To directly test whether Cand1/2 are driving A•SR exchange from cellular 
CRL4s, experiments were performed under three different conditions (Figure 3.2D): In 
lysates from cells (1) lacking Cand1/2, (2) pre-treated with small molecule inhibitor 
CSN5i-3 (Schlierf et al., 2016) to preserve endogenous Cul4 neddylation which prevents 
Cand1/2 binding (Figure 3.2E,F,), or (3) spiked with excess recombinant Cul4A•Rbx1 to 
act as a molecular sponge for unassembled  A•SR modules and Cand1/2 (Figure 3.2F). 
Under all three conditions, CRL4 complexes remained stable over the course of 60 minutes 
(Figure 3.2D, Figure Supplement 3.2B). DCAFs that differed from the norm included 
AMBRA1, PHIP, and PWP1. These proteins were significantly enriched in the bead 
background and displayed relatively low signal to noise ratios under our experimental 
conditions, as noted in later experiments (Figure Supplement 3.4E, Figure Supplement 
3.5E). To determine the functional impact of Cand1/2 on CRL4-mediated substrate 
degradation we chose to monitor the degradation of RBM39 upon treatment with 
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indisulam, a recently reported molecular glue that recruits RBM39 to CRL4DCAF15 (Han et 
al., 2017; Uehara et al., 2017). As anticipated, cells lacking Cand1/2 degraded RBM39 
significantly slower than a wild type population at the same dose of indisulam (Figure 
Supplement 3.2C, D). Taken together, these results confirm that Cand1/2 function as 
efficient A•SR exchange factors for most CRL4s, supporting a model of adaptive exchange 
(Figure 3.2F). Standing in contrast to the model, a subset of DCAFs including VPRBP 
(DCAF1) and BRWD3 were highly stable, dissociating less than 10% in 3 hours (Figure 
3.2B, Figure Supplement 3.2A). These unusually stable CRL4 complexes were not further 
destabilized by pre-treatment with Nedd8-E1 inhibitor MLN4924 (Brownell et al., 2010; 
Soucy et al., 2009), a condition that increased exchange of all A•SRs in the SCF system 
(Reitsma et al., 2017) (Figure Supplement 3.2E). One explanation for this is that Cand1-
mediated exchange might not be as efficient for some CRL4 complexes as for SCF. To test 
this, CRL4B complexes lacking Cand1 were purified from Cand1/2 KO cell lysates under 
conditions allowing for de-neddylation. Purified CRL4B complexes were then incubated 
for 1 hr with or without excess recombinant Cand1, followed by PRM LC-MS. While most 
(~70%) DDB1•DCAF modules were dislodged by exogenous Cand1, a few DCAFs 
showed much less dissociation (Figure Supplement 3.2F). VPRBP, DDB2, BRWD1/3, and 
DCAF11 displayed good signal-to-noise ratios and were dislodged much slower than other 
DCAFs, suggesting that these complexes either resist deneddylation or are refractory to 
Cand1/2 exchange.  
CRL4 complexes are stabilized by N8 Block and Molecular Sponge 
Having identified conditions to suppress post-lysis exchange, we were curious about the 
effects of such treatments on the immunoprecipitated CRL4 complexes. To assess the 
effect of N8 Block and molecular sponge on Cul4B complexes, we performed Cul4B IPs 
and PRM MS analysis from cells pulsed for 5 min with 1µM MLN4924+CSN5i-3, pulsed 
with either molecule alone, or from cells lysed in the presence of either 2.5 µM molecular 
sponge Cul4A•Rbx1GST or GST control. As anticipated, both N8 Block and molecular 
sponge substantially increased DDB1•DCAF complexes co-precipitated with endogenous 
Cul4B, indicating successful conservation of CRL4B assemblies during the IP process 
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(Figure 3.2G). Consistent with the finding that de-neddylation is fast in lysates (Figure 
3.2C), brief MLN4924 treatment did not display any additional destabilizing effect. 
Treatment with CSN5i-3 alone or in combination with MLN4924 had a very similar effect 
on CRL4B complexes which we attribute to the fact that most CRL4s are highly neddylated 
to begin. N8 Block and molecular sponge showed the same trends. Yet, discrepancies in 
preservation of individual DCAFs do occur, the consequences of which are likely minor as 
discussed below. Taken together, these observations provide evidence that the assembly 
and stability of most CRL4 complexes is regulated by the neddylation cycle and the 
Cand1/2 exchange factors. 
Individual CRL4 ligases show Cullin-scaffold preferences and differ up to 200-fold 
in absolute abundance   
Experimentally suppressing post-lysis exchange permitted us the unique opportunity to 
capture CRL4 assemblies in their native states. Next, we aimed to comprehensively define 
stoichiometries for the cellular CRL4 ligase network by measuring the cellular 
concentration of network components, the stoichiometry of assembled CRL4 complexes 
and the composition of the free DDB1•DCAF reserve. While synthetic peptide standards 
facilitate inter-sample relative quantification, direct comparisons of inter-protein 
stoichiometries and cellular concentrations remain challenging due to the cumulative 
variability of many independent concentration measurements. To circumvent this issue, we 
designed a synthetic CRL4 QconCAT polypeptide consisting of 67 concatenated equimolar 
reference peptides for 31 proteins (Pratt et al., 2006; Scott et al., 2016) (Figure 3.3A, Figure 
Supplement 3.3A, B). Whole cell lysates from 293T/17Flag-Cul4A/HA-Cul4B cells were mixed 
with the QconCAT standard and analyzed via PRM LC-MS (Figure 3.3B, Figure 
Supplement 3.3C). This data revealed three interesting findings: 1) Cul4B was ~2-fold 
more abundant than Cul4A, consistent with data from the proteome abundance atlas of 29 
healthy tissues (Wang et al., 2019), where Cul4B is on average found ~1.8-fold (range 0.8 
– 4.8-fold) more abundant than Cul4A (Figure Supplement 3.3D). 2) DDB1 was present in 
~7-fold excess over total Cul4. DDB1 protein levels detected in the 29 human tissues 
(Wang et al., 2019) are similarly ~3-fold in excess over Cul4 (range 1.5-4.9-fold) (Figure 
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Supplement 3.3E). 3) The concentration of all DCAFs combined to roughly equal the 
concentration of DDB1, exceeding DDB1 only by ~15%. This last observation supports 
the hypothesis that most DCAFs exist and function as stable heterodimers with DDB1. 
Next, we performed a combined immunoprecipitation of FLAG-Cul4A and HA-Cul4B 
from cells pulsed with N8 Block. Enriched samples were spiked with CRL4 QconCAT and 
analyzed with PRM LC-MS, allowing the determination of stoichiometric relationships for 
purified CRL4 complexes from aggregate peptide measurements (Figure 3.3D-E, Figure 
Supplement 3.3F). Importantly, these measurements meet several control criteria which are 
explicated in detail in the STAR methods. Overall, the 22 Cul4DCAF ligase complexes 
displayed dramatic differences in abundance. Cul4CRBN, the target of IMiD-based 
degraders, accounted for ~20% of all CRL4 ligases in our cell system, whereas Cul4DET1 
only totaled ~0.1% (Figure 3.3D). The data reveal that ~89% of Cul4 associated with 
DDB1 and only ~27% with Cand1. These measurements suggest a non-negligible 
population of Cul4 exists as a ternary complex with DDB1 and Cand1 (Figure 3.3E). 
Integrating the cellular amount of Cul4 and its relative occupancy with DDB1 allows 
estimation of CRL4 levels at ~200nM, or ~230,000 ligase complexes per cell. This estimate 
agrees well with the sum of calculated abundances of individual CRL4s (~180nM) which 
range from as little as 0.2nM (Cul4DET1) to 42nM (Cul4CRBN) (Figure 3F). Furthermore, 
~55% of Cul4 was neddylated and associated with a CSN complex, showing that the N8 
Block successfully conserved Cul4-neddylation and led to co-precipitation of large 
amounts of inhibited CSN (Figure 3.3E, Figure Supplement 3.3G). This is consistent with 
observations made for catalytically-dead CSN, which traps substrate in a high affinity 
conformation to prevent CRL4 release (Cavadini et al., 2016; Mosadeghi et al., 2016). In 
contrast, without blocking de-neddylation in lysates, the Cul4 occupancy shifted to 66% 
DDB1 and 54% Cand1, reflecting a net loss of ~25% CRL4 complexes due to post-lysis 
de-neddylation and dislocation of DDB1 by Cand1 (Figure Supplement 3.3G, H).  
DCAFs of highly abundant ligases show high relative assembly 
Interestingly, most DCAFs were expressed at similar levels (Figure 3.3G). This 
observation implies that the 200-fold differences in abundances of assembled CRL4 
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complexes wasn’t driven by protein expression. Consistent with this, no correlation could 
be found between protein expression and fractional contribution of each DCAF to all 
assembled CRL4 complexes (Figure Supplement 3.3I). Ultimately, this implies that the 
fraction of each DCAF that is Cul4-assembled versus in the free pool might correlate with 
ligase abundance. We call this parameter Relative Assembly (% assembly) which can be 
computed using the quantitative information of cellular concentrations and complex 
stoichiometries. Similar to overall abundance, calculated % assembly varied across two 
orders of magnitude and indeed correlated well with ligase abundance (% of individual 
Cul4DCAF amongst all CRL4s) (Figure 3.3H, Figure Supplement 3.3J). This supports the 
hypothesis that abundant CRL4s are formed by allowing high relative assembly of 
individual DCAFs over others. To test the accuracy of our calculations, we performed 
sequential Cul4A and Cul4B IPs in the presence of molecular sponge to capture the free 
pool of assembly-competent DDB1•DCAFs and the individual assemblages of CRL4A and 
CRL4B (Figure Supplement 3.3K). For DDB1, one of the most robust measurements in 
both assays, we calculated ~12% Cul4-bound and measured ~7% (Figure 3.3E, Figure 
Supplement 3.3L). Of 21 DCAFs that were accurately assessed in both assays, 15 (70%) 
showed values within +/- 2.5-fold (Figure Supplement 3.3M). DCAFs showing the largest 
discrepancies were previously noted proteins with low signal to noise ratios like PHIP and 
PWP1 (Figure Supplement 3.3N) or proteins with the lowest abundances like DET1 and 
RFWD2.  
DCAFs show selective binding to Cul4A or Cul4B 
In addition to providing measurements for relative assembly, the sequential IP approach 
revealed that certain DCAFs displayed preferences for either Cul4A or Cul4B. While all 
DDB1•DCAF modules detected associated with both Cul4 scaffolds, a subset showed up 
to 4-fold preference for one over the other. We further validated this finding via an 
orthogonal approach using the N8 Block and single IPs of Cul4A and Cul4B (Figure 3.3I). 
Interestingly, the two scaffolds show different localization patterns, with Cul4A localized 
in both the nuclear and cytoplasmic compartments and Cul4B primarily in the nucleus 
(Figure Supplement 3.3O). This agrees with previous studies (Zou et al., 2009) and begs 
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the question of whether subcellular compartmentalization is a key determinant of ligase 
assembly. The Cul4 family is unique amongst CRLs with two similar scaffolds serving as 
the catalytic cores (Hannah and Zhou, 2015). The lack of proper methods to analyze and 
quantify the CRL4 network has until now prevented functional and compositional 
differentiation between CRL4A and CRL4B complexes. If used in combination with more 
advanced model systems, we anticipate our PIKES assays could help illuminate long-
standing mysteries of why all vertebrates conserved two independent Cul4 genes which 
display different phenotypes when mutated in human diseases (Chen et al., 2012; Jiang et 
al., 2013; Liu et al., 2009; Vulto-van Silfhout et al., 2015; Wang et al., 2014; Zou et al., 
2007). 
CRL4s reshape their assemblies and form Cul4A•Cul4B dimers upon UV-induced 
DNA damage 
One fundamental question in CRL biology involves regulation of ligase assembly. For both 
CRL4 and SCF, protein levels of most SRs lie between 25-100 nM while the relative 
assembly of A•SR modules varies more than 200-fold (Figure 3B, Reitsma et. al. 2017). 
These dramatic differences in assembly must arise either from affinity differences of 
individual A•SR modules towards cullins or another more complex mechanism. SCF 
complexes are regulated by a just-in-time assembly system wherein substrate stabilizes 
ligase complexes by creating a disequilibrium favoring certain A•SRs over others (Liu et 
al., 2018; Reitsma et al., 2017). Based on many parallels observed in our experiments, we 
hypothesized that physiological stimuli which change substrate abundance might reshape 
CRL4 assemblies. To the test this idea, we used a UV-induced DNA damage model in 
which cells accumulate 4-6 photoproducts and pyrimidine-dimers which are recognized by 
the DCAF DDB2 (Chu and Chang, 1988). This is thought to create a ubiquitination zone 
around the lesions that initiates nucleotide excision repair (Fischer et al., 2011b; Scrima et 
al., 2008). In the process of initiating repair, DDB2 is itself auto-ubiquitinated, extracted 
from chromatin and quickly degraded (Figure 3.4A). To monitor changes in CRL4 
assemblies induced by DNA damage, we pulsed cells with UV light, incubated for varying 
times post-damage and analyzed Cul4B complexes via PRM-MS. While most proteins 
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associated with Cul4B did not change in abundance, we observed significant changes for 
four proteins (Figure 3.4B, Figure Supplement 3.4A). As expected, DDB2 rapidly 
dissociated from Cul4 after initiation of repair and was degraded by the proteasome (Figure 
3.4C). Additionally, association of VPRBP and DDA1 with Cul4B increased following 
DNA damage (Figure 3.4D, E). Cul4VPRBP functions as the E3 ligase that targets MCM10 
stalled on UV-induced DNA lesions for degradation (Kaur et al., 2012). DDA1 is thought 
to be a co-factor for CRL4 complexes (Han et al., 2017) that associates with multiple 
DDB1•DCAF modules (Olma et al., 2009; Shabek et al., 2018). Surprisingly, Cul4A also 
increased in Cul4B complexes isolated from UV-treated cells (Figure 3.4F). As for DDB2, 
VPRBP and DDA1, Cul4A signal was well above bead background, confirming the 
presence of Cul4A•Cul4B heterodimers in a physiological context (Figure Supplement 
3.4B-F). Dimerization of Cul4•DDB1•VPRBP has been proposed to enhance substrate 
ubiquitination in vitro (Ahn et al., 2011).  While future studies are needed to determine the 
functional consequences, these results demonstrate the power of PIKES to monitor 
dynamic and inducible interactions within conserved protein families. 
Abundance of pre-formed ligase complex does not predict turnover efficiency of 
individual CRL4s  
The approach of co-opting E3 ubiquitin ligases to target neo-substrates for proteasomal 
degradation raised interest in CRL4s as promising drug targets (Deshaies, 2015). IMiD-
based compounds have been shown to successfully induce degradation of a variety of neo-
substrates in human cell lines and mice via Cul4CRBN (Lu et al., 2015a; Nabet et al., 2018; 
Sun et al., 2019; Winter et al., 2015). Recently, CRL4DCAF15 was shown to inducibly 
specify degradation of RBM39 in the presence of aryl sulfonamides (Han et al., 2017; 
Uehara et al., 2017). Interestingly, CRL4CRBN and CRL4DCAF15 differ by ~70-fold in 
abundance in our cell system (Figure 3.5A, B). To test the efficiency of these two ligases 
in degrading neo-substrates we chose to evaluate four different degraders: the sulfonamide 
indisulam to target RBM39 via DCAF15, as well as lenalidomide (CK1a and ZFP91), 
dBET1 (BRD4) and dTAG-13 (exogenous FKBP12F36V-GFP) which each utilize CRBN. 
Surprisingly, despite substantially lower amounts of pre-formed CRL4DCAF15, RBM39 was 
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degraded faster than all endogenous CRBN neo-substrates (Figure 3.5C, D, Figure 
Supplement 3.5A-D). To derive substrate turnover in molecules per minute, substrate copy 
numbers were estimated from the proteome atlas (Wang et al., 2019) (Figure 3.5E-F). 
While substrate half-lives differed up to ~5-fold, the quantities of molecules per minute 
turned over by CRL4DCAF15 compared to CRL4CRBN differed by up to ~60-fold (Figure 
3.5G). This suggests that the degree of Cul4-occupancy at steady state is not indicative of 
how well a DCAF might serve as a co-opted ligase. Instead, factors like ternary complex 
stability (Roy et al., 2019), substrate lysine accessibility, differences in re-synthesis rates, 
counteracting de-ubiquitination or pre-proteasomal processing by factors like p97 (Nguyen 
et al., 2017), each have the potential to modulate degradation rates downstream of a 
substrate-ligase pair. Furthermore, high levels of endogenous and neo-substrates have the 
potential to competitively inhibit turnover, particularly in the case of IMiDs which target 
multiple zinc finger proteins for degradation (Sievers et al., 2018; Sperling et al., 2019).  
Degrader molecules minimally reshape ligase assemblies without disturbing the 
overall CRL4 network 
We were next interested in the broad effects of degrader molecules on the Cul4 network. 
Based on observations that Cand1 and Nedd8 establish adaptive disequilibria in favor of 
substrate engaged DCAFs, we hypothesized that ligase assembly might be elicited by 
degrader molecules. To test this, cells were treated with the four degrader compounds 
followed by Cul4 immuno-enrichment and PRM MS analysis. Surprisingly, lenalidomide 
caused a small decrease in assembled Cul4CRBN complexes, while dTAG-13 and dBET1 
showed little if any change in CRBN assembly (Figure 3.5H,I, Figure Supplement 3.5E). 
CRL4CRBN represents the highest assembled Cul4 ligase in the basal state, suggesting the 
presence of endogenous, likely transient stabilizing factors such as substrates. In this case, 
lenalidomide and IMiD-based PROTACs would need to compete for CRBN against 
endogenous substrates with the assembly disequilibrium depending on the relative 
abundance of neo-substrates versus endogenous substrates. DCAF15 on the other hand is 
one of the lowest assembled CRL4 ligases and we reasoned it might be a better candidate 
to observe this phenomenon of adaptive ligase assembly. Indeed, when cells were exposed 
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to indisulam, we detected a ~2-fold increase in DCAF15 assembly as early as 30 min 
following treatment (Figure 3.5J, K, Figure Supplement 3.5F). We hypothesized that if this 
increase in assembled DCAF15 ligase was stabilized via Nedd8, pretreatment of cells with 
MLN4924 should blunt this effect. MLN4924 indeed blocked indisulam-induced assembly 
of Cul4B complexes (Figure Supplement 3.5 G-I) and inhibited the degradation of RBM39 
(Figure Supplement 3.5J). Furthermore, brief pre-treatment with CSN inhibitor CSN5i-3 
also blocked degradation of RBM39, albeit not as dramatically as inhibition of Ub-E1, 
Nedd8-E1 or the proteasome (Figure Supplement 3.5J, K). While similar quantities of 
Cul4DCAF15 are assembled upon inhibition of CSN (Figure Supplement 3.5H, I), scaffold 
exchange is dramatically suppressed (Figure 3.2D). Together with the extension of RBM39 
half-life in Cand1/2 KO cells (Figure Supplement 3.2C, D), these results suggest that 
Cand1-driven recycling of Cul4 scaffolds enables sampling of the DDB1•DCAF pool for 
proper substrate degradation. Moreover, the quantities of pre-formed ligase play a minor 
role. These data provide a cell-based demonstration of substrate driven CRL assembly and 
the factors modulating this process. Furthermore, these results underscore the remarkable 
adaptability of CRL4s in response to physiological stimuli and degrader drugs that occurs 
without compromising other ligase assemblies within the Cul4 network. 
Higher DCAF expression can result in faster substrate degradation and increased 
degrader potency 
One fundamental question regarding multi-protein networks like CRLs is how quantities 
of individual components influence function. While our measurements showed that most 
DDB1•DCAF modules exist at cellular concentrations ≤100nM in 293T/17 cells (Figure 
3.3D), recent proteomic analyses reveal that levels of individual DCAFs can range across 
two orders of magnitude between different human tissues (Wang et al., 2019) (Figure 
3.6A). If DCAF expression positively affected ligase assembly and rate of substrate 
degradation, variations in DCAF levels could provide opportunities to fine tune the 
specificity of degrader molecules. However, a recently developed mathematical model of 
SCF regulation predicts that higher expression levels of Cul1 substrate receptor b-TRCP 
do not increase degradation of IkBa (Liu et al., 2018). Mechanistically, a significant 
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difference between endogenous IkBa and chemically induced neo-substrates is requisite 
IkBa phosphorylation, a potential limiting factor. To test this hypothesis in silico, we 
lowered the t1/2 of IkBa phosphorylation from 15min to 1min in the SCF model to simulate 
the rate of IkBa degradation at wild type or increased b-TRCP levels. Indeed, under 
conditions of rapid phosphorylation, higher levels of b-TRCP would shorten the predicted 
t1/2 of IkBa by 2.6-fold (Figure 3.6B). Translating this hypothesis to CRL4s, we engineered 
293T/17Flag-Cul4A/HA-Cul4B cells to stably over-express DCAF15 and tested whether higher 
DCAF expression can enhance chemically induced substrate turnover. Using the 
QconCAT PRM MS approach, the cellular concentration of DCAF15 measured 795nM 
versus 60nM in wild type cells (Figure 3.6C). This ~13-fold difference resulted in ~3.6-
fold faster t1/2 (Figure 3.6D). Mechanistically, this effect is explained by increases in pre-
assembled CRL4DCAF15 as well as increased ternary complex formation (Figure 3.6E, F). 
Furthermore, the faster RBM39 degradation rate in cells overexpressing DCAF15 
translates into a 17.5-fold lower DC50 (Figure 3.6G). These observations provide functional 
evidence that DCAF protein expression could serve as an important pharmacodynamic 
biomarker for agents invoking molecular glue mechanisms (Han et al., 2017). Moreover, 
since DCAF expression varies between tissues (Pontén et al., 2008; Wang et al., 2019), this 
provides an opportunity to achieve specific substrate degradation in cancer cells by 
engaging an CRL substrate receptor with elevated expression levels. 
3.4 Discussion 
A systematic proteomic profiling toolbox to study CRLs 
In this study, we developed PIKES (Protein Interaction Kinetics and Estimation of 
Stoichiometries), a proteomics platform to systematically decipher the composition, 
biochemical dynamics and regulatory mechanisms of endogenous Cul4-RING ligases. A 
set of mapping experiments defined the endogenous repertoire of assembled CRL4 ligases 
and served as the basis to develop targeted proteomics assays. A key breakthrough here 
was the CRL4 QconCAT reference standard (Pratt et al., 2006; Scott et al., 2016) that 
enabled the facile determination of stoichiometric relationships between ~30 proteins in 
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cell lysates and immunoprecipitated samples. Extending from the previously reported 
Molecular Sponge technique (Reitsma et al., 2017), another factor that propelled this work 
was the ability to freeze CRL4 pathway components chemically for isolation and 
quantitative analysis, allowing efficient determination of the stoichiometric relationships. 
Suppressing post-lysis exchange with a cocktail of MLN4924 (Brownell et al., 2010; Soucy 
et al., 2009) and CSN5i-3 (Schlierf et al., 2016) at the time of harvest dramatically 
enhanced experimental throughput and is extensible to other pathways where rich chemical 
biology toolboxes also exist.  
It still is underappreciated that many protein networks and scaffolding proteins form highly 
dynamic, rather than stable assemblies. Signaling networks like mitogen-activated protein 
kinase modules, or Cadherin-based cell adhesion complexes, long considered to form 
stable complexes have been shown to be very dynamic (Garbett and Bretscher, 2014). 
Another group of highly conserved proteins forming holoenzyme complexes from a shared 
catalytic subunit and various regulatory modules are Ser/Thr phosphatases (Shi, 2009) 
which have been successfully targeted with specific small molecule inhibitors (Das et al., 
2015; Krzyzosiak et al., 2018), yet much about their cellular abundances, stoichiometries, 
and dynamics remains elusive. Beyond Cullin RING ligases, we believe that PIKES 
analysis provides a powerful tool to elucidate dynamic protein assemblies to uncover novel 
biology. 
CRL4 assembly, exchange and function is regulated by Nedd8, CSN and Cand1/2 
The discovery of CRL4s as targets of molecular glues and their successful utilization as 
chemically inducible ligases raises interest in their key regulatory mechanisms. As our 
study was in progress, genetic screens were published identifying CSN and CAND1 as 
regulatory factors required for efficacy of IMiDs and IMiD-based PROTACs, but leave 
open the biochemical mechanisms underlying these effects (Liu et al., 2019a; Mayor-Ruiz 
et al., 2019; Patil et al., 2019; Sievers et al., 2018). Our mechanistic studies clearly show 
that neddylation and de-neddylation processes toggle the stability of assembled complexes, 
with Cand1/2 acting as a neddylation sensitive exchange factors for A•SR (DDB1•DCAF) 
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modules. Experiments in Cand1/2 deficient cells or those subjected to N8 Block with 
MLN4924 and CSN5i-3 revealed that dynamic re-cycling of Cul4 scaffolds is essential for 
efficient sampling of the free DDB1•DCAF pool and substrate degradation. The existence 
of a CRL4-Nedd8-Cand1 exchange regime predicts that substrate engagement drives the 
non-equilibrium assembly states of CRL4 ligases. In support of this, we show that 
physiological stimuli and degrader molecules induce disequilibrium states that favor 
binding of A•SRs based on substrate availability. The fact that our method detects specific 
rearrangements of endogenous CRL4 ligases opens up the possibility to use this technique 
to screen for new molecular glues or physiological states of substrate engagement early in 
the drug development process.  
Systematic quantitative assessment of CRLs promises deeper understanding of 
degrader MOAs and therapeutic windows 
Our analysis of cellular protein concentrations as well as complex stoichiometries of the 
CRL4 network revealed several insights into the organization of Cul4-RING ligases: (1) 
The DDB1•DCAF pool is in (~7x) excess over limiting amounts of Cul4 scaffold with only 
~10% of DDB1•DCAF modules being assembled into functional ligases at steady-state. 
This posits that substrate interactions primarily occur prior to engagement of a catalytic 
scaffold, which in turn requires efficient re-cycling to enable substrate ubiquitination. (2) 
Interestingly, the quantities of pre-assembled ligase do not correlate with the efficiency of 
substrate degradation. This is best demonstrated by CRL4CRBN which represents the most 
assembled CRL4 but turns over less neo-substrates per minute than the much lesser 
assembled CRL4DCAF15. In addition to more or less favorable ternary complex structures 
and stabilities, this divergence of activities implies the existence of counteracting 
mechanisms such as neo-substrate competition or de-ubiquitination which negatively 
impact the efficacy of degrader drugs. (3) The concentrations of most DCAFs in our 
cellular system lie between 20-100nM. However, analyses of a variety of human tissues 
show that protein levels of individual DCAFs span two orders of magnitude (Wang et al., 
2019). Our proof-of-concept study was restricted to one cell type and we do not generally 
conclude that concentrations and stoichiometries can be translated to other cell types or 
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tissues. However, we suggest that stoichiometric relationships between scaffold, exchange 
factors, adapter protein and regulatory proteins are likely conserved to support the complex 
regulatory mechanisms. This is illustrated by the tight regulation of CRL4 core subunit 
protein levels in all tissues while substrate receptor levels vary widely (Figure 3.6A). 
Individual substrate receptor expression and CRL4 complex formation is likely tissue 
specific and might even differ between single cells and clonal populations (Lin et al., 2014; 
Liu et al., 2019b). As a resource for future research, our CRL4 SpikeMix peptide library 
includes reference standards for each of these proteins and enables application of PIKES 
to other cell lines or model systems (Table Supplement 3.1). 
Using CRL4DCAF15 and indisulam-induced neo-substrate RBM39 as a case study, we 
demonstrate how PIKES analysis can be used to efficiently dissect complex mechanisms 
like chemically induced protein degradation. Through mimicking the potential 
physiological or pathophysiological scenario of different substrate receptor levels in two 
tissues we show that increased DCAF15 protein expression leads to higher pre-formed 
amounts CRL4DCAF15 and substrate engaged ternary complex. Functionally, this enhances 
substrate degradation leading to a significantly lower DC50 with the potential to translate 
into a wider therapeutic window in vivo.  While future studies are needed to understand 
whether the relationship of CRL substrate receptor expression and potency of degrader 
molecules extends to other DCAF family members, similarities in regulation across CRL4s 
and SCFs suggest that this will be a key consideration for degrader drug development 
efforts (Liu et al., 2018; Reitsma et al., 2017). 
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3.5 Materials and Methods 
Transient transfections. Plasmid DNA was transiently transfected into 293T/17 or 293 Flp-
In T-Rex cells using Lipofectamine3000 and the P3000 reagent following the manufacturer 
protocol.  
Generation of CRISPR/Cas9 reagents and knock-in cell lines. Cul4 specific pX330 
constructs were cloned as described in Cong et al. (2013) using the guide sequence 5’-
CACCGCGGCGGTTCCGGCCCAGCCA-3’ (Rev.: 5’-
AAACTGGCTGGGCCGGAACCGCCGC-3’) specifically targeting the region around the 
start codon for Cul4A as well as 5’-CACCGTTGGAAACATGAAAATAGCG–3’ (Rev.: 
5’-AAACCGCTATTTTCATGTTTCCAAC-3’) specifically targeting the start of Cul4B. 
To insert epitope tags at the N-termini of both Cul4 proteins, we engineered donor DNA 
plasmids to serve as templates for homologous repair after CRISPR/Cas9-induced double 
strand breaks. The general design included 300-500bp 5’ homology arm, a Kozak 
sequence, an antibiotic resistance cassette (puromycin or hygromycin) followed by a P2A 
site, the epitope tag sequence (3xFLAG/3xHA), and the 3’ homology arm of 300-500bp 
starting with the original start codon (Figure 3.1). These donor sequences were either 
synthesized as double stranded DNA gBlocks (Integrated DNA Technologies) or step-wise 
cloned via PCR techniques followed by blunt-end insertion into pCR II Blunt-Topo vectors 
(Invitrogen). 293T/17 or 293 Flp-in T-REx cells were transiently transfected with Cul4A 
or Cul4B px330/donor pairs at a molar ratio of 3:1 at ~90% confluency in a 6-well dish on 
day 1 followed by splitting into 10cm plates on day 2. On day 3, cells were exposed to 
either 1 µg/ml puromycin or 100µg/ml hygromycin to select for successful insertion of 
donor sequences. Heterogeneous cell populations carrying resistance were recovered, 
collected and single cells were seeded into 96-well plates via FACS or dilution. Once single 
cell clones reached confluency, they were screened for homozygous insertion of the donor 
sequences via genomic PCR (Figure S1D-F) and tested for protein expression of 
endogenous 3xFLAGCul4A and 3xHACul4B via western blot (Figure S1G, H). The cell clones 
used for experiments in this study are 293T/173xFLAG-Cul4A clone A22, 293T/173xHACul4B 
clone B15 and 293T/173xFLAG-Cul4A & 3xHA-Cul4B clone A22_B21. 
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Genomic DNA extraction and PCR genotyping. 100.000 cells or 25% of cells grown in a 
24-well plate were resuspended in 250µl QuickExtract solution followed by 15min 
incubation at 65C and 10min at 98C in a ThermoMixer to extract and solubilize genomic 
DNA. Subsequently, 1 µl per sample was used as a template for PCR which was carried 
out in 25µl total volume with 12.5 µl 2x Q5 High Fidelity Polymerase Master Mix (NEB) 
and 0.5µM of each primer. Primers used to amplify Cul4B locus: FWD 5’-
CACTCCCTGAGGTTGACACC-3’ and REV 5’- GCCGAATCCCTGGGTTGTAA-3’, 
Ta = 68C. Primers used to amplify Cul4A locus: FWD 5’-
GAGGGGGTGTCCGAATCTCT-3’ and REV 5’-TCACCTGGTAGAGCTCCTCG-3’, 
Ta = 64C. PCR cycle: 4min initial denaturation at 98C, 35 cycles of 1min denaturation at 
98C, 30sec annealing at Ta and 1min extension at 72C, followed by 4min final extension. 
DNA was resolved using agarose gels with ethidium bromide and imaged on an iBright 
FL1000 (Thermo Fisher Scientific).  
Quantitative reverse transcription PCR. RNA was extracted using the Qiagen RNeasy Kit 
following manufacturer instructions, RNA content measured via NanoDrop and 
concentrations adjusted to 0.5µg/µl for each sample. The reverse transcriptase reaction was 
performed using the Qiagen QuantiTect RT PCR Kit following manufacturer instructions. 
Quantitative PCR was carried out using Qiagen QuantiTect SYBR Green PCR Master Mix 
following manufacturer instructions at a Ta of 62°C on a Thermo Scientific StepOnePlus 
RT qPCR instrument using StepOne software v2.3. Primer efficiency E was determined 
for each primer pair by performing a dilution series, determination of the slope and 
calculation of E = -1+10(-1/slope). Data was analyzed and relative expression ratios calculated 
using the Pfaffl Method (Pfaffl, 2001). Primers used to quantify mRNA levels: GAPDH: 
Fwd: 5′-ACCCACTCCTCCACCTTTGAC-3′, Rev_5′-
CTGTTGCTGTAGCCAAATTCGT-3′; Cul4B: Fwd1_5’-GAAAGAAGCA-
GTGGAAGCTATTC-3′, Rev1_5′-TGCCAGCATCTATCAATCTTCT-3′; Cul4A: 
Fwd2_5’-CTCTACAAGCAACTGCGTCA-3′, Rev2_5′-GGCAGCGTGGAGTTCTG-3′; 
PCID2: FWD2_5’-CAAGTGCCAGACCGTGATAG-3′, REV2_5′-
CCGGAAACAGCTCATCAGT-AA-3′.   
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Denaturing cell lysis in 2xLDS buffer and western blotting. Cells grown in a 6-well dish 
(~2x10^6 cells/well) were lysed in 600µl 2x LDS (Lithium dodecyl sulfate) sample buffer 
, sonicated for 10sec with 1sec ON and 1sec OFF at 20% amplitude on a Qsonica Q500 
(Converter Model CL-334, Probe ½” #4220, microtip 1/8” #418-A) or for 10sec with 1sec 
ON and 1sec OFF at 55% amplitude on a Qsonica Q125 (Converter Model CL-18, microtip 
1/8” #422-A). Samples were then boiled at 70°C for 10-15min and either stored at -80°C 
or processed via SDS PAGE using Novex Bolt Bis-Tris 4-12% precast gels and Bolt MOPS 
SDS running buffer. Subsequently, proteins were transferred to PVDF membranes using a 
wet blot system and Tris-Glycine transfer buffer (Novex LC3675 + 20% Methanol) 
containing 20% methanol at 4°C. Membranes were blocked with 5% non-fat dry milk for 
at least 5min before incubation with primary antibodies. Primary and secondary antibody 
incubations were carried out for 60min, each followed by three brief washes with TBS-
Tween (Tris-buffered saline; 50mM Tris-Cl, 150mM NaCl, pH 7.5, 0.1% Tween) and one 
wash on an orbital shaker for 20min.   
To quantify proteins via western blotting, cells were lysed in 2xLDS and processed as 
described above. PVDF membranes were then blocked using LI-COR Odyssey blocking 
Buffer TBS (LI-COR Part No. 927-50000) for 30min followed by simultaneous incubation 
of primary and fluorescent secondary antibodies in 1% non-fat dry milk in TBS-Tween 
over-night. Membranes were then washed with three in-hand washes using TBS-Tween, 
one wash in TBS-Tween on an orbital shaker for 20min followed by one more wash in 
PBS for 10min. 
Native cell lysis and CRL-exchange blocking techniques. Cells were trypsinized and 
harvested in growth medium, followed by cell counting. If cells were exposed to 
treatments, cells were harvested in the pre-conditioned or treatment-containing growth 
medium. Cells were then collected via centrifugation at 1200xg for 2min, and (1) either 
lysed without blocking CRL-exchange or (2) lysed in the presence of 2.5 µM Molecular 
Sponge (His6-Cul4A•Rbx1GST) or (3) resuspended in 4ml growth medium containing 1µM 
MLN4924 and CSN5i-3 (N8 Block) followed by 3min incubation and another 2min 
centrifugation at 1200xg and resuspension in lysis buffer. The concentration of 1µM 
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MLN4924 was chosen as the maximum concentration that allows NAE1 specificity 
without inhibition of Ubiquitin E1 (Soucy et al., 2009). The treatment time was chosen as 
the shortest practically possible time in which full inhibtion of NAE1 as well as CSN could 
be achieved consistently as shown by samples treated with either inhibitor itself, resulting 
in either full de-neddylation or neddylation within 5min (Figure 3.2G). Cells from two 
15cm plates (~80x106) were lysed using sonication in 3.6ml and cells from one 15cm plate 
(~40x106) in 2.1ml of Pierce IP Buffer (25mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP-
40, 1mM EDTA, 5% glycerol) containing a protease inhibitor cocktail (Roche). Sonication 
was either carried out on a Qsonica Q500 (Converter Model CL-334, Probe ½” #4220, 
microtip 1/8” #418-A) for 10sec with 1sec ON and 1sec OFF at 20% amplitude or on a 
Qsonica Q125 (Converter Model CL-18, microtip 1/8” #422-A) for 10sec with 1sec ON 
and 1sec OFF at 55% amplitude. Lysates where cleared by centrifugation at 18.000xg for 
2min at 4°C and supernatants used for affinity purification. 
Whole cell lysis and sample preparation for LC-MS analysis. To estimate cellular protein 
concentrations via the CRL4 QconCAT PRM LC-MS assay, 4x106 cells were resuspended 
in 500µl of 8M urea in 100mM ammonium bicarbonate solution containing 5mM TCEP 
reducing agent and sonicated on a Qsonica Q125 (Converter Model CL-18, microtip 1/8” 
#422-A) for 20sec with 1sec ON and 1sec OFF at 55% amplitude. Lysates where cleared 
by centrifugation at 18.000xg for 2min at 4°C whereby no insoluble pellet was visible. 
Protein content of whole cell lysates was measured using NanoDrop A280. Subsequently, 
200µg of lysate was diluted to a final volume of 50µl containing 50fmol or 100fmol CRL4 
QconCAT standard. Samples were then incubated at 23°C for 30min in a ThermoMixer, 
before addition of 0.78µl of 700 mM iodoacetamide for alkylation of cysteine residues 
(final conc. 10.75 mM) for 15min. Subsequently, samples were diluted to 6M urea by 
adding 16µl of 50mM ammonium bicarbonate and the protein digest was started by adding 
7µg LysC for 1-4 hours at 23ºC. After that, samples were diluted using 50mM ammonium 
bicarbonate to a concentration of 2M urea before adding 1mM CaCl2 and 10µg trypsin for 
over-night incubation. 
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Affinity-Purification, elution and sample preparation for LC-MS analysis. All experiments 
and digests were performed in 5ml or 1.5ml LoBind Eppendorf tubes. Lysates at volumes 
of 3.6ml and 2.1ml were exposed to 150µl or 75µl of anti-FLAG or anti-HA resin (~75µl 
and ~37.5µl packed beads) for 45 min unless otherwise stated. Subsequently, the resin was 
collected via centrifugation at 2000xg for 2min and the flow through was removed with a 
26G subcutaneous needle under vacuum until the resin was almost dry. The beads were 
then washed once in 3ml and once in 1ml Pierce IP buffer, twice in 1ml reconstituted IP 
Buffer without NP-40 and twice in 1ml of 100mM Tris-HCl pH 7.5, followed by removal 
of as much liquid as possible with a 26G needle under vacuum. Immunoprecipitated 
complexes were eluted twice in 150µl 10% NH4OH at 37°C for 5min at 950rpm in a 
ThermoMixer. Eluates were then collected by filtering the bead suspension through 5µm 
spin filters at 8000xg followed by flash freezing on dry ice and lyophilization. Eluted 
proteins were then resuspended in 50µl 8M urea in 100mM ammonium bicarbonate 
solution containing 5mM TCEP reducing agent for 30min at 23ºC, followed by the addition 
of 0.78µl of 700 mM iodoacetamide for alkylation of cysteine residues (final conc. 10.75 
mM) for 15min at 23°C at 750rpm in a ThermoMixer protected from light. Subsequently, 
samples were diluted to 6M urea by adding 16µl of 50mM ammonium bicarbonate and the 
protein digest was started adding 1.78µg LysC for 1-4 hours at 23ºC. After that, samples 
were diluted using 50mM ammonium bicarbonate to a concentration of 2M urea before 
adding 1mM CaCl2 and 2.5µg trypsin for over-night incubation.   
C18 desalting of digested samples. Digested WCL or IP protein samples were acidified 
through addition of 25µl 50% formic acid and diluted by adding 250µl buffer A (98% H2O, 
2% acetonitrile, 0.2% formic acid) before a desalting step using 10mg SOLA HRP SPE 
cartridge (Thermo Scientific Prod. No. 11879163). SPE cartridges were equilibrated in 
methanol and washing steps were performed in H2O containing 0.2% formic acid. Elution 
of peptides was carried out in 300µl elution buffer (50% H2O, 50% acetonitrile, 0.2% 
formic acid) and samples were flash frozen on dry ice followed by lyophilization. 
Lyophilized samples were resuspended in 11-21 µl Buffer A for subsequent LC-MS 
analysis.  
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Mapping of endogenous CRL4 complexes using label-free AP-MS and SAINT. 293T/17 
wild type cells as well as 293T/173xFLAG-Cul4A (clone A22) and 293T/173xHA-Cul4B (clone 
B15) were grown to 90% confluency in 15cm plates, lysed and lysates immunoprecipitated 
with either anti-FLAG or anti-HA resin. Elution and sample preparation for LC-MS were 
carried out as described above. MS data was acquired on an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA) and peptide searches performed 
using COMET and analyzed using SAINT as described below.  
Mapping of DDB1-Cul4 associated factors (DCAFs) via SILAC AP-MS. On day 1, 293T/17 
cells were transiently transfected (~8x106 cells in a 10cm plate) with either wild type 
3xHA-Cul4 (transcript variant 1) or 3xHA-Cul4B (transcript variant 2) and grown in heavy 
SILAC medium (K8R6) or with 3xHA-Cul4A∆DBD(K41-L93) and 3xHA-Cul4B∆DBD(K177-L229) 
lacking the DDB1 binding domain and grown in light SILAC medium and split into a 15cm 
plate on day 2. Cells were then lysed on day 3 (w/o Nedd8-Block), and lysates 
immunoprecipitated with anti-HA resin and eluted as described above. IP-eluates of WT 
and mutant IPs were mixed 1:1 and subsequently processed for LC-MS analysis (described 
above, Figure S1A).  
CRL4 SILAC Exchange Assay. Wild type cells were grown in light SILAC medium and 
engineered cells carrying a 3xHA epitope tag on Cul4B were grown in heavy SILAC 
(K8R10) for at least ten doublings. Some individual experiments were carried out with 
swapped labels, whereby wild type cells were labeled heavy and epitope-tagged cells were 
labeled light, and no differences in results were observed. Cells were harvested via trypsin 
and mixed 1:1 (80x106 cells total, 1x15cm plate each) before lysis and 
immunoprecipitation as described above. IPs were carried out for 20min, 60min or 180min 
counting from moment of cell lysis by sonication. LC-MS data was acquired an Orbitrap 
Fusion Lumos mass spectrometer (Thermo Fisher Scientific, San Jose, CA) and peptide 
search as well as data analysis was performed as described below.  
CRL4 SpikeMix PRM LC-MS Assay. For development of a targeted proteomics assay to 
quantitatively monitor the CRL4 protein network, three, in some cases two, target peptides 
for each of 142 previously reported or predicted CRL4 network proteins were selected 
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following established guidelines (Picotti and Aebersold, 2012; Picotti et al., 2010) yielding 
a peptide library of 418 peptides. Priority was given to peptides observed in our initial AP-
MS experiments or to peptides that have previously been observed on our instruments, an 
approach that covered ~80% of all proteins of interest. Peptides for the other ~20% of 
proteins were chosen using SRMAtlas (Kusebauch et al., 2016). This comprehensive 
peptide library of 418 peptides was synthesized as a SpikeMix by JPT Peptide 
Technologies isotopically heavy labeled with (K8R10 = 13C6 15N2-lysine and 13C6 15N4-
arginine). Lyophilized peptide standards (0.3-0.5 nmol per peptide) were first resuspended 
in 80µl of 20% acetonitrile and 0.2% formic acid to yield a CRL4 SpikeMix master stock 
solution of ~3-5pmol/peptide/µl. The master stock was further diluted 1:50 in Buffer A 
(2% acetonitrile, 0.2% formic acid) to yield aliquots at ~60-100fmol/peptide/µl which were 
used for experiments or stored long term at -80C. PRM LC-MS analysis of standard 
peptides alone confirmed no significant signal in the light channel. A standard Cul4-IP 
eluate from 40x106 cells was resuspended in 21µl of Buffer A containing 1.5-
2.5fmol/peptide/µl, yielding a peptide mixture of ~0.25µg/µl of which 2-4 µl were injected 
for LC-MS analysis. After determining the specific Cul4-interactome in our cell system, 
we excluded proteins that did not interact with Cul4 and settled for a method targeting 58 
individual peptides to monitor 37 Cul4 interacting proteins (see Table Supplement 3.2 for 
PRM mass table). LC-MS data was acquired on an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA) and data analysis was performed as 
described below.  
QconCAT PRM LC-MS Assay. For development of targeted proteomics assay capable of 
measuring concentrations of CRL4 components within individual WCL or IP samples, we 
designed a CRL4 QconCAT protein standard consisting of 67 concatenated reference 
peptides (Table Supplement 3.3) for 31 proteins yielding one polypeptide chain with 
equimolar amounts of each standard (Pratt et al., 2006; Scott et al., 2016). The QconCAT 
was synthesized and purified by PolyQuant GmbH, Bad Abbach, Germany, with stable 
isotope labeled arginine (R10; 13C615N4) and and lysine (K8; (13C615N2) (labeling efficiency 
~98%) yielding a homogenous protein reagent (Figure Supplement 3.3A, B). The amounts 
of QconCAT standard added to WCL or IP samples was chosen so that all PRM ratios 
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measured were well beyond the ~2% background signal (Figure Supplement 3.3C, F). 
After initial tests, 61 peptides were targeted to monitor 31 proteins (see Table Supplement 
3.4 for PRM mass table). LC-MS data was acquired on an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA). Data analysis was performed as 
described below. 
LC-MS data acquisition for label-free and SILAC analyses. For all experiments, except the 
ones displayed in Figure Supplement 3.1D-F, peptides were separated using either a 
prepacked 25cm column from New Objective (PicoFrit Acquity® BEH130Å C18 column, 
1.7 µM, 100 µM x 250 mm) or IonOpticks (Aurora Series) via a Dionex UltiMate 3000 
RSLCnano Proflow system (Thermo Fisher Scientific, Sunnyvale, CA) or a nanoAcquity 
UPLC (Waters) with a gradient of 2% buffer A (98% H20, 2% ACN with 0.1% formic 
acid) to 35% buffer B (98% ACN, 2% H20, 0.1% formic acid) with a flow rate of 450 
nL/min over 90 minutes.  Eluting peptides were sprayed into a Fusion Lumos mass 
spectrometer (Thermo Fisher Scientific) at a voltage of 1.9kV (NewObjective column) or 
1.5kV (IonOpticks column). Full MS scans were collected in the orbitrap at 240,000 
resolution, across a range from 350 to 1350 m/z, with an automatic gain control (AGC) 
target of 1 x 106, and a maximum injection time of 50ms. MS2 ions were selected in 0.7 
Da isolation width using a top speed data dependent mode and fragmented with HCD 
energy of 30%, over a scan range of 200-1200 m/z and AGC target of 2 x 104 at a maximum 
injection time of 11ms. All mass spectrometry raw files have been deposited into the 
MassIVE database (http://massive.ucsd.edu/). 
For experiments displayed in Figure Supplement 3.1D-F, peptides were resuspended in 
0.2% formic acid and directly loaded onto a PicoFrit column (New Objective, Woburn, 
MA) packed in house with ReproSil-Pur C18AQ 1.9 um resin (120A° pore size, Dr. 
Maisch, Ammerbuch, Germany). The 25cm x 50µm ID column was heated to 60° C. The 
peptides were separated with a 120 min gradient at a flow rate of 220 nL/min using a 
nanoflow LC system, EASY-nLC 1000 or 1200 (Thermo Fisher Scientific). The gradient 
was as follows: 2–6% Solvent B (7.5 min), 6-25% B (82.5 min), and 25-40% B (30 min), 
to 100% B (1min) and 100% B (9min). Solvent A consisted of 97.8% H2O, 2% ACN, and 
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0.2% formic acid and solvent B consisted of 19.8% H2O, 80% ACN, and 0.2% formic 
acid. The separated peptides were ionized by a Nanospray Flex ion source and subjected 
to MS/MS analysis using either a QExactive HF Orbitrap or Fusion Orbitrap mass 
spectrometer (Thermo Fisher Scientific, San Jose). 
The QExactive HF Orbitrap was operated in data dependent mode. Spray voltage was set 
to 2.5 kV, S-lens RF level at 50, and heated capillary at 275 °C. Full scan resolution was 
set to 60,000 at m/z 200. Full scan target was 3 × 106 with a maximum injection time of 15 
ms (profile mode). Mass range was set to 300−1650 m/z. For data dependent MS2 scans 
the loop count was 12, target value was set at 1 × 105, and intensity threshold was kept at 
1 × 105. Isolation width was set at 1.2 m/z and a fixed first mass of 100 was used. 
Normalized collision energy was set at 28. Peptide match was set to off, and isotope 
exclusion was on. Ms2 data was collected in centroid mode. 
The Fusion Orbitrap was operated in data dependent mode using a top-speed approach 
(cycle time of 3 s). Spray voltage was set to 2.5 kV, S-lens RF level at 60, and heated 
capillary at 275 °C. Full scan resolution was set to 120,000 at m/z 200. Full scan target was 
4 × 105 with a maximum injection time of 50 ms (profile mode). Mass range was set to 
350−1500 m/z. The MS2 was performed in HCD cell with detection in Orbitrap. For MS2 
scans Orbitrap resolution was set to 30,000 at m/z 200 and target value was set at 1 × 105 
with a maximum injection time of 50 ms (centroid mode). Isolation width was set at 1.6 
m/z and a fixed first mass of 120 was used. Normalized collision energy was set at 35.  
LC-MS data acquisition for PRM analyses. For all PRM experiments, peptides were 
separated using either a prepacked 25cm column from New Objective (PicoFrit Acquity® 
BEH130Å C18 column, 1.7 µM, 100 µM x 250 mm) or IonOpticks (Aurora Series) via a 
Dionex UltiMate 3000 RSLCnano Proflow system (Thermo Fisher Scientific, Sunnyvale, 
CA) or a nanoAcquity UPLC (Waters) with a gradient of 2% buffer A (98% H20, 2% ACN 
with 0.1% formic acid) to 35% buffer B (98% ACN, 2% H20, 0.1% formic acid) with a 
flow rate of 450 nL/min over 75 minutes.  Eluting peptides were sprayed into a Fusion 
Lumos mass spectrometer (Thermo Fisher Scientific) at a voltage of 1.9kV (NewObjective 
column) or 1.5kV (IonOpticks column). MS1 scans were collected in the Orbitrap at 60,000 
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resolution, across a range from 300 to 1200 m/z, with an automatic gain control (AGC) 
target of 1 x 106 and a maximum injection time of 50ms. Trigger peptides were placed on 
an inclusion list with their corresponding m/z, z and retention time window of 5min (for 
inclusion lists see Table Supplement 3.2 and 3.4). Trigger peptides were selected for MS2 
across an isolation window of 1.2 m/z, fragmented by CID (Collision Energy 30%), and 
the resulting fragments analyzed in the Orbitrap (resolution 60,000, range 288-2000 m/z, 
AGC target 2e5). Hereby, the maximum injection time was 118ms for all peptides except 
DCAF15 (R0K0 DSPPASEAPASEPGYVNYTK, m/z 1040.47862) which was allowed a 
max. injection time of 500ms. All mass spectrometry raw files have been deposited into 
the MassIVE database (http://massive.ucsd.edu/). 
Expression and purification of recombinant proteins. His6Cul4A/Rbx1GST, Cul1/Rbx1GST, 
and Cand1 were expressed and purified from B21 E.coli cultures as described in Pierce et 
al. 2013, Liu et al. 2018.  
Quantitative western blotting. Images were acquired using a LI-COR Odyssey XR and 
quantified via the ImageStudio software using the median background subtraction method 
(Segment All). The signal of the protein of interest was normalized towards the signal of a 
loading control. Data from triplicate experiments (n=3) was plotted and further analyzed 
using GraphPad PRISM. Statistical parameters are reported in the figure legends.  
LC-MS Data analysis. SILAC AP-MS Data (QE-HF): Thermo raw files were processed 
and searched using MaxQuant (v. 1.5.5.1) (Cox and Mann, 2008; Cox et al., 2011). Spectra 
were searched against human UniProt entries and a common contaminant database. 
Trypsin was specified as the digestion enzyme and up to two missed cleavages were 
allowed. False discovery rates were estimated using a target-decoy approach, where the 
decoy database was generated by reversing the target database sequences. Protein, peptide, 
and PSM scores were thresholded to achieve a 1% FDR at each level. 
Carbamidomethylation of cysteine was specified as a fixed modification. Protein N-
terminal acetylation and methionine oxidation were specified as variable modifications. 
Precursor mass tolerance was 4.5 ppm after mass recalibration and fragment ion tolerance 
was 20 ppm. Search type was specified as “Standard”, with multiplicity of 2 and K8 (13C6 
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15N2-lysine) and R6 (13C6-arginine) were specified as heavy labels. Both re-quantify and 
match-between-runs were enabled. In some cases, multiple technical replicates were 
included and these were pooled together under the same experiment name. 
Protein ratios were calculated as the geometric mean of the biological replicates. Statistical 
significance of the protein ratio was calculated using the moderated t-test in the R package 
limma (Smyth et al., 2011). 
SILAC Exchange Data (Fusion Lumos): MS/MS spectra were searched using Mascot 
(v.2.4.1) (Pappin et al., 1999) against a human UniProt DB (2017_08) database with a 
taxonomy filter of ‘9606’ containing common contaminating proteins and concatenated by 
all decoy sequences. Search parameters included trypsin cleavage with allowance of up to 
2 missed cleavage events, a precursor ion tolerance of 50 ppm, and a fragment ion tolerance 
of 0.8 Da. Searches permitted variable modifications of methionine oxidation (+15.9949 
Da), K8 (+8.0142 Da), R10 (+10.00827 Da), and static modifications of cysteine (+57.0215 
Da) for carbamidomethylation. Peptide spectra matches (PSMs) were filtered with a false 
discovery rate (FDR) of 5% on the peptide level and subsequently at 5% on the protein 
level using linear discrimination. SILAC log2 ratios of identified peptides were quantified 
with an in-house software package known as VistaQuant (Bakalarski et al., 2008). SILAC 
log2 ratios of each sample were transformed to H/L ratios and normalized to the overall 
median H/L ratio to account for variations in cell mixing. If epitope-tagged cells were 
grown in light and wild type cells were grown in heavy, percent exchange was determined 
based on the median normalized H/L ratio, a ratio of 1 indicating 100% exchange of the 
individual Cul4 interacting protein. 
Label-free data: All MS/MS spectra were searched using the Comet (v2017.01) (Eng et 
al., 2013) search algorithm against a concatenated target-decoy database composed of the 
UniProt (2017_08) human protein sequences, known contaminants and the reversed 
versions of each sequence. A 50ppm precursor ion mass tolerance and 0.8 Da fragment ion 
tolerant were selected and tryptic specificity was defined with up to 2 missed cleavages.  
Variable modifications were permitted for methionine oxidation (+15.9949 Da) and the 
iodoacetamide adduct for cysteine residues (+57.0215 Da).  Peptide assignments were first 
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filtered to a 1% false discovery rate (FDR) at the peptide level and subsequently to a 1% 
FDR at the protein level. Peptide Spectral Matches (PSMs) per protein were summed per 
sample and used as input for the Statistical Analysis of INTeractome (SAINT) algorithm 
(SAINTExpress-spc 3.6.1) (Choi et al., 2011). SAINT was run with default settings 
comparing the sum of PSMs for all identified proteins enriched in bait IPs versus the 
respective control IPs, across all replicates. Interactions with a positive SAINT 
logOddsScore and Bayesian False Discovery Rate (BFDR) < 0.05 were marked as 
significant. 
PRM data: PRM raw files were loaded into Skyline version 4.1 (MacLean et al., 2010) pre-
populated with target peptides and proteins using a transition filter allowing for precursor 
charges 2 and 3, ion charges 1 and 2 and y-ion types, followed by manual peak analysis. 
To be considered for quantitative analysis, peptides needed to yield at least two product 
ions with intensities > 1000 counts/second present in all samples of the experiment. 
Peptides that were not detected and inferring product ions were removed. Peptide ratio data 
were exported using the Export>Report>Peptide Ratio Results function. Peptide Ratio 
Result files were further processed using RStudio version 1.1.442 (R version 3.4.4) to 
transform individual peptide data into protein ratios or concentrations. Statistical analysis 
was performed using GraphPad Prism and statistical parameters are indicated in individual 
figure legends.  
In general, experiments analyzed with CRL4 SpikeMix peptides and relative quantification 
included a control sample that was left untreated to which every other condition was 
compared to. In experiments analyzed with CRL4 QconCAT standard and “absolute” 
quantification samples were directly compared to each other.  
Calculation of cellular abundances. Data was manually analyzed via Skyline as described 
above and the peptide ratio results output file was loaded into R Studio to perform 
calculations of cellular abundances using the following script: 
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Stoichiometric analysis of CRL4 complexes. As displayed in Figure Supplement 3.3F, all 
DCAFs except RFWD2, PHIP, and PWP1 displayed a signal to noise ratio of > 5. If the 
measurements displayed in Figure 3C were accurate, several control criteria should be met: 
First, our assay detected peptides that were either shared (representing all Cul4 = 
Cul4A+Cul4B) by or unique to Cul4A and Cul4B. Therefore, the values measured for the 
shared peptides need to approximately match the sum of values obtained for the unique 
peptides. Second, since cullin proteins are only stable when in complex with Rbx1, the 
amount of total Cul4 should match Rbx1. Third, based on excess Cand1 and DDB1•DCAF 
over total Cul4 within cells and relatively high binding affinities, we would expect the 
scaffold to be occupied by either Cand1 or DDB1•DCAFs at all times. If so, the sum of 
DDB1 and Cand1 should approximately match total Cul4 or exceed Cul4 by a bit if ternary 
#Read Skyline output file 
df <- fread(PeptideRatioResults ") 
 
# Select columns for calculations 
df <- select(df,Peptide_Sequence, Protein_Name, Replicate_Name, Ratio_To_Standard) 
 
# Group and Summarize by protein name - CAVE: ONLY for QconCAT possible to group al peptide ratios 
 
df <- df %>%  
  group_by(Protein_Name, Replicate_Name) %>% 
  summarise(avg_Ratio = mean(Ratio_To_Standard, na.rm = T),  
            peptides = paste(unique(Peptide_Sequence), collapse = ", ")) 
 
# Spread for horizontal display of samples 
df <- spread(df, Replicate_Name, avg_Ratio) 
 
# Parameters for Calculation - units µl, excep Vc is L, and nM:  
# VL=Vol Lysate, VS = Volume Sample, Vst = Vol Standard, VD = Vol digest, Cst = Conc standard, Nc = Number of cells, Dc = Diameter of Cells, 
effNc = Number of cells used,effective number Vc = Vol of Cell 
# measure and adjust for individual experiments 
 
VL=500 
VS=36.5 
Vst1=4 
VD=50 
Cst=25 
Nc=4.39*10^6 
Dc1=15.09 
pi=3.14159265359 
effNc = Nc*(VS/VL) 
Vc1=((4/3*pi*(((Dc1/10^6)/2)^3))*1000) 
Na=6.022140857*10^23 
 
 
# Calculation of nM cellular concentration 
# Formula: (((((avg_Ratio *((Cst*Vst)/VD))*(VD*10^-6))/effNc)/10^9)/Vc)*10^9 
 
df <- df %>% 
  mutate(S1_nM = (((((S1 *((Cst*Vst1)/VD))*(VD*10^-6))/effNc)/10^9)/Vc1)*10^9) 
   
# Calculation of molecules per cell 
#Formula ((((avg_Ratio *((Cst*Vst)/VD))*(VD*10^-6))/effNc)/10^9)*Na 
 
 
df <- df %>% 
  mutate(S1_molecules = (((((S1 *((Cst*Vst1)/VD))*(VD*10^-6))/effNc)/10^9)*Na)) 
   
 
write_csv(df, 'WCL_cellular_nM_Molecules.csv') 
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complexes are detected. Fourth, every DCAF bound to Cul4 requires one adapter molecule 
DDB1. Hence, if DDB1 doesn’t occupy Cul4 by itself, the sum of all 22 DCAFs assessed 
in our assay should roughly equal the total amount of DDB1. All four control criteria are 
met with relatively small discrepancies: (1) Cul4A + Cul4B = Cul4 +/- 12%; (2) Cul4 = 
Rbx1 +/- 5-18%; (3) Cand1 + DDB1 = Cul4 +/- 10-23%, (4) 22 DCAFs Total = DDB1 +/- 
15%. 
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3.6 Figures and Supplemental Figures 
Figure 3.1 
Figure 3.1. A toolbox to monitor endogenous CRL4 complexes. Schematic representation of the PIKES 
approach: (1) 293T/17 cells were genetically engineered to carry a 3xFLAG or 3xHA on Cul4A or Cul4B or 
both to enable rapid and efficient (2) immunoprecipitation of endogenous CRL4 assemblages.  (3) 
Endogenous CRL4 ligase complexes were then evaluated systematically using global and targeted proteomic 
approaches. First, the protein interaction network of interest was analyzed at endogenous protein levels 
followed by a kinetic characterization of these interactions, which prompted the development of chemical 
and biochemical methods to control and preserve the composition of protein complexes. Subsequently, the 
cellular concentrations and complex stoichiometries were analyzed using QconCAT standards, and induced 
changes in complex composition were monitored quantitatively. 
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Figure 3.2. CRL4 complexes exchange DDB1•DCAFs via Cand1 and are stabilized by CSN5i-3 and 
Molecular Sponge. (A) Schematic display of CRL4 SILAC exchange assay. (B) and (D) CRL4B interactor 
exchange is suppressed in Cand1/2 KO, upon CSN de-neddylase inhibition with CSN5i-3 (maintaining 
Nedd8-Cul4), and in the presence of molecular sponge. (C) and (E) Conservation of CRL neddylation via 
N8-block, a brief pre-treatment with 1µM MLN4924 and CSN5i-3 for 5min before cell lysis. F) Schematic 
representation of CRL4 Nedd8-Cand1-cycle and methods to suppress it post-lysis. The N8 Block is based on 
Figure 3.2 
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rapid and simultaneous chemical inhibition of both arms of the Nedd8 cycle using MLN4924 to inhibit NAE1 
and CSN5i-3 to inhibit CSN. The molecular sponge technique was pioneered by Reitsma et al. 2017 on the 
SCF system and is based on biochemical inhibition of Cand1/2-mediated CRL exchange. The recombinant 
cullin scaffold added in excess “sponges up” any free A•SR complexes as well as exchange factors Cand1/2, 
thereby preventing artifacts caused by post-lysis exchange while conserving protein assemblies that were 
formed pre-lysis. (G) Effect of CRL4 stabilizing treatments N8-Block and molecular sponge on endogenous 
Cul4B complexes as measured by PRM LC-MS. 
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Figure 3.3. Individual CRL4 ligases show Cullin-scaffold preferences and differ up to 100-fold in 
absolute abundance. (A) Schematic of CRL4 QconCAT experiments to determine cellular concentrations 
and complex stoichiometries. (B-D) Absolute quantification of CRL4 components in whole cell lysates as 
well as immunoprecipitated Cul4 complexes. *Cul4 scaffolds were measured by targeting peptides common 
(cP) or unique (uP) to Cul4A and Cul4B (E) Summary of cellular organization of CRL4 complexes. (F) and 
(G) Cellular concentrations of assembled CRL4s as well as DCAFs. (H) Correlation plot of % assembled and 
% all CRL ligases (i.e. fraction of overall CRL4 pool) of individual DCAFs. (I) Cul4 Scaffold preference of 
individual DCAFs as measured via two independent assays and six independent experiments. In all figures, 
error bars represent the mean ± SEM. The box and whisker plots represent the median, lower, and upper 
quartile as well as the highest and lowest observation. 
  
Figure 3.3 
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Figure 3.4. CRL4s reshape their assemblies and form Cul4A•Cul4B dimers upon UV-induced DNA 
damage. (A) 293T/173xHA-Cul4B cells were exposed to UV light at a dose of 50 J/m2 and lysed in SDS 
sample buffer at indicated time points followed by SDS PAGE and western blot. (B) Heatmap of CRL4B 
response to UV light at a dose of 50 J/m2, as measured via PRM LC-MS analysis of immunoprecipitated 
CRL4B complexes. Mean changes in proteins associated with Cul4B were transformed to log2 values and 
graphed as heatmap. (C-F) Individual bar graphs of protein responses displayed in (B). Error bars represent 
the mean ± SEM. The specificity of the signals measured was tested against bead-background as displayed 
in Figure S5.  
Figure 3.4 
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Figure 3.5. Degrader molecules minimally reshape ligase assemblies without disturbing the overall 
CRL4 network. (A) and (B) Schematic representation of degrader drugs, ligases and substrates used in this 
study. Bar graphs show % of all CRL4s for CRBN and DCAF as obtained in experiments displayed in Figure 
3. (C) and (D) Turnover of CRL4 neo-substrates CK1 , ZFP91, BRD4 and RBM35 as assessed via 
quantitative western blot. Data of Figure S5C was fitted to a single exponential decay function to obtain t1/2. 
(E) and (F) Copy number estimates for DCAF-neo-substrate pairs extracted from data published by Wang et 
al. 2019. Each dot represents the copy number in one tissue and the red line represents the median. (G) 
Calculations of molecule turnover rates for studied CRL4-neosubstrates. (H-K) Changes in DCAF binding 
to Cul4 upon treatment with different degrader molecules. For (H, I), cells were treated for 1 hour with 30µM 
lenalidomide, 100nM dBET1 or 500nM dTAG-13. Each dot represents a DCAF, yellow dots represent 
CRBN. For (J, K), cells were treated with 2µM indisulam for different times. Immunoprecipated Cul4 
Figure 3.5 
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complexes were analysed via PRM LC-MS, for details see Material & Methods. Each dot represents a DCAF, 
and yellow dots represent DCAF15. Error bars represent the mean ± SEM. 
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Figure 3.6. Higher DCAF expression can result in faster substrate degradation and increased degrader 
potency. (A) Variation of CRL4 component protein expression across 29 healthy human tissues. Data 
extracted from Wang et al. 2019. The box and whisker plots represent the median, lower and upper quartile 
as well as the highest and lowest observation of iBAQ values for each protein in up to 29 tissues. (B) 
Simulation of IkBa degradation using the Liu et al. 2018 model of SCF regulation under different conditions. 
(C) Protein levels of Cul4 and DCAF15 as measured via CRL4 QconCAT PRM LC-MS in wild type and 
DCAF15 over-expressing 293T/173xFLAG-Cul4A & 3xHA-Cul4B cells. (D) Turnover of RBM39 assessed via 
quantitative western blot in wild type and DCAF15 over-expressing cells. Data of Figure S6D was fitted to 
a single exponential decay function to obtain t1/2. (E) Change in composition of CRL4 complexes when 
DCAF15 is overexpressed as assessed via CRL4 SpikeMix PRM LC-MS. Data was corrected for unspecific 
binding to beads of over-expressed DCAF15 as shown and described in Figure S6B, C. (F) Ternary complex 
formation of DCAF15•indisulam•RBM39 as assessed via capturing free DCAFs using molecular sponge and 
Figure 3.6 
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quantitative western blot, for details see Material & Methods. (G) Dose response curve of indisulam assessed 
in 293T/173xFLAG-Cul4A & 3xHA-Cul4B wild type or DCAF15 over-expressing cells. The figure was generated on 
the basis of data from Figure S6A and dose response model ([drug] vs. normalized response) fit was applied 
to obtain a DC50. Error bars represent mean ± SEM, except for box-whisker plots in (A). 
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Figure Supplement 3.1. A toolbox to study endogenous CRL4 complexes. (A-C) 293T/173xFLAG-Cul4A 
(clone A22) and   293T/173xHA-Cul4B (clone B15) were lysed and immunoprecipitated via anti-FLAG and anti-
HA resin followed by elution of CRL4 complexes and LC-MS analysis. SDS-PAGE and western blot analysis 
(A) confirms successful capture of intact CRL4 complexes and specifically enriched proteins are pictured in 
two volcano-plot like graphs featuring average spectral counts and logOddsScores. (D-F) 293T/17 cells were 
Figure Supplement 3.1 
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either grown in heavy (R6K8) SILAC medium or light medium and transiently transfected with wild type 
3xHA-Cul4A or Cul4B (heavy labeled cells) or a 3xHA-Cul4A/B deletion mutant missing the DDB1-binding 
domain (∆DBD) (light labeled cells). Cells were lysed and immunoprecipitated via anti-HA resin followed 
by elution and 1:1 mixing of Cul4A/B wild type and Cul4A/B∆DBD complexes followed by LC-MS analysis 
(D). Volcano plots showing DDB1-dependent Cul4 interacting proteins significantly enriched in the analyzed 
immunoprecipitates (E, F). (G) Table summarizing the composition of endogenous CRL4 complexes based 
on experiments displayed in (A-F). (H-F) Assessment of CRL4 SpikeMix PRM MS assay. 
Immunoprecipitated Cul4B complexes were eluted and digested followed by addition of CRL4 SpikeMix 
standards at four different concentrations and PRM analysis. Displayed are the PRM ratios of all successfully 
targeted and detected peptides on a log scale as well as the ratio to concentration relationship for three 
peptides with a high (DDB1), medium (CRBN) and low PRM-Ratio (DCAF15) (H). (I) Raw Skyline 
chromatograms of the lowest abundant peptide in the assay. 
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Figure Supplement 3.2. CRL4 complexes exchange DDB1•DCAFs via Cand1 and are stabilized by 
CSN5i-3 and Molecular Sponge. (A) 293T/173xHA-Cul4B cells were grown in heavy medium and 293T/17 
WT cells in light medium, harvested and mixed at a ratio of 1:1, followed by lysis and anti-HA 
immunoprecipitation for different periods of time as well as LC-MS analysis. SILAC ratios of Cul4-binding 
proteins of ~1 translate to 100% exchange. This data is displayed as a dot-plot in Figure 3.2B. (B) Flp-In T-
REx HEK2933xHA-Cul4B Cand1/2 double knock out (DKO) cells were grown in light medium and Flp-In 
Figure Supplement 3.2 
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T-REx HEK293 DKO cells in heavy medium and processed as for (A). This data is displayed as a dot-plot 
in Figure 3.2C. (C, D) Flp-In T-REx HEK2933xHA-Cul4B Cand1/2 double knock out (DKO) and wild type 
cells were treated with 2µM indisulam for indicated times, lysed in 2x LDS buffer and processes for 
quantitative western blotting. Data was plotted and fitted to a single exponential to yield t1/2. (E)  
293T/173xHA-Cul4B cells were grown in heavy medium and 293T/17 WT cells in light medium, either pre-
treated with 1µM MLN4924 or 1µM CSN5i-3 for 4h and processes as for (A).  (F) Flp-In T-REx 
HEK2933xHA-Cul4B Cand1/2 double knock out (DKO) cells were grown in light medium, lysed and 
immunoprecipated via anti-HA resin and either exposed to lysis buffer or lysis buffer with 1µM Cand1 and 
incubated for 60min under rotation at 4C. Bead-bound complexes were then washed and processed for PRM 
LC-MS analysis. Error bars represent the main ± SEM. 
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Figure Supplement 3.3. Individual CRL4 ligases show Cullin-scaffold preferences and differ up to 200-
fold in absolute abundance. (A) Coomassie stained SDS-PAGE gel of 1µg CRL4 QconCAT standard. (B) 
CRL4 QconCAT protein was digested with trypsin and analysis via PRM MS to determine the labeling 
efficiency. (C) 293T/173xFLAG-Cul4A & 3xHA-Cul4B cells were lysed in 8M Urea, spiked with CRL4 
QconCAT protein standard followed by tryptic digest and PRM LC-MS analysis. Heavy to Light ratios were 
Figure Supplement 3.3 
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converted to nM cellular concentrations as described in the methods section. Shown in (C) are the PRM ratios 
measured for the experiment displayed in Figure 3B. The spiked concentration of the QconCAT standard 
was chosen so that all PRM ratios measured were well beyond the ~2% background signal. (D, E) iBAQ 
values for the indicated proteins were extracted from Wang et al. 2019 and Cul4B/Cul4A ratios as well as 
DDB1/Cul4 Ratios calculated and plotted. (F) CRL4 complexes were immunopurified from 
293T/173xFLAG-Cul4A & 3xHA-Cul4B cells pulsed N8 Block (5min 1µM CSN5i-3 & 1µM MLN4924) 
via combined anti-HA and anti-FLAG IP, eluates spiked with CRL4 QconCAT protein standard and analyzed 
via PRM LC-MS. Shown are the PRM ratios measured for the experiment displayed in Figure 3C. (G) 
Occupancies of the Cul4 scaffold by various proteins as calculated from experiments displayed in Figure 3B, 
C. (H) CRL4 stoichiometries as measured for a Cul4 IP sample from cells where post-lysis exchange was not 
inhibited. (I) Correlation plot of cellular concentrations of DCAFs and their overall % representation within 
all captured CRL4 complexes. (J) Percent Assembly (Percent of DCAF bound to Cul4 versus free) of each 
DCAF as calculated from stoichiometry data. (K) 293T/173xFLAG-Cul4A & 3xHA-Cul4B cells were pulsed 
with N8 Block and lysed in the presence of 2.5 µM rCul4A•Rbx1GST molecular sponge followed by 
sequential immunoprecipation via anti-FLAG, anti-HA and GSH resin to capture assembled CRL4 
complexes or free DDB1•DCAF modules. IP-eluates were digested, spiked with CRL4 SpikeMix peptide 
standard and analyzed via PRM LC-MS. (L) Percent Assembly of DDB1 as measured via (K) or calculated 
from stoichiometries and cellular concentrations. (M) comparing Percent Assembly for all assessed DCAF 
proteins as measured in (K) or calculated from stoichiometries and concentrations. (N) Lysates from 
293T/173xFLAG-Cul4A & 3xHA-Cul4B or 293T/17 wild type cells were immunoprecipitated with either 
anti-FLAG or anti-HA resin and eluates spiked with CRL4 SpikeMix followed by PRM analysis. PRM ratios 
obtained from CRL4 IPs were then related to PRM ratios obtained from bead background samples to derive 
the displayed signal to noise ratios. (O) 293T/173xFLAG-Cul4A and 293T/173xFLAG-Cul4B cells were 
fixed on a cover slip and stained with anti-FLAG antibodies followed by microscopic analysis. In all figures, 
error bars represent the mean ± SEM. 
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Figure Supplement 3.4. CRL4s reshape their assemblies and form Cul4A•Cul4B dimers upon UV-
induced DNA damage. (A) 293T/173xHA-Cul4B cells were exposed to UV light at a dose of 50 J/m2 and lysed 
indicated time points followed by anti-HA immunoprecipitation and PRM MS analysis. Displayed is data 
from Figure 3.4B as a dot plot. (B-E) Background signal assessment for individual proteins in experiment 
(A). Untagged wild type 293T/17 cells were either treated or not with 50 J/m2 UV light followed by lysis and 
incubation with anti-HA resin followed by PRM MS analysis. (F) Dot plot of signal to noise ratios as 
computed from measured PRM ratios in a HA-Cul4B IP sample divided by measured PRM ratios in a HA 
background sample. In all figures, error bars represent the mean ± SEM. 
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Figure Supplement 3.5. Degrader molecules minimally reshape ligase assemblies without disturbing 
Figure Supplement 3.5 
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the overall CRL4 network.  (A) 293T/17 cells were treated with 100nM dBET1 (A) or 30µM Lenalidomide 
(B) for indicated times, lysed in SDS sample buffer followed by SDS Page and quantitative western blot. (C, 
D) 293T/173xFLAG-Cul4A & 3xHA-Cul4B cells stably over-expressing FKBP12F36V-GFP were treated 
with 500nM dTAG-13 for indicated times, lysed in SDS sample buffer followed by SDS-PAGE and 
quantitative wester blotting (C) or treated for 12 hours and imaging of GFP-fluorescence signal per light 
microscope (D). (E) 293T/173xFLAG-Cul4A & 3xHA-Cul4B cells were treated for 1 hour with 30µM 
Lenalidomide, 100nM dBET1 or 500nM dTAG-13, pulsed with N8 Block before harvest. Lysates were 
immunoprecipitated with anti-HA and anti-FLAG resin to capture CRL4 complexes followed by PRM LC-
MS analysis. Heatmap for data displayed in Figure 3.5H and 5I. (F) 293T/173xFLAG-Cul4A & 3xHA-Cul4B 
cells were treated with 2µM Indisulam for the indicated times, pulsed with N8 Block and lysates 
immunoprecipitated for via anti-HA and anti-FLAG to capture CRL4 complexes followed by PRM LC-MS. 
Heatmap for data displayed in Figure 3.5J and 5K. (G) 293T/173xFLAG-Cul4A & 3xHA-Cul4B cells were 
pre-treated or not with 1µM MLN4924 or 1µM CSN5i-3 for 30 min followed by treatment with 2µM 
Indisulam for 60 min, pulsed with N8 Block and lysates immunoprecipitated for either via anti-FLAG or 
anti-HA to capture CRL4A and CRL4B complexes individually, followed by PRM LC-MS. (H, I) Bar graphs 
of log2 fold changes of DCAF15 bound to Cul4B and Cul4A for data displaye din heatmap (G). (J) 
293T/173xFLAG-Cul4A & 3xHA-Cul4B cells were treated with 2µM indisulam for indicated times with or 
without co-treatment of MLN4924 or CSN5i-3 followed by lysis in 2x SDS sample buffer and SDS-PAGE 
as well as western blotting. (K) 293T/173xFLAG-Cul4A & 3xHA-Cul4B cells were treated with 2µM 
indisulam for 3 hours with or without co-treatment of 1µM ubiquitin E1 inhibitor MLN7243, 1µM Nedd8 
E1 inhibitor MLN4924, 1µM CSN inhibitor CSN5i-3, 5µM proteasome inhibitor Bortezomib or 5µM 
p97/VCP inhibitor CB5083, followed by lysis in 2x SDS sample buffer and SDS-PAGE as well as western 
blotting. In all figures, error bars represent the mean ± SEM. 
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Figure Supplement 3.6. Higher DCAF expression can result in faster substrate degradation via 
increased substrate occupancy. (A) 293T/173xFLAG-Cul4A & 3xHA-Cul4B wild type or DCAF15 over-expressing 
cells were treated with 2µM indisulam for indicated times, lysed in 2xSDS sample buffer and processed via 
SDS-PAGE for quantitative western blotting. (B) 293T/17 and 293T/173xFLAG-Cul4A & 3xHA-Cul4B cells over-
expressing DCAF15 were lysed in 8M urea and processed for CRL4 QconCAT PRM analysis to measure 
cellular concentrations. (C) Anti-HA resin was exposed to lysates from 293T/173xFLAG-Cul4A & 3xHA-Cul4B cells, 
293T/17 cells over-expressing DCAF15 or 293T/173xFLAG-Cul4A & 3xHA-Cul4B cells over-expressing DCAF15 to 
evaluate the unspecific background binding of over-produced DCAF15 to Anti-HA resin. The measured 
PRM ratios were normalized to over-expressed DCAF15 levels. To correct for ~40% unspecific background 
signal, DCAF15 PRM ratios displayed in Figure 3.6E were corrected by a factor of 0.6. 
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Supplemental Item 3.1. Genetic engineering of epitope tagged cell lines. (A-E) Assessment of 
CRISPR/Cas9-engineered 293T/173xHA-Cul4B single cell clones using genomic PCR to evaluate genomic 
insertion (A), SDS-PAGE and western blotting to evaluate protein levels (B), light microscopy to evaluate 
morphology (C), growth assessment (D) as well as quantitative RT-PCR to evaluate mRNA levels. (F-H) 
Assessment of CRISPR/Cas9-engineered 293T/173xFLAG-Cul4A single cell clones using genomic PCR (F), 
SDS-PAGE and western blotting (G) and RT-qPCR (H). Western blotting for the FLAG-tag revealed 
successful integration and unaffected neddylation status. Therefore, the anti-Cu4A antibody against a C-
terminal epitope likely does not associate well with the C-terminally neddyalted Cul4A. RT-qPCR of the 
essential gene PCID2 that is located upstream of Cul4A on chromosome 13 revealed normal levels for 3 out 
Supplemental Item 3.1 
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of 4 genes while Cul4A levels were slightly lower after in clones carrying the insert. (I) Assessment of 
CRISPR/Cas9-engineered 293T/173xFLAG-Cul4A & 3xHA-Cul4B via genomic PCR. (J-L) Assessment of 
CRISPR/Cas9-engineered Flp-In T-REx HEK2933xHA-Cul4B wild type and Cand1/2 double knock out (DKO) 
single cell clones via SDS-PAGE and western blotting (J) and genomic PCR (K-L). The clones marked in 
red in each figure were used for experiments in this study. 
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Supplemental Table 3.1 
CRL4 SpikeMix Library – 418 peptides, 142 proteins 
Index Sequences Customer C-terminus Peptide ID 
1 TLLASTHVNHNIYITEVK K AMBRA1 
2 TVGVAFNQETGHWER R AMBRA1 
3 WLPEPGLGLAYGTNK K AMBRA1 
4 EQNYSDDVLANMISEPR R APP 
5 MQQNGYENPTYK K APP 
6 THPHFVIPYR R APP 
7 LIDPQTQVSR R APPL2 
8 LNQTALQAVTPITSFGK K APPL2 
9 TGLVTTTWER R APPL2 
10 DISQDSLQDIK K ARIH1 
11 LFAECHVINPSK K ARIH1 
12 VLLQHVHEGYEK K ARIH1 
13 GCLTFVSK K ARPC1A 
14 LAWVSHDSTVSVADASK K ARPC1A 
15 TLESSIQGLR R ARPC1A 
16 ASSEGGTAAGAGLDSLHK K ARPC1B 
17 TLESSIQGLR R ARPC1B 
18 VAWVSHDSTVCLADADK K ARPC1B 
19 HQEELTELHK K ATG16L1 
20 ITALDLNPER R ATG16L1 
21 TTEENQELVTR R ATG16L1 
22 HVAPDHLLQICQR R BRWD1 
23 IIPELVGSPTQSTSSR R BRWD1 
24 TFNEPESVIAR R BRWD1 
25 IWQYQQQEWK K BRWD3 
26 LAFLDPISGK K BRWD3 
27 LINEGDVPHLPVNR R BRWD3 
28 GLDHIAENILSYLDAK K BTRC 
29 GVYCLQYDDQK K BTRC 
30 DFITALPAR R BTRC 
31 ALTLIAGSPLK K CAND1 
32 ITSEALLVTQQLVK K CAND1 
33 LTLIDPETLLPR R CAND1 
34 FLISDQPHPIDPLLK K CAND2 
35 LGDDLEPTLLLLLDR R CAND2 
36 SNPELAALFESIQK K CAND2 
37 EPGLLASCSDDGEVAFWK K CIAO1 
38 SVAWAPSGNLLATCSR R CIAO1 
39 SVLSEGHQR R CIAO1 
40 ASNLENSTYDLYTIPK K COPA 
41 GITGVDLFGTTDAVVK K COPA 
42 LLHDQVGVIQFGPYK K COPA 
43 LQFIADHCPTLR R COPS1 
44 GHDDLGDHYLDCGDLSNALK K COPS1 
45 AHTDFFEAFK K COPS2 
46 IHIPFISK K COPS2 
47 SINSILDYISTSK K COPS2 
48 YATDTFAGLCHQLTNALVER R COPS3 
49 VQLSGPQEAEK K COPS3 
50 YTSQIVGR R COPS3 
51 NAAQVLVGIPLETGQK K COPS4 
52 AIQLSGAEQLEALK K COPS4 
53 LYLEDDDPVQAEAYINR R COPS4 
54 LEQSEAQLGR R COPS5 
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55 LLELLWNK K COPS5 
56 QYYALEVSYFK K COPS5 
57 ASEAGEVPFNHEILR R COPS6 
58 FNVLYDR R COPS6 
59 IGVDHVAR R COPS6 
60 ELAESDFASTFR R COPS7A 
61 NLPPLTEAQK K COPS7A 
62 HLTIVSLASR R COPS7B 
63 NQLLEVDFCIGR R COPS7B 
64 FIPLSEPAPVPPIPNEQQLAR R COPS8 
65 SANSELGGIWSVGQR R COPS8 
66 KPVAGALDVSFNK K COPS8 
67 EAQFGTTAEIYAYR R CRBN 
68 EEQDFGIEIVK K CRBN 
69 SALLPTIPDTEDEISPDK K CRBN 
70 GGQQALLQHWSEYIK K CUL4A 
71 LPDNYTQDTWR R CUL4A 
72 TLGHNLLVSELYNQLK K CUL4A 
73 SIFLFLDR R CUL4A_B 
74 DVFEAFYK K CUL4A_B 
75 QYQIDAAIVR R CUL4A_B 
76 EAFETFINK K CUL4B 
77 LPENYTDETWQK K CUL4B 
78 TLSHNLLVSEVYNQLK K CUL4B 
79 FSPTHCQIASGCLSGR R DCAF10 
80 HGLGAGLGGPGAR R DCAF10 
81 LTHYIEEANVGR R DCAF10 
82 FAVFSIAVSSDGR R DCAF11 
83 FSPIHSTGQQFIYSGCSTGK K DCAF11 
84 TQVELATGQLGLR R DCAF11 
85 DGSMGLWEVTDDVLTK K DCAF12 
86 TLLATGGDNPNSLAIYR R DCAF12 
87 VFASQWLNHR R DCAF12 
88 ASSSLDSMPGPAGR R DCAF12L2 
89 GPAGLQGFEGELR R DCAF12L2 
90 VFASQWLNAR R DCAF12L2 
91 MDGPGYGDEEEPLHTILGK K DCAF13 
92 NYDPALHPFEVPR R DCAF13 
93 SIYSQIQEQR R DCAF13 
94 AHSEPLALCGETAPR R DCAF15 
95 DSPPASEAPASEPGYVNYTK K DCAF15 
96 ISGQLSPR R DCAF15 
97 DHATLNGALQFATK K DCAF16 
98 LLDPSTPVHILR R DCAF16 
99 TEPINTTYSYTDFQK K DCAF16 
100 IIHVGPNQVK K DCAF17 
101 NENVLTVTASGR R DCAF17 
102 YLSWDTPQEVIAVK K DCAF17 
103 FNLILADTNSDR R DCAF4 
104 LLPGHNNCNPLTK K DCAF4 
105 YGIINLQSLK K DCAF4 
106 GAAPGLLMAVR R DCAF4L1 
107 SLDPSSLASDR R DCAF4L1 
108 SQLGFLNVTSYSR R DCAF4L1 
109 GAPGLLMAVR R DCAF4L2 
110 VQIHSWDPSSLASDR R DCAF4L2 
111 DGETSLVTGEADEGR R DCAF5 
112 GLHGDPLLTQDFQR R DCAF5 
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113 SLETICANHNNGR R DCAF5 
114 FIPSHLNNK K DCAF6 
115 GGSYPHLLWDVR R DCAF6 
116 NTITVPASFMLR R DCAF6 
117 GVYPDLLATSGDYLR R DCAF7 
118 LALGSFVEEYNNK K DCAF7 
119 NTFDHPYPTTK K DCAF7 
120 GTWLASGSDDLK K DCAF8 
121 IWAPTAEASTELTGLK K DCAF8 
122 LQHGLEGHTGCVNTLHFNQR R DCAF8 
123 FLDLWNK K DCUN1D1 
124 LDVATDNFFQNPELYIR R DCUN1D1 
125 TAVSCLSQNDWK K DCUN1D1 
126 DFYQFTFTFAK K DCUN1D2 
127 EFLDGMTELGCDSMEK K DCUN1D2 
128 LDEATDSFFQNPDSLHR R DCUN1D2 
129 EEQVPPCGKPGGDILVNGTK K DCUN1D3 
130 FCNDLCVDPTEFR R DCUN1D3 
131 FTFQFGLDSEEGQR R DCUN1D3 
132 DQWCNVLEFSR R DCUN1D4 
133 LDAQNMGYFTLQEWLK K DCUN1D4 
134 SFLNDSTNFK K DCUN1D4 
135 LISGEEHFSSK K DCUN1D5 
136 SMLALLLGR R DCUN1D5 
137 SQLNDISSFK K DCUN1D5 
138 DQEQVELEGESSAPPR R DDA1 
139 FHADSVCK K DDA1 
140 GLPVYNK K DDA1 
141 ICYQEVSQCFGVLSSR R DDB1 
142 LPSFELLHK K DDB1 
143 SVLLLAYKPMEGNFEEIAR R DDB1 
144 YLAIAPPIIK K DDB1 
145 ASFLYSLPHR R DDB2 
146 ATSLAWHPTHPSTVAVGSK K DDB2 
147 VYSASQWDCPLGLIPHPHR R DDB2 
148 AGTHWHQVR R DET1 
149 NATLHSEVQFPCSASSNNFAR R DET1 
150 YTSEDVVTLR R DET1 
151 DEEQTDEELAVDLEALVSK K DNAI2 
152 DPVYGTIWLQSK K DNAI2 
153 GSLVAELSTIESSHR R DNAI2 
154 NWLLAMAAK K DTL 
155 LSTVGWASQK K DTL 
156 TPSSSPPITPPASETK K DTL 
157 EGDPLVFATVGSNR R EED 
158 HYVGHGNAINELK K EED 
159 VTLYECHSQGEIR R EED 
160 ALTPQTAETDAIR R EIPR1 
161 NVLLHQAGEIWHISASPADR R EIPR1 
162 YNHSHDQLVLTGSSDSR R EIPR1 
163 ASPSPQPSSQPLQIHR R EML4 
164 LAISEDHVASVK K EML4 
165 LSLPQNETVADTTLTK K EML4 
166 IHGGGINTLDIEPVEGR R ERCC8 
167 VNGLCFTSDGLHLLTVGTDNR R ERCC8 
168 YDYILATASADSR R ERCC8 
169 EGFITEDWDQPVADWK K FBXO44 
170 EVSHTFSNYPPGVR R FBXO44 
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171 IFDLGSDNEEVVAGPAPAHAK K FBXW5 
172 LYDTVPCVEVQTLR R FBXW5 
173 TFFSWLASQR R FBXW5 
174 DNILVSGNADSTVK K FBXW7 
175 ITSVQPPTGLQEWLK K FBXW7 
176 NFVITSSDDGTVK K FBXW7 
177 IVSGGEEGLVSVWDYR R FBXW8 
178 LCQQEGHLPDSSISDYSCWK K FBXW8 
179 SGNIALSLSAHQLR R FBXW8 
180 HIISGSEDHTLVVVDR R FBXW9 
181 NFDWPAACIALEQHLSR R FBXW9 
182 NVNLWDLR R FBXW9 
183 LPFAAAQIGNSFR R GARS 
184 NNIIQTWR R GARS 
185 TVNVVQFEPSK K GARS 
186 AHYEAEIK K GLMN 
187 CIEEGHTDQLLEIIQNEK K GLMN 
188 IMASLNLLR R GLMN 
189 LFVSGACDASAK K GNB1 
190 LLLAGYDDFNCNVWDALK K GNB1 
191 LLLAGYDDFNCNIWDAMK K GNB2 
192 TFVSGACDASIK K GNB2 
193 LIVWDSYTTNK K GNB3 
194 LLVSASQDGK K GNB3 
195 VGILSGHDNR R GNB3 
196 LLLAGYDDFNCNVWDTLK K GNB4 
197 TFVSGACDASSK K GNB4 
198 LHDVELHQVAER R GNB5 
199 SGQCVQAFETHESDINSVR R GNB5 
200 VSILFGHENR R GNB5 
201 GQVEVFALR R GRWD1 
202 LLQVVEEPQALAAFLR R GRWD1 
203 VSWLGEEPVAGVWSEK K GRWD1 
204 FCPSGAWELPGTPR R GTF3C2 
205 FSSITAHPER R GTF3C2 
206 LGLLALACSDGK K GTF3C2 
207 IINEPTAAAIAYGLDR R HSPA6 
208 EVLAWLEHNQLAEK K HSPA6 
209 ELEQICRPIFSR R HSPA6 
210 AEIQNAEDYNEIFQPK K KATNB1 
211 IPQQAELVDEDAMSQIR R KATNB1 
212 LNTPEELIVAGSQSGSIR R KATNB1 
213 EGIPPQQQR R NEDD8 
214 EIEIDIEPTDK K NEDD8 
215 ILGGSVLHLVLALR R NEDD8 
216 FWDLSTETPHFTCK K NLE1 
217 TLESQAVETEK K NLE1 
218 YLASGSGDTTVR R NLE1 
219 IEITSLLPSR R NUP43 
220 TPEILTVNSIGQLK K NUP43 
221 VPLHCVDR R NUP43 
222 GHTDSVQDISFDHSGK K PAFAH1B1 
223 TAPYVVTGSVDQTVK K PAFAH1B1 
224 VWDYETGDFER R PAFAH1B1 
225 FFDCDSLVCLCEFK K PAK1IP1 
226 GQVTFLSIHPSGK K PAK1IP1 
227 LALSVGTDK K PAK1IP1 
228 GEQLVVSGSWDQTVK K PEX7 
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229 HGYAAEFSPYLPGR R PEX7 
230 IVIPAHQAEILSCDWCK K PEX7 
231 AQSYDIQAWK K PHIP 
232 NNALVPGTIQVNGHGGQPSK K PHIP 
233 VVVDPVVTEQPSTSSAAK K PHIP 
234 LLYTLHGHQGPATTVAFSR R POC1A 
235 SNFDIVDHGEVTK K POC1A 
236 TGEYFASGGSDEQVMVWK K POC1A 
237 AAITSLDLSPNGK K POC1B 
238 DVVTSVQFSPHGNLLASASR R POC1B 
239 LHFDSPPHLLDIYPR R POC1B 
240 FIASTGMDR R PRPF19 
241 IWSVPNASCVQVVR R PRPF19 
242 QELSHALYQHDAACR R PRPF19 
243 AQEALDFYGEVR R PTEN 
244 EYLVLTLTK K PTEN 
245 YVYYYSYLLK K PTEN 
246 GCLVTASADK K PWP1 
247 NSSISGPFGSR R PWP1 
248 SVALYDCR R PWP1 
249 CWEVQDSGQTIPK K RAE1 
250 GHEFYNPQK K RAE1 
251 GLIVYQLENQPSEFR R RAE1 
252 GEFGGFGSVSGK K RBBP4 
253 LHSFESHK K RBBP4 
254 YMPQNPCIIATK K RBBP4 
255 HVVLPVDDDSDLNVVASFDR R RBBP5 
256 TDSQDLVASFR R RBBP5 
257 VTTGTSNTTAIK K RBBP5 
258 LHTFESHK K RBBP7 
259 VHIPNDDAQFDASHCDSDK K RBBP7 
260 YMPQNPHIIATK K RBBP7 
261 QVCPLDNR R RBX1 
262 WNAVALWAWDIVVDNCAICR R RBX1 
263 LTAHFEDLEQCYFSTR R RFWD2 
264 LWSTNLDNSVASIEAK K RFWD2 
265 TASQLDEFQECLSK K RFWD2 
266 VQVMDACLR R RNF7 
267 CPLCQQDWVVQR R RNF7 
268 WNAVAMWSWDVECDTCAICR R RNF7 
269 IPEEHDLESQIR R RPTOR 
270 QDLLVASLFR R RPTOR 
271 SYNCTPVSSPR R RPTOR 
272 LPENQTSPGESPER R SCAP 
273 LPLPGTGPVEFTTPVK K SCAP 
274 YISLLPVIPVTLR R SCAP 
275 NPEHFVVCNR R SMU1 
276 SLGSTAGTDITVNSVILLPK K SMU1 
277 YIHLENLLAR R SMU1 
278 GHTSFVNSCYPAR R SNRNP40 
279 GPQLVCTGSDDGTVK K SNRNP40 
280 IFQGNVHNFEK K SNRNP40 
281 VLAQASGNGVIHLLDLK K SPAG16 
282 VLEEALGMGLTAAGDAR R SPAG16 
283 VVGQISGLQETLK K SPAG16 
284 ALIASAGADALAK K STRN4 
285 APPGPAGLSGGESLLVK K STRN4 
286 NAALDVEPIHAFR R STRN4 
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287 EELFGEASAGK K STXBP5L 
288 SLSGSTNTVASEGVTK K STXBP5L 
289 TAGMMTSAEAFSK K STXBP5L 
290 LQEDSYNYLIR R TAF5L 
291 LWSAQQGNSVR R TAF5L 
292 YLASAGEDQR R TAF5L 
293 EGGSHFINTSSPR R TBL1X 
294 GNYILSAGVDK K TBL1X 
295 GVCTHTLTK K TBL1X 
296 TFQGHTNEVNAIK K TBL1XR1 
297 HQEPVYSVAFSPDGR R TBL1XR1 
298 AATMTPAAISQQNPPK K TBL1Y 
299 GLQYVEAEISINK K TBL1Y 
300 IWTENGNLASTLGQHK K TBL1Y 
301 LPVPAAAPTPWETHK K TBL3 
302 NTAPDNGPILLQAQTTQR R TBL3 
303 VNILEVASGAVLR R TBL3 
304 DDVVTFIDAK K THOC3 
305 EFLAHSAK K THOC3 
306 TLSFSHDGK K THOC3 
307 GHTDYIHCLALR R THOC6 
308 HLLSAGDGEVK K THOC6 
309 SPEVLSGGEDGAVR R THOC6 
310 DASSSPASTASSASSTSLK K TLE1 
311 EPGTSNSLLVPDSLR R TLE1 
312 FTIPESLDR R TLE1 
313 ELILNDLPASTPASK K TLE2 
314 LWTGGLDNTVR R TLE2 
315 SPVMAFESHPHLR R TLE2 
316 ESSSVLSCDISADDK K TLE3 
317 NDAPTPGTSTTPGLR R TLE3 
318 QFQGHTDGASCIDISHDGTK K TLE3 
319 ADAHLGSSSVALPK K TOR1AIP2 
320 DHQEVETEGPESADTGDK K TOR1AIP2 
321 FTNSDTPTSFNHMDSDK K TOR1AIP2 
322 ETVSILLNPDR R TRPC4AP 
323 GTTSYADQMFLLK K TRPC4AP 
324 WSGIPQLLLK K TRPC4AP 
325 EAAEVLQNNR R UBE2M 
326 LFEQNVQR R UBE2M 
327 TCDISFSDPDDLLNFK K UBE2M 
328 ILVLQNELER R UVRAG 
329 TILLQVDQNCVR R UVRAG 
330 YQHGLGTPDLR R UVRAG 
331 HSFTEDHYVEFSK K VPRBP 
332 LLTLFNPDLANNYK K VPRBP 
333 VLLSLLSIK K VPRBP 
334 APLYDLAAHEDK K WDR12 
335 GHAGSVDSIAVDGSGTK K WDR12 
336 VFNCISYSPLCK K WDR12 
337 LSQSDEDVIR R WDR26 
338 MSQSHEDSLTSVAWNPDGK K WDR26 
339 TVLASDTHQR R WDR26 
340 DPSHQLLILR R WDR27 
341 GEQVEVTFPVLR R WDR27 
342 SGLCSQPEESQLPSTSALGK K WDR27 
343 DAITQALFLR R WDR3 
344 SFDLIHSPHGELK K WDR3 
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345 YVASAVFGVIGSQK K WDR3 
346 DNTLLLWDVVTGQSVER R WDR31 
347 GLQVAHMFPAK K WDR31 
348 YGRPDEIIEER R WDR31 
349 EFENLYIENLELR R WDR37 
350 IIALPHDNR R WDR37 
351 LAAEGQAIDGAELSK K WDR37 
352 GVLDVAHTCAFTPDGK K WDR38 
353 ILVSGAADQTR R WDR38 
354 SIAFSPDELWLASAGYSR R WDR38 
355 ATFDNVTSYLK K WDR4 
356 CTALTFIASEEK K WDR4 
357 SGDVYSFSVLEPHGCGR R WDR4 
358 AAYADLLTPLISK K WDR47 
359 LTHDASNIHTSTPR R WDR47 
360 MVQSYHPHSSDVR R WDR47 
361 DAGFSSPDGSDPK K WDR48 
362 DTNNNVAYWDVLK K WDR48 
363 SADPPPAIWVATTK K WDR48 
364 FTLAGHTK K WDR5 
365 IWDTASGQCLK K WDR5 
366 TLPAHSDPVSAVHFNR R WDR5 
367 FQGADDVTSVLFSPSCPTK K WDR53 
368 ITLWDANSEVEK K WDR53 
369 LYASHGETISVLDVR R WDR53 
370 DGSGEVGTTLQGHTR R WDR59 
371 NANCLATSHDGDVR R WDR59 
372 VIIQDIACLLPVHK K WDR59 
373 AQLALSSSANQSK K WDR5B 
374 FSPNGEWLASSSADR R WDR5B 
375 TLVDDDNPPVSFVK K WDR5B 
376 ENSETVVTGSLDDLVK K WDR61 
377 LWDLENGK K WDR61 
378 VNIFGVESGK K WDR61 
379 DTLAHSAPLLTEK K WDR66 
380 SFEVLGYTNSK K WDR66 
381 YLATISDAEVQK K WDR66 
382 IPDSHEITLK K WDR70 
383 LVTGGYDYDVK K WDR70 
384 VGTHGGTLSSYIVK K WDR70 
385 AESTLQNSSSAVHTESNK K WDR76 
386 DTHIYDAR R WDR76 
387 SIASAYFSPLTGNR R WDR76 
388 ETPPPLVPPAAR R WDR77 
389 EWNLPPNAPACMER R WDR77 
390 VWDLAQQVVLSSYR R WDR77 
391 DTNIYLAGTEEGHIHK K WDR78 
392 SSYIFAAANENR R WDR78 
393 TNPDLLAVGYGHFGFK K WDR78 
394 HTGPITCLQFNPK K WDR82 
395 IHVWNGESGIK K WDR82 
396 YTHAANTVVYSSNK K WDR82 
397 DGQCTLVSSLDSTLR R WDR83 
398 LDCCLSER R WDR83 
399 TLDCGQGAVR R WDR83 
400 AWDILSGEQLR R WDR86 
401 GGINWLSLSPDGQR R WDR86 
402 ILVANNQLFSSSYDR R WDR86 
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403 ATDLQILSTQVEQR R WDR87 
404 DIFPSAHASVEK K WDR87 
405 DVTYSVLTDGANR R WDR87 
406 ELFLTAGGAGGLHLWK K WDR92 
407 GFNYTVFDCK K WDR92 
408 GTGVIQLYEIQHGDLK K WDR92 
409 ILITGAADSK K WDTC1 
410 VHVHDLTVK K WDTC1 
411 YHVTDPFIR R WDTC1 
412 FGQDQLLLATGLNNGR R WSB1 
413 SVSFSHDGLHVASLADDK K WSB1 
414 TIGELLAPAAPFDK K WSB1 
415 DLSFTPSGSLILVSASR R WSB2 
416 LIPWPLEEQFIPK K WSB2 
417 SFLTTYQVLALPIPK K WSB2 
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Supplemental Table 3.2 
CRL4 SpikeMix Mass Table – 116 targets, 58 peptides, 37 proteins 
Compound Formul
a 
Adduct m/z z t start (min) t stop (min) 
LEQSEAQLGR 
  
565.7937 2 17.25 22.25 
LEQSEAQLGR 
  
570.79783 2 17.25 22.25 
IIHVGPNQVK 
  
552.82933 2 18.41 23.41 
IIHVGPNQVK 
  
556.83643 2 18.41 23.41 
LTHYIEEANVGR 
  
701.359455 2 22.95 27.95 
LTHYIEEANVGR 
  
706.36359 2 22.95 27.95 
FTNSDTPTSFNHMDSDK 
  
972.40641 2 25.77 30.77 
FTNSDTPTSFNHMDSDK 
  
976.41351 2 25.77 30.77 
DQEQVELEGESSAPPR 
  
885.910175 2 28.5 33.5 
DQEQVELEGESSAPPR 
  
890.91431 2 28.5 33.5 
TAVSCLSQNDWK 
  
704.82951 2 30.36 35.36 
TAVSCLSQNDWK 
  
708.83661 2 30.36 35.36 
VVVDPVVTEQPSTSSAAK 
  
907.48045 2 32.83 37.83 
VVVDPVVTEQPSTSSAAK 
  
911.48755 2 32.83 37.83 
AQSYDIQAWK 
  
605.29814 2 33.18 38.18 
AQSYDIQAWK 
  
609.30524 2 33.18 38.18 
NATLHSEVQFPCSASSNNFA
R 
  
1169.03664 2 35.06 40.06 
NATLHSEVQFPCSASSNNFA
R 
  
1174.04077 2 35.06 40.06 
ASFLYSLPHR 
  
595.818985 2 35.51 40.51 
ASFLYSLPHR 
  
600.82312 2 35.51 40.51 
TASQLDEFQECLSK 
  
828.3823 2 39.4 44.4 
TASQLDEFQECLSK 
  
832.3894 2 39.4 44.4 
LLDPSTPVHILR 
  
680.900465 2 40.53 45.53 
LLDPSTPVHILR 
  
685.9046 2 40.53 45.53 
GGSYPHLLWDVR 
  
700.35954 2 43.01 48.01 
GGSYPHLLWDVR 
  
705.36367 2 43.01 48.01 
FNLILADTNSDR 
  
689.851515 2 44.52 49.52 
FNLILADTNSDR 
  
694.85565 2 44.52 49.52 
YGIINLQSLK 
  
574.83671 2 46.54 51.54 
YGIINLQSLK 
  
578.84381 2 46.54 51.54 
TLSHNLLVSEVYNQLK 
  
620.007147 3 47.56 52.56 
TLSHNLLVSEVYNQLK 
  
622.678547 3 47.56 52.56 
YLSWDTPQEVIAVK 
  
824.93333 2 51.55 56.55 
YLSWDTPQEVIAVK 
  
828.94043 2 51.55 56.55 
WSGIPQLLLK 
  
577.84989 2 55.08 60.08 
WSGIPQLLLK 
  
581.85699 2 55.08 60.08 
SIFLFLDR 
  
505.786485 2 57.68 62.68 
SIFLFLDR 
  
510.79062 2 57.68 62.68 
VHVHDLTVK 
  
349.869702 3 13.25 18.25 
VHVHDLTVK 
  
352.541102 3 13.25 18.25 
HGLGAGLGGPGAR 
  
373.872106 3 17.05 22.05 
HGLGAGLGGPGAR 
  
377.208196 3 17.05 22.05 
SVALYDCR 
  
492.234295 2 22.62 27.62 
SVALYDCR 
  
497.23843 2 22.62 27.62 
ILITGAADSK 
  
494.78712 2 23.85 28.85 
ILITGAADSK 
  
498.79422 2 23.85 28.85 
NSSISGPFGSR 
  
554.772175 2 25.26 30.26 
NSSISGPFGSR 
  
559.77631 2 25.26 30.26 
DSPPASEAPASEPGYVNYTK 
  
1040.47862 2 32.11 37.11 
DSPPASEAPASEPGYVNYTK 
  
1044.48572 2 32.11 37.11 
LPDNYTQDTWR 
  
704.828015 2 32.65 37.65 
LPDNYTQDTWR 
  
709.83215 2 32.65 37.65 
TVGVAFNQETGHWER 
  
577.61302 3 31.72 36.72 
TVGVAFNQETGHWER 
  
580.94911 3 31.72 36.72 
C h a p t e r  3  
 
1 2 7  
GTWLASGSDDLK 
  
625.30619 2 34.52 39.52 
GTWLASGSDDLK 
  
629.31329 2 34.52 39.52 
LINEGDVPHLPVNR 
  
524.954606 3 36.75 41.75 
LINEGDVPHLPVNR 
  
528.290696 3 36.75 41.75 
YDYILATASADSR 
  
723.348705 2 38.28 43.28 
YDYILATASADSR 
  
728.35284 2 38.28 43.28 
TQVELATGQLGLR 
  
693.390645 2 40.27 45.27 
TQVELATGQLGLR 
  
698.39478 2 40.27 45.27 
TLLATGGDNPNSLAIYR 
  
888.468155 2 44.31 49.31 
TLLATGGDNPNSLAIYR 
  
893.47229 2 44.31 49.31 
ALTLIAGSPLK 
  
542.34208 2 43.7 48.7 
ALTLIAGSPLK 
  
546.34918 2 43.7 48.7 
IMASLNLLR 
  
515.80756 2 45.68 50.68 
IMASLNLLR 
  
520.8117 2 45.68 50.68 
LAFLDPISGK 
  
530.80516 2 48.1 53.1 
LAFLDPISGK 
  
534.81226 2 48.1 53.1 
NWLLAMAAK 
  
509.28074 2 48.18 53.18 
NWLLAMAAK 
  
513.28784 2 48.18 53.18 
LLTLFNPDLANNYK 
  
818.44059 2 54.98 59.98 
LLTLFNPDLANNYK 
  
822.44769 2 54.98 59.98 
SNPELAALFESIQK 
  
773.90867 2 57.5 62.5 
SNPELAALFESIQK 
  
777.91577 2 57.5 62.5 
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Supplemental Table 3.3 
CRL4 QconCAT protein standard sequence: 
MAGRSSYVGDEASSKEAVEAIQNSTSIKYNLEELYQAVENLCSYKAVQSSTSIRYNLEELYQAVEN
LCSHKQLLGEHLTAILQKETVEEQVSTTERQVCPLDNRETVEEQASTTERSIFLFLDRAHTDFFEAF
KTASQLDEFQECLSKLEELHVIDVKALTLIAGSPLKDGETSLVTGEADEGRADVFHAYLSLLKNAA
QVLVGIPLETGQKLYLEDDDPVQAEAYINRIHIPFISKEIEIDIEPTDKILGGSVLHLVLALRGLPVYN
KYLHQQWDKTFHLLHTVPALDQCRASFLYSLPHRVISHFLPNDLGFTDSYSQKYLAIAPPIIKYNPP
VDATPDTRVLLSLLSIKLTHYIEEANVGRSLEVGSYPILRLYNTESQSFRLVTAAGDQTAKEEQDFG
IEIVKDDSLPSNPIDFSYRSALLPTIPDTEDEISPDKYDYILATASADSRIHGGGINTLDIEPVEGRIWA
PTAEASTELTGLKILITGAADSKLNFTDEWSSIASSSRQSPSAGVHTFCDRSCGVPEESASSEKTLLA
STHVNHNIYITEVKFVTDLLLHFIKEWEFQKLAFLDPISGKLINEGDVPHLPVNRISLPFVVTDLRST
FLLAFSPDRWSGIPQLLLKETVSILLNPDRVVVDPVVTEQPSTSSAAKDSPPASEAPASEPGYVNYT
KSVALYDCRLQHGLEGHTGCVNTLHFNQRNSSISGPFGSRLLDPSTPVHILRYTSEDVVTLRTEPIN
TTYSYTDFQKNATLHSEVQFPCSASSNNFARLWSTNLDNSVASIEAKSLETICANHNNGRDGSMGL
WEVTDDVLTKVFASQWLNHRFNLILADTNSDRGGDIMLWNFGIKYGIINLQSLKAAAPEPETETET
SSKLAAALEHHHHHH 
67 concatenated peptides, representing 32 proteins 
Peptide ID Peptide Sequence 
DET NATLHSEVQFPCSASSNNFAR 
DCAF8 LQHGLEGHTGCVNTLHFNQR 
DCAF11 VISHFLPNDLGFTDSYSQK 
DCAF15 DSPPASEAPASEPGYVNYTK 
CUL4B YNLEELYQAVENLCSYK 
AMBRA1 TLLASTHVNHNIYITEVK 
CUL4A YNLEELYQAVENLCSHK 
COPS4 LYLEDDDPVQAEAYINR 
CRBN SALLPTIPDTEDEISPDK 
PHIP VVVDPVVTEQPSTSSAAK 
DCAF16 TEPINTTYSYTDFQK 
ERCC8 IHGGGINTLDIEPVEGR 
DCAF13 DGSMGLWEVTDDVLTK 
VPRBP TFHLLHTVPALDQCR 
RFWD2 LWSTNLDNSVASIEAK 
DCAF6 LNFTDEWSSIASSSR 
DCAF8 IWAPTAEASTELTGLK 
COPS4 NAAQVLVGIPLETGQK 
CRBN DDSLPSNPIDFSYR 
RFWD2 TASQLDEFQECLSK 
BRWD3 LINEGDVPHLPVNR 
none AAAPEPETETETSSK 
DCAF15 DGETSLVTGEADEGR 
CUL4AB QLLGEHLTAILQK 
NEDD8 ILGGSVLHLVLALR 
ERCC8 YDYILATASADSR 
DCAF5 SLETICANHNNGR 
none LAAALEHHHHHH 
CUL4A ETVEEQVSTTER 
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WDTC1 QSPSAGVHTFCDR 
DCAF10 LTHYIEEANVGR 
CUL4B EAVEAIQNSTSIK 
CUL4B ETVEEQASTTER 
DCAF4 FNLILADTNSDR 
CAND1 ADVFHAYLSLLK 
DCAF16 LLDPSTPVHILR 
DDB2 GGDIMLWNFGIK 
PHIP FVTDLLLHFIK 
DCAF11 YNPPVDATPDTR 
DCAF6 SCGVPEESASSEK 
CRBN EEQDFGIEIVK 
NEDD8 EIEIDIEPTDK 
DCAF15 ISLPFVVTDLR 
DCAF12 VFASQWLNHR 
TRPC4AP ETVSILLNPDR 
AMBRA1 STFLLAFSPDR 
DTL LYNTESQSFR 
DCAF10 SLEVGSYPILR 
COPS2 AHTDFFEAFK 
DDB1 LEELHVIDVK 
DDB2 ASFLYSLPHR 
DET1 YTSEDVVTLR 
TRPC4AP WSGIPQLLLK 
DCAF4 YGIINLQSLK 
none SSYVGDEASSK 
DDA1 YLHQQWDK 
PWP1 NSSISGPFGSR 
DDB1 YLAIAPPIIK 
CAND1 ALTLIAGSPLK 
DTL LVTAAGDQTAK 
BRWD3 LAFLDPISGK 
CUL4AB SIFLFLDR 
WDTC1 ILITGAADSK 
VPRBP VLLSLLSIK 
COPS2 IHIPFISK 
CUL4A AVQSSTSIR 
RBX1 QVCPLDNR 
PWP1 SVALYDCR 
RBX1 EWEFQK 
DDA1 GLPVYNK 
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Supplemental Table 3.4 
CRL4 QconCAT Mass Table – 122 targets, 61 peptides, 31 proteins 
Pepide ID Compound Formu
la 
Adduct m/z z t start (min) t stop (min) 
AMBRA1 STFLLAFSPDR 
  
627.32987 2 50.88 58.88 
AMBRA1 STFLLAFSPDR 
  
632.33400
4 
2 50.88 58.88 
AMBRA1 TLLASTHVNHNIYITEVK 
  
685.04073
9 
3 32.65 40.65 
AMBRA1 TLLASTHVNHNIYITEVK 
  
687.71213
9 
3 32.65 40.65 
BRWD3 LINEGDVPHLPVNR 
  
524.95460
6 
3 35.12 43.12 
BRWD3 LINEGDVPHLPVNR 
  
528.29069
6 
3 35.12 43.12 
BRWD3 LAFLDPISGK 
  
530.80549
9 
2 46.48 54.48 
BRWD3 LAFLDPISGK 
  
534.81259
9 
2 46.48 54.48 
CAND1 ADVFHAYLSLLK 
  
688.88227 2 57.06 65.06 
CAND1 ADVFHAYLSLLK 
  
692.88936
9 
2 57.06 65.06 
CAND1 ALTLIAGSPLK 
  
542.34224
9 
2 42.07 50.07 
CAND1 ALTLIAGSPLK 
  
546.34934
8 
2 42.07 50.07 
COPS2 AHTDFFEAFK 
  
606.78783
8 
2 38.08 46.08 
COPS2 AHTDFFEAFK 
  
610.79493
7 
2 38.08 46.08 
COPS2 IHIPFISK 
  
477.79219
5 
2 41.9 49.9 
COPS2 IHIPFISK 
  
481.79929
4 
2 41.9 49.9 
COPS4 NAAQVLVGIPLETGQK 
  
819.46468
6 
2 47.19 55.19 
COPS4 NAAQVLVGIPLETGQK 
  
823.47178
6 
2 47.19 55.19 
COPS4 LYLEDDDPVQAEAYINR 
  
1012.484 2 47.36 55.36 
COPS4 LYLEDDDPVQAEAYINR 
  
1017.4881
4 
2 47.36 55.36 
CRBN EEQDFGIEIVK 
  
653.8299 2 41.66 49.66 
CRBN EEQDFGIEIVK 
  
657.83699
9 
2 41.66 49.66 
CRBN DDSLPSNPIDFSYR 
  
813.37573
4 
2 48 56 
CRBN DDSLPSNPIDFSYR 
  
818.37986
9 
2 48 56 
CRBN SALLPTIPDTEDEISPDK 
  
970.98858
5 
2 49.5 57.5 
CRBN SALLPTIPDTEDEISPDK 
  
974.99568
5 
2 49.5 57.5 
CUL4A ETVEEQVSTTER 
  
704.33353
5 
2 19.51 27.51 
CUL4A ETVEEQVSTTER 
  
709.33766
9 
2 19.51 27.51 
CUL4B EAVEAIQNSTSIK 
  
695.36463
8 
2 25.9 33.9 
CUL4B EAVEAIQNSTSIK 
  
699.37173
7 
2 25.9 33.9 
CUL4AB SIFLFLDR 
  
505.78711 2 56.09 64.09 
CUL4AB SIFLFLDR 
  
510.79124
4 
2 56.09 64.09 
CUL4AB QLLGEHLTAILQK 
  
488.62419
7 
3 41.54 49.54 
CUL4AB QLLGEHLTAILQK 
  
491.29559
7 
3 41.54 49.54 
CUL4B ETVEEQASTTER 
  
690.31788
5 
2 13.34 21.34 
CUL4B ETVEEQASTTER 
  
695.32201
9 
2 13.34 21.34 
VPRBP VLLSLLSIK 
  
493.33643
5 
2 54.41 62.41 
VPRBP VLLSLLSIK 
  
497.34353
5 
2 54.41 62.41 
VPRBP TFHLLHTVPALDQCR 
  
603.31391
7 
3 35.64 43.64 
VPRBP TFHLLHTVPALDQCR 
  
606.65000
7 
3 35.64 43.64 
DCAF10 SLEVGSYPILR 
  
617.34552 2 43.15 51.15 
DCAF10 SLEVGSYPILR 
  
622.34965
4 
2 43.15 51.15 
DCAF10 LTHYIEEANVGR 
  
701.35969 2 21.31 29.31 
DCAF10 LTHYIEEANVGR 
  
706.36382
4 
2 21.31 29.31 
DCAF11 YNPPVDATPDTR 
  
673.32277
3 
2 23.18 31.18 
DCAF11 YNPPVDATPDTR 
  
678.32690
8 
2 23.18 31.18 
DCAF11 VISHFLPNDLGFTDSYSQ
K 
  
723.36013
8 
3 47.15 55.15 
DCAF11 VISHFLPNDLGFTDSYSQ
K 
  
726.03153
7 
3 47.15 55.15 
DCAF12 VFASQWLNHR 
  
419.88775
6 
3 31.28 39.28 
DCAF12 VFASQWLNHR 
  
423.22384
6 
3 31.28 39.28 
DCAF13 DGSMGLWEVTDDVLTK 
  
883.41928
4 
2 60.23 68.23 
DCAF13 DGSMGLWEVTDDVLTK 
  
887.42638
4 
2 60.23 68.23 
DCAF15 DSPPASEAPASEPGYVNY
TK 
  
1040.4789
2 
2 30.56 38.56 
DCAF15 DSPPASEAPASEPGYVNY
TK 
  
1044.4860
2 
2 30.56 38.56 
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DCAF15 ISLPFVVTDLR 
  
630.37153
8 
2 58.27 66.27 
DCAF15 ISLPFVVTDLR 
  
635.37567
2 
2 58.27 66.27 
DCAF16 LLDPSTPVHILR 
  
680.90099
4 
2 38.9 46.9 
DCAF16 LLDPSTPVHILR 
  
685.90512
8 
2 38.9 46.9 
DCAF16 TEPINTTYSYTDFQK 
  
904.42288
1 
2 36.55 44.55 
DCAF16 TEPINTTYSYTDFQK 
  
908.42998
1 
2 36.55 44.55 
DCAF4 FNLILADTNSDR 
  
689.85169
8 
2 43.02 51.02 
DCAF4 FNLILADTNSDR 
  
694.85583
2 
2 43.02 51.02 
DCAF4 YGIINLQSLK 
  
574.83733
1 
2 44.96 52.96 
DCAF4 YGIINLQSLK 
  
578.84443 2 44.96 52.96 
DCAF15 DGETSLVTGEADEGR 
  
768.34463
1 
2 27.34 35.34 
DCAF15 DGETSLVTGEADEGR 
  
773.34876
5 
2 27.34 35.34 
DCAF5 SLETICANHNNGR 
  
495.90028
4 
3 12.95 20.95 
DCAF5 SLETICANHNNGR 
  
499.23637
4 
3 12.95 20.95 
DCAF6 LNFTDEWSSIASSSR 
  
850.39974 2 49.91 57.91 
DCAF6 LNFTDEWSSIASSSR 
  
855.40387
5 
2 49.91 57.91 
DCAF8 LQHGLEGHTGCVNTLHF
NQR 
  
773.37842 3 22.07 30.07 
DCAF8 L HGLEGHTGCVNTLHF
NQR 
  
776.71450
9 
3 22.07 30.07 
DCAF8 IWAPTAEASTELTGLK 
  
844.44870
2 
2 46.98 54.98 
DCAF8 IWAPTAEASTELTGLK 
  
848.45580
2 
2 46.98 54.98 
DDA1 GLPVYNK 
  
395.72652
1 
2 18.58 26.58 
DDA1 GLPVYNK 
  
399.73362 2 18.58 26.58 
DDA1 YLHQQWDK 
  
373.18569 3 13.22 21.22 
DDA1 YLHQQWDK 
  
375.85709 3 13.22 21.22 
DDB1 LEELHVIDVK 
  
398.89580
6 
3 32.87 40.87 
DDB1 LEELHVIDVK 
  
401.56720
5 
3 32.87 40.87 
DDB1 YLAIAPPIIK 
  
549.84971 2 47.05 55.05 
DDB1 YLAIAPPIIK 
  
553.85680
9 
2 47.05 55.05 
DDB2 GGDIMLWNFGIK 
  
675.84737
3 
2 58.18 66.18 
DDB2 GGDIMLWNFGIK 
  
679.85447
2 
2 58.18 66.18 
DDB2 ASFLYSLPHR 
  
397.54874 3 33.84 41.84 
DDB2 ASFLYSLPHR 
  
400.88483 3 33.84 41.84 
DET1 YTSEDVVTLR 
  
591.80368
5 
2 29.28 37.28 
DET1 YTSEDVVTLR 
  
596.80781
9 
2 29.28 37.28 
DET NATLHSEVQFPCSASSNN
FAR 
  
1169.0374
7 
2 33.48 41.48 
DET N TLHSEVQFPCSASSNN
FAR 
  
1174.0416
1 
2 33.48 41.48 
DTL LYNTESQSFR 
  
622.79893
4 
2 20.86 28.86 
DTL LYNTESQSFR 
  
627.80306
8 
2 20.86 28.86 
ERCC8 IHGGGINTLDIEPVEGR 
  
888.96558
2 
2 35.23 43.23 
ERCC8 IHGGGINTLDIEPVEGR 
  
893.96971
6 
2 35.23 43.23 
ERCC8 YDYILATASADSR 
  
723.34898
8 
2 43.42 51.42 
ERCC8 YDYILATASADSR 
  
728.35312
2 
2 43.42 51.42 
NEDD8 EIEIDIEPTDK 
  
651.32719 2 37.88 45.88 
NEDD8 EIEIDIEPTDK 
  
655.33428
9 
2 37.88 45.88 
NEDD8 ILGGSVLHLVLALR 
  
487.64856
6 
3 60.14 68.14 
NEDD8 ILGGSVLHLVLALR 
  
490.98465
5 
3 60.14 68.14 
PHIP FVTDLLLHFIK 
  
449.26746
2 
3 63.23 71.23 
PHIP FVTDLLLHFIK 
  
451.93886
2 
3 63.23 71.23 
PHIP VVVDPVVTEQPSTSSAA
K 
  
907.48073 2 31.27 39.27 
PHIP VVVDPVVTEQPSTSSAA
K 
  
911.48783 2 31.27 39.27 
PWP1 SVALYDCR 
  
492.23438
4 
2 20.97 28.97 
PWP1 SVALYDCR 
  
497.23851
9 
2 20.97 28.97 
PWP1 NSSISGPFGSR 
  
554.77271
9 
2 23.56 31.56 
PWP1 NSSISGPFGSR 
  
559.77685
4 
2 23.56 31.56 
RBX1 QVCPLDNR 
  
501.24528
3 
2 15.13 23.13 
RBX1 QVCPLDNR 
  
506.24941
8 
2 15.13 23.13 
RFWD2 TASQLDEFQECLSK 
  
828.38270
2 
2 37.88 45.88 
RFWD2 TASQLDEFQECLSK 
  
832.38980
1 
2 37.88 45.88 
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RFWD2 LWSTNLDNSVASIEAK 
  
874.44669
1 
2 45.75 53.75 
RFWD2 LWSTNLDNSVASIEAK 
  
878.45379 2 45.75 53.75 
TRPC4AP WSGIPQLLLK 
  
577.85024
1 
2 53.46 61.46 
TRPC4AP WSGIPQLLLK 
  
581.85734
1 
2 53.46 61.46 
 
 
  
1 3 3  
BIBLIOGRAPHY 
Ahn, J., Novince, Z., Concel, J., Byeon, C.H., Makhov, A.M., Byeon, I.J.L., Zhang, P., and Gronenborn, 
A.M. (2011). The cullin-RING E3 ubiquitin ligase CRL4-DCAF1 complex dimerizes via a short helical 
region in DCAF1. Biochemistry. 
Alexandru, G., Graumann, J., Smith, G.T., Kolawa, N.J., Fang, R., and Deshaies, R.J. (2008). UBXD7 Binds 
Multiple Ubiquitin Ligases and Implicates p97 in HIF1 a Turnover. 804–816. 
Ambroggio, X.I., Rees, D.C., and Deshaies, R.J. (2004). JAMM: A metalloprotease-like zinc site in the 
proteasome and signalosome. PLoS Biol. 
An, S., and Fu, L. (2018). Small-molecule PROTACs: An emerging and promising approach for the 
development of targeted therapy drugs. EBioMedicine. 
Angers, S., Li, T., Yi, X., MacCoss, M.J., Moon, R.T., and Zheng, N. (2006). Molecular architecture and 
assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature. 
Aufderheide, A., Unverdorben, P., Baumeister, W., and F??rster, F. (2015). Structural disorder and its role 
in proteasomal degradation. FEBS Lett. 589, 2552–2560. 
Bakalarski, C.E., Elias, J.E., Villen, J., Haas, W., Gerber, S.A., Everley, P.A., and Gygi, S.P. (2008). The 
impact of peptide abundance and dynamic range on stable-lsotope-based quantitative proteomic analyses. J. 
Proteome Res. 
Bennett, E.J., Rush, J., Gygi, S.P., and Harper, J.W. (2010). Dynamics of cullin-RING ubiquitin ligase 
network revealed by systematic quantitative proteomics. Cell. 
Berger, I., Fitzgerald, D.J., and Richmond, T.J. (2004). Baculovirus expression system for heterologous 
multiprotein complexes. Nat. Biotechnol. 
Besten, W. Den, Verma, R., Kleiger, G., Oania, R.S., and Deshaies, R.J. (2012). NEDD8 links cullin-RING 
ubiquitin ligase function to the p97 pathway. Nat. Struct. Mol. Biol. 
Birol, M., Enchev, R.I., Padilla, A., Stengel, F., Aebersold, R., Betzi, S., Yang, Y., Hoh, F., Peter, M., Dumas, 
C., et al. (2014). Structural and biochemical characterization of the Cop9 signalosome CSN5/CSN6 
heterodimer. PLoS One. 
Boh, B.K., Smith, P.G., and Hagen, T. (2011). Neddylation-induced conformational control regulates cullin 
RING ligase activity in vivo. J. Mol. Biol. 
Bondeson, D.P., Mares, A., Smith, I.E.D., Ko, E., Campos, S., Miah, A.H., Mulholland, K.E., Routly, N., 
Buckley, D.L., Gustafson, J.L., et al. (2015). Catalytic in vivo protein knockdown by small-molecule 
PROTACs. Nat. Chem. Biol. 
Bosu, D.R., Feng, H., Min, K., Kim, Y., Wallenfang, M.R., and Kipreos, E.T. (2010). C. elegans CAND-1 
regulates cullin neddylation, cell proliferation and morphogenesis in specific tissues. Dev. Biol. 
Briggs, G.E., and Haldane, J.B.S. (1925). A Note on the Kinetics of Enzyme Action. Biochem. J. 19, 338–
339. 
Brownell, J.E., Sintchak, M.D., Gavin, J.M., Liao, H., Bruzzese, F.J., Bump, N.J., Soucy, T.A., Milhollen, 
M.A., Yang, X., Burkhardt, A.L., et al. (2010). Substrate-Assisted Inhibition of Ubiquitin-like Protein-
  
1 3 4  
Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ. Mol. 
Cell. 
Bulatov, E., and Ciulli, A. (2015). Targeting Cullin–RING E3 ubiquitin ligases for drug discovery: structure, 
assembly and small-molecule modulation. Biochem. J. 
Cavadini, S., Fischer, E.S., Bunker, R.D., Potenza, A., Lingaraju, G.M., Goldie, K.N., Mohamed, W.I., Faty, 
M., Petzold, G., Beckwith, R.E.J., et al. (2016). Cullin-RING ubiquitin E3 ligase regulation by the COP9 
signalosome. Nature 531, 598–603. 
Chen, C.-Y., Tsai, M.-S., Lin, C.-Y., Yu, I.-S., Chen, Y.-T., Lin, S.-R., Juan, L.-W., Chen, Y.-T., Hsu, H.-
M., Lee, L.-J., et al. (2012). Rescue of the genetically engineered Cul4b mutant mouse as a potential model 
for human X-linked mental retardation. Hum. Mol. Genet. 21, 4270–4285. 
Choi, H., Larsen, B., Lin, Z.Y., Breitkreutz, A., Mellacheruvu, D., Fermin, D., Qin, Z.S., Tyers, M., Gingras, 
A.C., and Nesvizhskii, A.I. (2011). SAINT: Probabilistic scoring of affinity purificationg-mass spectrometry 
data. Nat. Methods. 
Chu, G., and Chang, E. (1988). Xeroderma pigmentosum group E cells lack a nuclear factor that binds to 
damaged DNA. Science (80-. ). 
Chuang, H.W., Zhang, W., and Gray, W.M. (2004). Arabidopsis ETA2, an apparent ortholog of the human 
cullin-interacting protein CAND1, is required for auxin responses mediated by the SCF TIR1 ubiquitin ligase. 
Plant Cell. 
Cope, G.A., and Deshaies, R.J. (2003). COP9 signalosome: A multifunctional regulator of SCF and other 
cullin-based ubiquitin ligases. Cell. 
Cope, G.A., and Deshaies, R.J. (2006). Targeted silencing of Jab1 / Csn5 in human cells downregulates SCF 
activity through reduction of F-box protein levels. 10, 1–10. 
Cope, G.A., Suh, G.S.B., Aravind, L., Schwarz, S.E., Zipursky, S.L., Koonin, E. V, and Deshaies, R.J. (2002). 
Role of Predicted Metalloprotease Motif of Jab1 / Csn5 in Cleavage of Nedd8 from Cul1. 298, 608–611. 
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-
range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 
Cox, J., Neuhauser, N., Michalski, A., Scheltema, R.A., Olsen, J. V., and Mann, M. (2011). Andromeda: A 
peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 
Das, I., Krzyzosiak, A., Schneider, K., Wrabetz, L., D’Antonio, M., Barry, N., Sigurdardottir, A., and 
Bertolotti, A. (2015). Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory 
subunit. Science (80-. ). 
Deshaies, R.J. (1995). The self-destructive personality of a cell cycle in transition. Curr. Opin. Cell Biol. 
Deshaies, R.J. (2015). prime time for PROTACS. ACS Chem. Biol. 10, 1831–1837. 
Deshaies, R.J., and Joazeiro, C. a P. (2009a). RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 
399–434. 
Deshaies, R.J., and Joazeiro, C.A.P. (2009b). RING Domain E3 Ubiquitin Ligases. Annu. Rev. Biochem. 
Dimova, N. V., Hathaway, N.A., Lee, B.H., Kirkpatrick, D.S., Berkowitz, M.L., Gygi, S.P., Finley, D., and 
King, R.W. (2012). APC/C-mediated multiple monoubiquitylation provides an alternative degradation signal 
for cyclin B1. Nat. Cell Biol. 
Dougherty, W.G., Cary, S.M., and Dawn Parks, T. (1989). Molecular genetic analysis of a plant virus 
polyprotein cleavage site: A model. Virology. 
  
1 3 5  
Duda, D.M., Borg, L.A., Scott, D.C., Hunt, H.W., Hammel, M., and Schulman, B.A. (2008). Structural 
Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation. Cell. 
Duda, D.M., Olszewski, J.L., Tron, A.E., Hammel, M., Lambert, L.J., Waddell, M.B., Mittag, T., DeCaprio, 
J.A., and Schulman, B.A. (2012). Structure of a Glomulin-RBX1-CUL1 Complex: Inhibition of a RING E3 
Ligase through Masking of Its E2-Binding Surface. Mol. Cell. 
Echalier, A., Pan, Y., Birol, M., Tavernier, N., Pintard, L., Hoh, F., Ebel, C., Galophe, N., Claret, F.X., and 
Dumas, C. (2013). Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1. 
Proc. Natl. Acad. Sci. U. S. A. 
Emberley, E.D., Mosadeghi, R., and Deshaies, R.J. (2012). Deconjugation of Nedd8 from Cul1 is directly 
regulated by Skp1-F-box and substrate, and the COP9 signalosome inhibits deneddylated SCF by a 
noncatalytic mechanism. J. Biol. Chem. 
Enchev, R.I., Schreiber, A., Beuron, F., and Morris, E.P. (2010). Structural Insights into the COP9 
Signalosome and Its Common Architecture with the 26S Proteasome Lid and eIF3. Structure. 
Enchev, R.I., Scott, D.C., da Fonseca, P.C.A., Schreiber, A., Monda, J.K., Schulman, B.A., Peter, M., and 
Morris, E.P. (2012). Structural Basis for a Reciprocal Regulation between SCF and CSN. Cell Rep. 
Enchev, R.I., Schulman, B.A., and Peter, M. (2015). Protein neddylation: Beyond cullin-RING ligases. Nat. 
Rev. Mol. Cell Biol. 
Eng, J.K., Jahan, T.A., and Hoopmann, M.R. (2013). Comet: an open-source MS/MS sequence database 
search tool. Proteomics. 
Feldman, R.M.R., Correll, C.C., Kaplan, K.B., and Deshaies, R.J. (1997). A complex of Cdc4p, Skp1p, and 
Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell. 
Feng, S., Shen, Y., Sullivan, J.A., Rubio, V., Xiong, Y., Sun, T.P., and Deng, X.W. (2004). Arabidopsis 
CAND1, an unmodified CUL1-interacting protein, is involved in multiple developmental pathways 
controlled by ubiquitin/proteasome-mediated protein. Plant Cell. 
Fischer, E.S., Scrima, A., Böhm, K., Matsumoto, S., Lingaraju, G.M., Faty, M., Yasuda, T., Cavadini, S., 
Wakasugi, M., Hanaoka, F., et al. (2011a). The molecular basis of CRL4 DDB2/CSA ubiquitin ligase 
architecture, targeting, and activation. Cell. 
Fischer, E.S., Scrima, A., B??hm, K., Matsumoto, S., Lingaraju, G.M., Faty, M., Yasuda, T., Cavadini, S., 
Wakasugi, M., Hanaoka, F., et al. (2011b). The molecular basis of CRL4 DDB2/CSA ubiquitin ligase 
architecture, targeting, and activation. Cell 147, 1024–1039. 
Förster, F., Unverdorben, P., Śledź, P., and Baumeister, W. (2013). Unveiling the long-held secrets of the 
26S proteasome. Structure 21, 1551–1562. 
Gandhi, A.K., Kang, J., Havens, C.G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M.F., 
Thakurta, A., et al. (2014). Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells 
  
1 3 6  
by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase 
complex CRL4 CRBN. Br. J. Haematol. 
Garbett, D., and Bretscher, A. (2014). The surprising dynamics of scaffolding proteins. Mol. Biol. Cell. 
Goldberg, A.L. (2007). Functions of the proteasome: From protein degradation and immune surveillance to 
cancer therapy. In Biochemical Society Transactions, p. 
Goldenberg, S.J., Cascio, T.C., Shumway, S.D., Garbutt, K.C., Liu, J., Xiong, Y., and Zheng, N. (2004). 
Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the 
multisubunit cullin-dependent ubiquitin ligases. Cell. 
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T.C., Xie, Y., Williams, N.S., and Nijhawan, 
D. (2017). Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to 
DCAF15. Science (80-. ). 
Hannah, J., and Zhou, P. (2015). Distinct and overlapping functions of the cullin E3 ligase scaffolding 
proteins CUL4A and CUL4B. Gene 573, 33–45. 
He, Y.J., McCall, C.M., Hu, J., Zeng, Y., and Xiong, Y. (2006a). DDB1 functions as a linker to recruit 
receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev. 
He, Y.J., McCall, C.M., Hu, J., Zeng, Y., and Xiong, Y. (2006b). DDB1 functions as a linker to recruit 
receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev. 20, 2949–2954. 
Hershko, A., and Ciechanover, A. (1998). The Ubiquitin System. Annu. Rev. Biochem. 67, 425–479. 
Hershko, A., and Ciechanover, A. (2003). The Ubiquitin System for Protein Degradation. Annu. Rev. 
Biochem. 
Higa, L.A., Wu, M., Ye, T., Kobayashi, R., Sun, H., and Zhang, H. (2006). CUL4-DDB1 ubiquitin ligase 
interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat. Cell Biol. 8, 1277–
1283. 
Hyer, M.L., Milhollen, M.A., Ciavarri, J., Fleming, P., Traore, T., Sappal, D., Huck, J., Shi, J., Gavin, J., 
Brownell, J., et al. (2018). A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. 
Nat. Med. 
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., and Handa, H. (2010). 
Identification of a primary target of thalidomide teratogenicity. Science 327, 1345–1350. 
Jackson, S., and Xiong, Y. (2009). CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem. Sci. 34, 
562–570. 
Jiang, T., Tang, H., Wu, Z., Chen, J., Lu, S., Zhou, C., Yan, D., and Peng, Z. (2013). Cullin 4B is a novel 
prognostic marker that correlates with colon cancer progression and pathogenesis. Med. Oncol. 30, 534. 
Jin, J., Cardozo, T., Lovering, R.C., Elledge, S.J., Pagano, M., and Harper, J.W. (2004). Systematic analysis 
and nomenclature of mammalian F-box proteins. Genes Dev. 
Jin, J., Arias, E.E., Chen, J., Harper, J.W., and Walter, J.C. (2006). A Family of Diverse Cul4-Ddb1-
Interacting Proteins Includes Cdt2, which Is Required for S Phase Destruction of the Replication Factor Cdt1. 
Mol. Cell. 
Kaur, M., Khan, M.M., Kar, A., Sharma, A., and Saxena, S. (2012). CRL4-DDB1-VPRBP ubiquitin ligase 
mediates the stress triggered proteolysis of Mcm10. Nucleic Acids Res. 
Kelley, L.A., Mezulis, S., Yates, C.M., Wass, M.N., and Sternberg, M.J.E. (2015). The Phyre2 web portal 
for protein modeling, prediction and analysis. Nat. Protoc. 
  
1 3 7  
King, R.W., Deshaies, R.J., Peters, J.M., and Kirschner, M.W. (1996). How proteolysis drives the cell cycle. 
Science (80-. ). 
Komander, D., and Rape, M. (2012). The Ubiquitin Code. Annu. Rev. Biochem. 
Kortüm, K.M., Zhu, Y.X., Shi, C.X., Jedlowski, P., and Stewart, A.K. (2015). Cereblon binding molecules 
in multiple myeloma. Blood Rev. 
Krönke, J., Udeshi, N.D., Narla, A., Grauman, P., Hurst, S.N., McConkey, M., Svinkina, T., Heckl, D., 
Comer, E., Li, X., et al. (2014). Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple 
myeloma cells. Science 343, 301–305. 
Krzyzosiak, A., Sigurdardottir, A., Luh, L., Carrara, M., Das, I., Schneider, K., and Bertolotti, A. (2018). 
Target-Based Discovery of an Inhibitor of the Regulatory Phosphatase PPP1R15B. Cell. 
Kurz, T., Özlü, N., Rudolf, F., O’Rourke, S.M., Luke, B., Hofmann, K., Hyman, A.A., Bowerman, B., and 
Peter, M. (2005). The conserved protein DCN-1/Dcn1p is required for cullin neddylation in C. elegans and 
S. cerevisiae. Nature. 
Kusebauch, U., Campbell, D.S., Deutsch, E.W., Chu, C.S., Spicer, D.A., Brusniak, M.Y., Slagel, J., Sun, Z., 
Stevens, J., Grimes, B., et al. (2016). Human SRMAtlas: A Resource of Targeted Assays to Quantify the 
Complete Human Proteome. Cell. 
Lee, J., and Zhou, P. (2007). DCAFs, the Missing Link of the CUL4-DDB1 Ubiquitin Ligase. Mol. Cell 26, 
775–780. 
Leitner, A., Walzthoeni, T., and Aebersold, R. (2014). Lysine-specific chemical cross-linking of protein 
complexes and identification of cross-linking sites using LC-MS/MS and the xQuest/xProphet software 
pipeline. Nat. Protoc. 
Li, T., Robert, E.I., van Breugel, P.C., Strubin, M., and Zheng, N. (2010). A promiscuous α-helical motif 
anchors viral hijackers and substrate receptors to the CUL4–DDB1 ubiquitin ligase machinery. Nat. Struct. 
Mol. Biol. 
Liakopoulos, D., Doenges, G., Matuschewski, K., and Jentsch, S. (1998). A novel protein modification 
pathway related to the ubiquitin system. EMBO J. 
Lin, Y.C., Boone, M., Meuris, L., Lemmens, I., Van Roy, N., Soete, A., Reumers, J., Moisse, M., Plaisance, 
S., Drmanac, R., et al. (2014). Genome dynamics of the human embryonic kidney 293 lineage in response to 
cell biology manipulations. Nat. Commun. 
Lingaraju, G.M., Bunker, R.D., Cavadini, S., Hess, D., Hassiepen, U., Renatus, M., Fischer, E.S., and Thomä, 
N.H. (2014). Crystal structure of the human COP9 signalosome. Nature. 
Linghu, B., Callis, J., and Goebl, M.G. (2002). Rub1p processing by Yuh1p is required for wild-type levels 
of Rub1p conjugation to Cdc53p. Eukaryot. Cell. 
Liu, J., Furukawa, M., Matsumoto, T., and Xiong, Y. (2002). NEDD8 modification of CUL1 dissociates 
p120CAND1, an inhibitor of CUL1-SKP1 binding and SCF ligases. Mol. Cell. 
Liu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.T., Hideshima, T., Anderson, K.C., 
et al. (2019a). A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of 
immunomodulatory drug sensitivity. Leukemia. 
Liu, L., Lee, S., Zhang, J., Peters, S.B., Hannah, J., Zhang, Y., Yin, Y., Koff, A., Ma, L., and Zhou, P. (2009). 
CUL4A Abrogation Augments DNA Damage Response and Protection against Skin Carcinogenesis. Mol. 
Cell. 
Liu, X., Reitsma, J.M., Mamrosh, J.L., Zhang, Y., Straube, R., and Deshaies, R.J. (2018). Cand1-Mediated 
Adaptive Exchange Mechanism Enables Variation in F-Box Protein Expression. Mol. Cell. 
  
1 3 8  
Liu, Y., Mi, Y., Mueller, T., Kreibich, S., Williams, E.G., Van Drogen, A., Borel, C., Frank, M., Germain, 
P.L., Bludau, I., et al. (2019b). Multi-omic measurements of heterogeneity in HeLa cells across laboratories. 
Nat. Biotechnol. 
Lo, S.-C., and Hannink, M. (2006). CAND1-Mediated Substrate Adaptor Recycling Is Required for Efficient 
Repression of Nrf2 by Keap1. Mol. Cell. Biol. 
Lu, G., Middleton, R.E., Sun, H., Naniong, M., Ott, C.J., Mitsiades, C.S., Wong, K.-K., Bradner, J.E., and 
Kaelin, W.G. (2014). The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros 
proteins. Science 343, 305–309. 
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J.D., Crew, A.P., Coleman, 
K., et al. (2015a). Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem. Biol. 
Lu, Y., Wang, W., and Kirschner, M.W. (2015b). Specificity of the anaphase-promoting complex: A single-
molecule study. Science (80-. ). 
Lyapina, S., Cope, G., Shevchenko, A., Serino, G., Tsuge, T., Zhou, C., Wolf, D.A., Wei, N., Shevchenko, 
A., and Deshaies, R.J. (2001). Promotion of NEDD8-CUL1 conjugate cleavage by COP9 signalosome. 
Science (80-. ). 
Lydeard, J.R., Schulman, B.A., and Harper, J.W. (2013). Building and remodelling Cullin-RING E3 
ubiquitin ligases. EMBO Rep. 
MacLean, B., Tomazela, D.M., Shulman, N., Chambers, M., Finney, G.L., Frewen, B., Kern, R., Tabb, D.L., 
Liebler, D.C., and MacCoss, M.J. (2010). Skyline: An open source document editor for creating and 
analyzing targeted proteomics experiments. Bioinformatics. 
Matyskiela, M.E., and Martin, A. (2013). Design principles of a universal protein degradation machine. J. 
Mol. Biol. 425, 199–213. 
Mayor-Ruiz, C., Jaeger, M.G., Bauer, S., Brand, M., Sin, C., Hanzl, A., Mueller, A.C., Menche, J., and 
Winter, G.E. (2019). Plasticity of the Cullin-RING Ligase Repertoire Shapes Sensitivity to Ligand-Induced 
Protein Degradation. Mol. Cell. 
Meyer, H.J., and Rape, M. (2014). Enhanced protein degradation by branched ubiquitin chains. Cell. 
Mindell, J.A., and Grigorieff, N. (2003). Accurate determination of local defocus and specimen tilt in electron 
microscopy. J. Struct. Biol. 
Mosadeghi, R., Reichermeier, K.M., Winkler, M., Schreiber, A., Reitsma, J.M., Zhang, Y., Stengel, F., Cao, 
J., Kim, M., Sweredoski, M.J., et al. (2016). Structural and kinetic analysis of the COP9-Signalosome 
activation and the cullin-RING ubiquitin ligase deneddylation cycle. Elife 5. 
Nabet, B., Roberts, J.M., Buckley, D.L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A.L., Erb, M.A., Lawlor, 
M.A., Souza, A., et al. (2018). The dTAG system for immediate and target-specific protein degradation. Nat. 
Chem. Biol. 
Neklesa, T.K., Winkler, J.D., and Crews, C.M. (2017). Targeted protein degradation by PROTACs. 
Pharmacol. Ther. 
Nguyen, T. Van, Li, J., Lu, C.-C. (Jean), Mamrosh, J.L., Lu, G., Cathers, B.E., and Deshaies, R.J. (2017). 
p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. Proc. Natl. Acad. 
Sci. 
Olma, M.H., Roy, M., Le Bihan, T., Sumara, I., Maerki, S., Larsen, B., Quadroni, M., Peter, M., Tyers, M., 
and Pintard, L. (2009). An interaction network of the mammalian COP9 signalosome identifies Dda1 as a 
core subunit of multiple Cul4-based E3 ligases. J. Cell Sci. 
  
1 3 9  
Orthwein, A., Noordermeer, S.M., Wilson, M.D., Landry, S., Enchev, R.I., Sherker, A., Munro, M., Pinder, 
J., Salsman, J., Dellaire, G., et al. (2015). A mechanism for the suppression of homologous recombination in 
G1 cells. Nature. 
Ottis, P., Toure, M., Cromm, P.M., Ko, E., Gustafson, J.L., and Crews, C.M. (2017). Assessing Different E3 
Ligases for Small Molecule Induced Protein Ubiquitination and Degradation. ACS Chem. Biol. 
Paiva, S.L., and Crews, C.M. (2019). Targeted protein degradation: elements of PROTAC design. Curr. Opin. 
Chem. Biol. 
Pappin, D.J.C., Creasy, D.M., Perkins, D.N., and S., C.J. (1999). Probability-based protein identification by 
searching sequence databases using mass spectrometry data. Electrophoresis. 
Patil, A., Manzano, M., and Gottwein, E. (2019). Genome-wide CRISPR Screens Reveal Genetic Mediators 
of Cereblon Modulator Toxicity in Primary Effusion Lymphoma. BioRxiv. 
Patton, E.E., Willems, A.R., Sa, D., Kuras, L., Thomas, D., Craig, K.L., and Tyers, M. (1998). Cdc53 is a 
scaffold protein for multiple Cdc34/Skp1/F-box protein complexes that regulate cell division and methionine 
biosynthesis in yeast. Genes Dev. 
Peterson, A.C., Russell, J.D., Bailey, D.J., Westphall, M.S., and Coon, J.J. (2012). Parallel Reaction 
Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics. Mol. Cell. 
Proteomics. 
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and Ferrin, T.E. 
(2004). UCSF Chimera - A visualization system for exploratory research and analysis. J. Comput. Chem. 
Pfaffl, M.W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic 
Acids Res. 
Pickart, C.M. (2004). Back to the Future with Ubiquitin Review. 116, 181–190. 
Picotti, P., and Aebersold, R. (2012). Selected reaction monitoring–based proteomics: workflows, potential, 
pitfalls and future directions. Nat. Methods 9, 555–566. 
Picotti, P., Rinner, O., Stallmach, R., Dautel, F., Farrah, T., Domon, B., Wenschuh, H., and Aebersold, R. 
(2010). High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat. 
Methods. 
Pierce, N.W., Kleiger, G., Shan, S.O., and Deshaies, R.J. (2009). Detection of sequential polyubiquitylation 
on a millisecond timescale. Nature. 
Pierce, N.W., Lee, J.E., Liu, X., Sweredoski, M.J., Graham, R.L.J., Larimore, E. a., Rome, M., Zheng, N., 
Clurman, B.E., Hess, S., et al. (2013). Cand1 promotes assembly of new SCF complexes through dynamic 
exchange of F box proteins. Cell 153, 206–215. 
Politis, A., Stengel, F., Hall, Z., Hernández, H., Leitner, A., Walzthoeni, T., Robinson, C. V., and Aebersold, 
R. (2014). A mass spectrometry-based hybrid method for structural modeling of protein complexes. Nat. 
Methods. 
Pontén, F., Jirström, K., and Uhlen, M. (2008). The Human Protein Atlas - A tool for pathology. J. Pathol. 
Del Pozo, J.C., and Estelle, M. (1999). The Arabidopsis cullin AtCUL1 is modified by the ubiquitin-related 
protein RUB1. Proc. Natl. Acad. Sci. U. S. A. 
Pratt, J.M., Simpson, D.M., Doherty, M.K., Rivers, J., Gaskell, S.J., and Beynon, R.J. (2006). Multiplexed 
absolute quantification for proteomics using concatenated signature peptides encoded by QconCAT genes. 
Nat. Protoc. 
  
1 4 0  
Ravid, T., and Hochstrasser, M. (2008). Diversity of degradation signals in the ubiquitin-proteasome system. 
Nat. Rev. Mol. Cell Biol. 9, 679–690. 
Reitsma, J.M., Liu, X., Reichermeier, K.M., Moradian, A., Sweredoski, M.J., Hess, S., and Deshaies, R.J. 
(2017). Composition and Regulation of the Cellular Repertoire of SCF Ubiquitin Ligases. Cell. 
Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). Limma powers 
differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 
Rock, K.L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A.L. (1994). 
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides 
presented on MHC class I molecules. Cell. 
Rosenthal, P.B., and Henderson, R. (2003). Optimal determination of particle orientation, absolute hand, and 
contrast loss in single-particle electron cryomicroscopy. J. Mol. Biol. 
Roy, M.J., Winkler, S., Hughes, S.J., Whitworth, C., Galant, M., Farnaby, W., Rumpel, K., and Ciulli, A. 
(2019). SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation 
Rate. ACS Chem. Biol. 
Saha, A., and Deshaies, R.J. (2008). Multimodal Activation of the Ubiquitin Ligase SCF by Nedd8 
Conjugation. Mol. Cell 32, 21–31. 
Sakamoto, K.M., Kim, K.B., Kumagai,  a, Mercurio, F., Crews, C.M., and Deshaies, R.J. (2001). Protacs: 
chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. 
Proc. Natl. Acad. Sci. U. S. A. 98, 8554–8559. 
Sakamoto, K.M., Kim, K.B., Verma, R., Ransick, A., Stein, B., Crews, C.M., and Deshaies, R.J. (2003). 
Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol. Cell. 
Proteomics 2, 1350–1358. 
Sarikas, A., Hartmann, T., and Pan, Z.Q. (2011). The cullin protein family. Genome Biol. 
Sato, Y., Yoshikawa, A., Yamagata, A., Mimura, H., Yamashita, M., Ookata, K., Nureki, O., Iwai, K., 
Komada, M., and Fukai, S. (2008). Structural basis for specific cleavage of Lys 63-linked polyubiquitin 
chains. Nature. 
Scheres, S.H.W. (2012). RELION: Implementation of a Bayesian approach to cryo-EM structure 
determination. J. Struct. Biol. 
Scheres, S.H.W., and Chen, S. (2012). Prevention of overfitting in cryo-EM structure determination. Nat. 
Methods. 
Schlierf, A., Altmann, E., Quancard, J., Jefferson, A.B., Assenberg, R., Renatus, M., Jones, M., Hassiepen, 
U., Schaefer, M., Kiffe, M., et al. (2016). Targeted inhibition of the COP9 signalosome for treatment of 
cancer. Nat. Commun. 
Schmidt, M.W., McQuary, P.R., Wee, S., Hofmann, K., and Wolf, D.A. (2009). F-Box-Directed CRL 
Complex Assembly and Regulation by the CSN and CAND1. Mol. Cell. 
Scott, K.B., Turko, I. V., and Phinney, K.W. (2016). QconCAT: Internal Standard for Protein Quantification. 
In Methods in Enzymology, p. 
Scrima, A., Koníčková, R., Czyzewski, B.K., Kawasaki, Y., Jeffrey, P.D., Groisman, R., Nakatani, Y., Iwai, 
S., Pavletich, N.P., and Thomä, N.H. (2008). Structural Basis of UV DNA-Damage Recognition by the 
DDB1-DDB2 Complex. Cell 135, 1213–1223. 
Scudellari, M. (2019). Protein-slaying drugs could be the next blockbuster therapies. Nature. 
  
1 4 1  
Shabek, N., Ruble, J., Waston, C.J., Garbutt, K.C., Hinds, T.R., Li, T., and Zheng, N. (2018). Structural 
insights into DDA1 function as a core component of the CRL4-DDB1 ubiquitin ligase. Cell Discov. 
Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S., Heckl, D., Ebert, B.L., Root, 
D.E., Doench, J.G., et al. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 
(80-. ). 
Shi, Y. (2009). Serine/Threonine Phosphatases: Mechanism through Structure. Cell. 
Sievers, Q.L., Gasser, J.A., Cowley, G.S., Fischer, E.S., and Ebert, B.L. (2018). Genome-wide screen 
identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood. 
Skaar, J.R., Pagan, J.K., and Pagano, M. (2013). Mechanisms and function of substrate recruitment by F-box 
proteins. Nat. Rev. Mol. Cell Biol. 
Skowyra, D., Craig, K.L., Tyers, M., Elledge, S.J., and Harper, J.W. (1997). F-box proteins are receptors that 
recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell. 
Smyth, G.K. limma: Linear Models for Microarray Data. In Bioinformatics and Computational Biology 
Solutions Using R and Bioconductor, p. 
Smyth, G.K., Ritchie, M., and Thorne, N. (2011). Linear Models for Microarray Data User ’ s Guide. 
Bioinformatics. 
Soucy, T. a, Smith, P.G., Milhollen, M. a, Berger, A.J., Gavin, J.M., Adhikari, S., Brownell, J.E., Burke, 
K.E., Cardin, D.P., Critchley, S., et al. (2009). An inhibitor of NEDD8-activating enzyme as a new approach 
to treat cancer. Nature 458, 732–736. 
Sperling, A.S., Burgess, M., Keshishian, H., Gasser, J.A., Bhatt, S., Jan, M., Słabicki, M., Sellar, R.S., Fink, 
E.C., Miller, P.G., et al. (2019). Patterns of substrate affinity, competition and degradation kinetics underlie 
biological activity of thalidomide analogs. Blood. 
Straube, R., Shah, M., Flockerzi, D., and Wolf, D.A. (2017). Trade-off and flexibility in the dynamic 
regulation of the cullin-RING ubiquitin ligase repertoire. PLoS Comput. Biol. 
Suh, G.S.B., Poeck, B., Chouard, T., Oron, E., Segal, D., Chamovitz, D.A., and Zipursky, S.L. (2002). 
Drosophila JAB1/CSN5 acts in photoreceptor cells to induce glial cells. Neuron. 
Sun, X., Wang, J., Yao, X., Zheng, W., Mao, Y., Lan, T., Wang, L., Sun, Y., Zhang, X., Zhao, Q., et al. 
(2019). A chemical approach for global protein knockdown from mice to non-human primates. Cell Discov. 
Theile, C.S., Witte, M.D., Blom, A.E.M., Kundrat, L., Ploegh, H.L., and Guimaraes, C.P. (2013). Site-
specific N-terminal labeling of proteins using sortase-mediated reactions. Nat. Protoc. 
Thibaudeau, T.A., and Smith, D.M. (2019). A practical review of proteasome pharmacology. Pharmacol. 
Rev. 
Tran, H.J.T.T., Allen, M.D., Löwe, J., and Bycroft, M. (2003). Structure of the Jab1/MPN domain and its 
implications for proteasome function. Biochemistry. 
Tron, A.E., Arai, T., Duda, D.M., Kuwabara, H., Olszewski, J.L., Fujiwara, Y., Bahamon, B.N., Signoretti, 
S., Schulman, B.A., and DeCaprio, J.A. (2012). The Glomuvenous Malformation Protein Glomulin Binds 
Rbx1 and Regulates Cullin RING Ligase-Mediated Turnover of Fbw7. Mol. Cell. 
Uehara, T., Minoshima, Y., Sagane, K., Sugi, N.H., Mitsuhashi, K.O., Yamamoto, N., Kamiyama, H., 
Takahashi, K., Kotake, Y., Uesugi, M., et al. (2017). Selective degradation of splicing factor CAPERα by 
anticancer sulfonamides. Nat. Chem. Biol. 
Varshavsky, A. (1997). The ubiquitin system. Trends Biochem. Sci. 22, 383–387. 
  
1 4 2  
Vulto-van Silfhout, A.T., Nakagawa, T., Bahi-Buisson, N., Haas, S.A., Hu, H., Bienek, M., Vissers, 
L.E.L.M., Gilissen, C., Tzschach, A., Busche, A., et al. (2015). Variants in CUL4B are associated with 
cerebral malformations. Hum. Mutat. 36, 106–117. 
Wang, D., Eraslan, B., Wieland, T., Hallström, B., Hopf, T., Zolg, D.P., Zecha, J., Asplund, A., Li, L., Meng, 
C., et al. (2019). A deep proteome and transcriptome abundance atlas of 29 healthy human tissues. Mol. Syst. 
Biol. 
Wang, Y., Zhang, P., Liu, Z., Wang, Q., Wen, M., Wang, Y., Yuan, H., Mao, J.-H., and Wei, G. (2014). 
CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to Erlotinib via 
transcriptional regulation of EGFR. Mol. Cancer 13, 252. 
Wee, S., Geyer, R.K., Toda, T., and Wolf, D.A. (2005). CSN facilitates Cullin-RING ubiquitin ligase function 
by counteracting autocatalytic adapter instability. Nat. Cell Biol. 
Wei, N., and Deng, X.W. (2003). The COP9 Signalosome. Annu. Rev. Cell Dev. Biol. 
Wenzel, D.M., Lissounov, A., Brzovic, P.S., and Klevit, R.E. (2011). UBCH7 reactivity profile reveals parkin 
and HHARI to be RING/HECT hybrids. Nature. 
Winter, G.E., Buckley, D.L., Paulk, J., Roberts, J.M., Souza, A., Dhe-Paganon, S., and Bradner, J.E. (2015). 
Phthalimide conjugation as a strategy for in vivo target protein degradation. Science (80-. ). 
Wolfenden, R., and Snider, M.J. (2001). The Depth of Chemical Time and the Power of Enzymes as 
Catalysts. 34, 938–945. 
Wu, S., Zhu, W., Nhan, T., Toth, J.I., Petroski, M.D., and Wolf, D.A. (2013). CAND1 controls in vivo 
dynamics of the cullin 1-RING ubiquitin ligase repertoire. Nat. Commun. 
Yamoah, K., Oashi, T., Sarikas, A., Gazdoiu, S., Osman, R., and Pan, Z.Q. (2008). Autoinhibitory regulation 
of SCF-mediated ubiquitination by human cullin 1’s C-terminal tail. Proc. Natl. Acad. Sci. U. S. A. 
Yau, R., and Rape, M. (2016). The increasing complexity of the ubiquitin code. Nat. Cell Biol. 
Zemla, A., Thomas, Y., Kedziora, S., Knebel, A., Wood, N.T., Rabut, G., and Kurz, T. (2013). CSN-and 
CAND1-dependent remodelling of the budding yeast SCF complex. Nat. Commun. 
Zengerle, M., Chan, K.H., and Ciulli, A. (2015). Selective Small Molecule Induced Degradation of the BET 
Bromodomain Protein BRD4. ACS Chem. Biol. 
Zhang, W., Ito, H., Quint, M., Huang, H., Noël, L.D., and Gray, W.M. (2008). Genetic analysis of CAND1-
CUL1 interactions in Arabidopsis supports a role for CAND1-mediated cycling of the SCFTIR1 complex. 
Proc. Natl. Acad. Sci. U. S. A. 
Zhang, X., Crowley, V.M., Wucherpfennig, T.G., Dix, M.M., and Cravatt, B.F. (2018). 
[Cravatt]Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. BioRxiv. 
Zheng, N., and Shabek, N. (2017). Ubiquitin Ligases: Structure, Function, and Regulation. Annu. Rev. 
Biochem. 
Zheng, J., Yang, X., Harrell, J.M., Ryzhikov, S., Shim, E.H., Lykke-Andersen, K., Wei, N., Sun, H., 
Kobayashi, R., and Zhang, H. (2002a). CAND1 binds to unneddylated CUL1 and regulates the formation of 
SCF ubiquitin E3 ligase complex. Mol. Cell. 
Zheng, N., Schulman, B.A., Song, L., Miller, J.J., Jeffrey, P.D., Wang, P., Chu, C., Koepp, D.M., Elledge, 
S.J., Pagano, M., et al. (2002b). Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. 
Nature. 
Zimmerman, E.S., Schulman, B. a, and Zheng, N. (2010). Structural assembly of cullin-RING ubiquitin 
ligase complexes. Curr. Opin. Struct. Biol. 20, 714–721. 
  
1 4 3  
Zou, Y., Liu, Q., Chen, B., Zhang, X., Guo, C., Zhou, H., Li, J., Gao, G., Guo, Y., Yan, C., et al. (2007). 
Mutation in CUL4B, which encodes a member of cullin-RING ubiquitin ligase complex, causes X-linked 
mental retardation. Am. J. Hum. Genet. 80, 561–566. 
Zou, Y., Mi, J., Cui, J., Lu, D., Zhang, X., Guo, C., Gao, G., Liu, Q., Chen, B., Shao, C., et al. (2009). 
Characterization of nuclear localization signal in the N terminus of CUL4B and its essential role in cyclin E 
degradation and cell cycle progression. J. Biol. Chem. 
  
 
 
